MXPA06011145A - Selected cgrp antagonists, methods for the production thereof and their use as medicaments - Google Patents

Abstract

The invention relates to CGRP antagonists of general formula (I), in which A, X, D, E, G, M, Q and R1 to R3 are defined as in Claim 1, to their tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and their salts as well as the hydrates of the salts, particularly their physiologically compatible salts having inorganic or organic acids, to medicaments containing these compounds, to their use, and to methods for the production thereof.

Description

SELECTED CGRP ANTAGONISTS, METHOD FOR YOUR PREPARATION AS WELL AS YOUR USE AS A MEDICINE DESCRIPTION OF THE INVENTION Object of the present invention are the CGRP antagonists of the general formula wherein A, D, E, G, M, Q, X, R1, R2 and R3 are defined as in claim .1, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for their preparation. In the general formula (I) above, in a first embodiment A means an oxygen or sulfur atom, X an oxygen or sulfur atom, (a) D, E, independently of one another, in each case a methine group or the nitrogen atom and G a methino group substituted with the group Ra, M a methino group substituted with the group Rb, Q a methino group substituted with the group Rc, wherein one or two of the groups G, M and Q can in each case also means a nitrogen atom, or (b) D and E, in each case, a methine group, one of groups D and E also being able to mean a nitrogen atom, and G, M and Q in each case a nitrogen atom, wherein Ra, Rb and Rc, independently of each other, mean in each case a hydrogen or halogen atom, a C-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, cyclo- C3_7alkyl, C3_7-cycloalkenyl, cyano, hydroxy, hydroxy-C6_6alkyl, C3_6-hydroxy-alkenyl, C3_6-hydroxy-alkynyl-C6-alkoxy, C-alkoxy? -6-C 1-6 -alkyl, C 1-6 alkoxy-C 3-6 alkenyl, C 1-6 alkoxy-C 3-6 alkynyl, C 3-6 alkenoxy-C 1-6 alkyl, C 3-6 alkenyl-alkenyl -C3-6, C3-6 alkenoxy-C3_6 alkynyl, C3_6-alkyloxy-C-6 alkyl, C3-6 alkynyl-C3-6 alkenyl, C3-6 alkynyl-C3-6 alkynyl, thiohydroxy , alkylthio-C? _6, alkenylthio-C3_6, alkynylthio-C3-6, amino, alkyl-C? _6-amino, alkenyl-C3_6-amino, alkynyl-? C3-S-amino, di- (alkyl-C? _6) ) -amino, di- (alkenyl-C3_6) -amino, di- (C3_6 alkynyl) -amino, amino-C-alkyl -6, alkyl-C? -3-amino-C? _6 alkyl, di- (alkyl-C? -3) -amino-C? -6 alkyl, C3-6 alkylamino-C? -3-amino-C3_6 alkenyl, di- (C3-alkyl) -amino- C3-6 alkenyl, C3_6 amino-alkynyl, C3_3-amino-alkynyl-C3-6 alkyl, di- (C3_3 alkyl) -amino-C3_6 alkynyl, hydroxycarbonyl, f-enylcarbonyl, pyridylcarbonyl, alkyl -C? _6-carbonyl, C2_6-alkenyl-carbonyl, C2_6-alkynyl-carbonyl, formyl, C6-alkoxy -6-carbonyl, C3-6-alkenoxy-carbonyl, C3-6-alkyanoxycarbonyl, aminocarbonyl, alkyl- C6-aminocarbonyl, C3_6-aminocarbonyl alkenyl, C3-6 alkynylaminocarbonyl, di- (alkyl-Ci-β) -aminocarbonyl, di- (C3_6 alkenyl) -aminocarbonyl, di- (C3_6 alkynyl) - aminocarbonyl, formylamino, C 1 -C 6 alkylcarbonylamino, C 2 6 -carbonylamino alkenyl, C 2-6 alkynyl carbonylamino, formyl-C 1 -C 6 -alkylamino, formyl-C 3-6 -alkenyl-amino, formyl-alkynyl-C 3,6-amino , alkyl-C? _6-carbonyl-alkyl-C? -6-amino, alkenyl-C2_6-carbonyl -alkyl-C? -6-amino, alkynyl-C2_6-carbonyl-alkyl-C? _6-amino, alkyl- C6-carbonyl-alkenyl-C3_6-amino, C2_6-alkenyl-carbonyl-C3_6-amino-alkenyl, C2_6-alkynyl-carbonyl-C3_6-amino-alkenyl, C6_6-carbonyl-C3-6 alkynyl- amino, C2-6-alkenyl-carbonyl-C3_6-amino-alkynyl, C2_6-alkynyl-carbonyl-C3_6-amino-alkynyl, C6_6-sulfonyl-alkyl, C2_6-alkenyl-sulfonyl, C2-6-alkynyl-sulfonyl , alkyl-C-6-sulfinyl, alkenyl-C2_6-sulfinyl, alkynyl-C2_6-sulfinyl, alkyl-C6-6-sulfonylamino, alkenyl- C2-6-sulfonylamino, alkynyl-C2_6-sulfonylamin or, alkyl-C6-6-sulfonyl-alkyl-C6-amino, alkyl-C6-6-sulfonyl-alkenyl-C3_6-amino, alkyl-C6-6-sulfonyl-alkynyl-C3_6-amino, alkenyl-C2_6-sulfonyl-alkyl-C6-amino, alkenyl-C2_6-sulfonyl-alkenyl-C3-6-amino, alkenyl-C2_6-sulfonyl-alkynyl-C3-6-amino, alkynyl-C2-6-sulfonyl -alkyl-C? _6-amino, C2_6-sulfonyl-alkenyl-C3_6-amino alkynyl, C2_6 alkynyl-sulfonyl-C3-6-amino-alkynyl, aminosulfonyl, alkyl-C6-aminosulfonyl, di- (alkyl-C? -d) -aminosulfonyl, alkenyl-C3_6-aminosulfonyl, di- (alkenyl-C3-6) -aminosulfonyl, alkynyl-C3_6-aminosulfonyl or di- (alkynyl) -C3_6) -aminosulfonyl with the conditions that, insofar as none of the groups D, E, G, M and Q represents a nitrogen atom, (i) Ra does not mean a hydrogen atom, when Rb, as well as Rc represent in each case an alkyl-C? _6 group, (ii) Rc does not mean a hydrogen atom, when Ra, as well as Rb represent in each case a C-alkyl group -6, (iii) Ra do not adopt the meanings of a hydrogen, fluorine, chlorine, bromine or iodine atom or of a difluoro or trifluoromethyl group, when Rc represents a-C6-6 alkyl, C2-6 alkenyl or C2-6 alkynyl group and Rb represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, (iv) Rc does not have the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoro or trifluoromethyl group or, when Ra represents a C-6-alkenyl, C 2-6 alkenyl or C 2-6 alkynyl group and R represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, R 1 a heterocycle aza, diaza, triaza, oxaza, thiaza, thiadiaza or S, S-dioxido-thiadiaza of 5 to 7 members, saturated, unsaturated once or twice, the aforementioned heterocycles being linked to the piperidine ring in formula I through a carbon atom or nitrogen or being linked in a spirocyclic manner with the piperidine ring in formula I through two carbon atoms, through a carbon atom and an oxygen atom or through a carbon atom and a sulfur atom , containing one or two contiguous carbonyl or thiocarbonyl groups, to a nitrogen atom, being able to be substituted in one of the nitrogen atoms with a C 1 -C 6 alkyl, C 3-6 alkenyl or C 3-6 alkynyl group, being able to be replaced in one or two - carbon atoms with a group or C6-alkyl, C2_6 alkenyl or C2_6 alkynyl, with a phenyl, phenylmethyl, naphthyl, biphenylyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl group , pyrazolyl, 1- (alkyl-C-3) -pyrazolyl, imidazolyl or 1- (alkyl-C? -3) -imidazolyl, the substituents may be the same or different, and an olefinic double bond may be condensed. one of the above-mentioned unsaturated heterocycles with a ring of phenyl, naphthyl, pyridine, diazine, 1, 3-oxazole, thienyl, furan, thiazole, pyrrolo, N-alkyl-C? -3-pyrrolo or quinoline, with one ring of linoquinolin-2-one substituted at the nitrogen atom optionally with a C 1 -C 6 alkyl, C 3 6 alkenyl or C 3 -C 6 alkynyl group, or it may be fused with an imidazole ring or N-alkyl-C 3 -3 -imidazole, two olefinic double bonds of one of the unsaturated heterocycles mentioned above may also be condensed in each case with a phenyl ring or * pyridine, the groups being phenyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl, 1-alkyl-C? -3-pyrazolyl, imidazolyl or l-alkyl -C? _3-imidazolyl contained in R1, thus -as the heterocycles condensed with benzo, thieno, pyrido and diazino being mono-, di- or trisubstituted in the carbon framework additionally with halogen atoms, C-alkyl groups -6 , C2_6 alkenyl, C2_6 alkynyl, C3_7 cycloalkyl, C3_7 cycloalkenyl, cyano, hydroxy, hydroxy-C6 alkyl, C3_6 hydroxy-alkenyl, C3-6 hydroxy-alkynyl, alkoxy -C? -6, C 1-6 alkoxy-C? -6-alkoxy, C? -6-alkenyl-C3-6 alkoxy, C? _6-alkynyl-C3_6 alkoxy, C3_6-alkenoxy-alkyl-? C? -6, C3-6 alkenoxy-C3_6 alkenyl, C3-6 alkenoxy-C3-6 alkynyl, C3_6 alkynoxy-C? _6 alkyl, C3-6 alkynyl-C3-6 alkenyl, C3-alkynoxy? -6-C3_6-alkynyl, thiohydroxy, C, -6-alkylthio, C3-6 alkenylthio, C3-6 alkynylthio, amino, C6-alkyl-amino, C3-6-amino-alkenyl, C3-alkynyl 6-a mino, di- (C 1 -C 6 alkyl) -amino, di- (C 3-6 alkenyl) -amino, di- (C 3-6 alkynylamino), amino-C 1 -C 6 alkyl, C 1 -C 3 alkyl amino-C 1 -C 6 -alkyl, di- (C 1 -C 3 -alkyl) -amino-C 1 -C 6 -alkyl, C 3 -C 6 -alkenyl, C 3 -C 6 alkylamino-C 3-6 alkenyl, (C3_6 alkyl- C3-) amino-alkenyl, C3-6 amino-alkynyl, C3_6 alkyl-amino-alkynyl, di- (C3_3 alkyl) -amino-alkynyl- C3_6, hydroxycarbonyl, phenylcarbonyl, pyridylcarbonyl, C 1 -C 6 alkylcarbonyl, C 2-6 alkenylcarbonyl, C 2-6 alkynylcarbonyl, formyl, C 1 -C 6 alkoxycarbonyl, C 3 -C 6 alkoxycarbonyl, C 3 -C 8 alkynyl -6-carbonyl, aminocarbonyl, alkyl-C6-aminocarbonyl, alkenyl-C3_6-aminocarbonyl, alkynyl-C3_6-aminocarbonyl, di- (alkyl-C6-6) -aminocarbonyl, di- (alkenyl-C3_6) -aminocarbonyl, di- (C3-6 alkynyl) -aminocarbonyl, for -ylamino, C6-alkylcarbonylamino, C2_6-carbonylamino alkenyl, C2-6-alkynyl-carbonylamino, -yl-alkyl-C6-amino, formyl -alkenyl-C3-6-amino-, formyl-alkynyl-C3-6-amino, alkyl-C6-6-carbonyl -alkyl-C6-amino, alkenyl-C2_6-carbonyl-alkyl-C6-amino-alkynyl-C2-6-carbonyl-alkyl-C-6-amino, alkyl-C6-carbonyl-alkenyl-C3 -6-amino, C2-6-alkenyl-carbonyl-C3-6alkenyl-alkenyl, C2-6-alkynyl-carbonyl-C3-6-alkenyl-amino, C6-6-alkylcarbonyl-C3-6-amino-alkynyl , C2_6-carbonyl-C3-6-alkynyl-amino, C2_6-alkynyl-carbonyl-C3_6-amino-alkynyl, C6-6-sulfyl onyl, C2_6_sulfonyl-alkenyl, C2-6-alkynyl-sulfonyl, alkyl - C? ^ .6-sulphonyl, C2_6-alkenyl-sulfyl, C2-6-alkynyl-sulfyl, alkyl-C6-6-sulfonylamino, C2_6-alkenyl-sulfonylamino, C2-6-alkynyl-sulfonylamino, alkyl - C6-sulfonyl-alkyl-C? -g-amino, alkyl-C6-6-sulfonyl-alkenyl-C3-6-amino, alkyl-C? -6-sulfonyl-alkynyl-C3-6-amino, alkenyl-C2_6-sulfonyl-alkyl-C6- amino, alkenyl-C2-6-sulfonyl-alkenyl-C3-6-amino, alkenyl-C2_6-sulfonyl-alkynyl-C3-6-amino, alkynyl-C2_6-sulfonyl- alkyl-C6-amino, alkynyl-C2_6-sulfonyl-alkenyl-C3-6-amino, alkynyl-C2_6-sulfonyl-alkynyl-C3_6-amino, a Methylsulfonyl, C 1 -C 6 alkylsulfonyl, di- (C 1 -C 6 alkyl) -aminosulfonyl, C 3-6 alkenyl-aminosulfonyl, 4-alkenyl-3-alkylaminosulfonyl, C 3 -alkynyl 6-aminosulfonyl, di- (C3-C3-alkynyl) -aminosulfonyl, the substituents being the same or different and the double and triple bonds being of the C3_6 alkenyl or C3-6 alkynyl groups contained in the groups defined above for Ra, Rb , Rc and R1 isolated from heteroatoms optionally also contained in these groups, R2 the hydrogen atom, a phenylmethyl group or a C2-7 alkyl group, which in position? may be substituted with a group C3_7-cycloalkyl, C3_7-cycloalkenyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, -alkyl-6-amino, di- (alkyl-C? -β) -amino , C3_6-amino alkenyl, di- (C3_6 alkenyl) amino, C3_6-amino alkynyl, di- (C3-6 alkynyl) amino, hydroxycarbonyl, C6-alkoxy-6-carbonyl, aminocarbonyl, aminocarbonylamino, alkyl- C6-carbonylamino, alkenyl-C2_6-carbonylamino, alkynyl-C2_6-carbonylamino, 4-morpholinyl, [bis- (2-hydroxyethyl)] amino, 4- (C-6 alkyl) -1-piperazinyl or 4- (β-hydroxy-C2-7) -1-piperazinyl, a phenyl or pyridinyl group , the phenyl, pyridinyl and diazinyl groups mentioned in the groups defined above for R2 or contained as substituents can be mono-,. di- or tri-substituted additionally in the carbon framework with halogen, with C 1 -C 3 -alkyl groups, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3 alkoxy, hydroxy, amino, C 1 -C 3 -alkylamino , di- (alkyl-C? _3) -amino, amino-C-3-alkyl-, C3-alkyl-amino-C? -3 alkyl, di- (C3-alkyl) -amino-alkyl- C? _3, alkyl-C? -3-carbonylamino, alkyl-C? _3-carbonylamino-C? _3 alkyl, aminocarbonyl, alkyl-C? -3-aminocarbonyl, di- (alkyl-C? -3) -aminocarbonyl, cyano , aminosulfonyl, C 1 -C 3 alkylsulfonyl, di- (C 1 -C 3 alkyl) aminosulfonyl, C 1 -C 3 alkyl, C 1 -C 3 alkylsulfonyl or C 1 -C 3 alkylsulfonyl, and the substituents being the same or different, R3 the hydrogen atom or a C3_3-alkyl group substituted with a phenyl or pyridinyl group, the C3_3 alkyl group may be linked with an alkyl group contained in R2 or with a phenyl or pyridyl ring contained in R2, under the inclusion of the nitrogen atom to which R2 and R3 are attached, under the formation of a ring of 4-7 members, or R2 and R3, together with the included nitrogen atom, a radical of the in which Y1 the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the numbers 0, 1 or 2, oqyr, when Y1 represents the nitrogen atom, the numbers 1 or 2, R4 the hydrogen atom, an amino group, alkyl C? _-amino, di- (C? -4 alkyl) -alkylamino, alkylo C? -6, a cycloalkyl group C3_7 or C3_cycloalkenyl optionally substituted by a hydroxycarbonyl group, C6-6-carbonyl alkoxy, hydroxycarbonyl-C3-3alkyl or C6-6alkoxycarbonyl-C3alkyl, an amino-C2-7alkyl group, alkyl C? _-Amino-C2_7alkyl, di- (C_-aminoalkyl) -C2_7alkyl, aminoiminomethyl, aminocarbonylamino, C4_4-aminocarbonylamino alkyl, di- (C1_) alkyl-aminocarbonylamino, C4_4-aminocarbonyl alkyl -alkyl C 4 -amino, di- (alkyl C) -aminocarbonyl-C 4 -4 -alkylamino, phenylaminocarbonylamino, aminocarbonyl, C 1 4 -aminocarbonyl alkyl, di- (C 1 -4 alkyl) -aminocarbonyl, aminocarb onyl-C3 alkyl, C3-4alkylaminocarbonyl-C3 alkyl, di- (C3- alkyl) -aminocarbonylalkyl C3-3, aminocarbonylamino-C3-3alkyl, C6-6alkoxycarbonyl, C3-alkenoxy 6-carbonyl, C3_6-carbonyl alkyloxy, C6-6-carbonyl-C3-C3-alkoxy, C3-6-carbonyl-C3-C3-alkenoxy, C6-6-carbonyl-C3-C3 alkyl or hydroxycarbonyl-alkyl C? _3, a phenyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl, pyridylcarbonyl or phenylcarbonyl group, which in each case may be mono-, di- or tri-substituted additionally in the carbon framework with halogen, with groups C 1 -C 3 -alkyl, C 2 -C 3 alkenyl, C 2 -3 alkynyl, C 1 -C 3 alkoxy, hydroxy, amino, C 1 -4 -alkylamino, di- (C 1 -C 4 alkyl) -amino, amino- alkyl-C? -3, alkyl-C? -amino-alkyl-C? _3, di- (alkyl-C? _4) -amino-alkyl-C? _3, alkyl-C-4-carbonylamino, alkyl-C? -4- carbonylamino-C 1 -C 3 alkyl, aminocarbonyl, C 1 -alkylaminocarbonyl, di- (C 1 -C 4 alkyl) -aminocarbonyl, cyano, aminosulfonyl, C 1 -alkylaminosulfonyl, di- (alkylamino) lC? _4) -aminosulfonyl, alkyl-C? _4-thio, alkyl-C? _-sulfinyl or alkyl-C? _4-sulphonyl, and the substituents being the same or different, a heterocycle selected from an azacycloalkyl group of 4 to 10 members, an oxaza, thiaza, S, S-dioxothiaza and diazacycloalkyl group of 6 to 10 members, as well as an azabiocycloalkyl group of 6 to 10 members, a l-alkyl-4-piperidinicarbonyl group or 4-alkyl-1-piperazinylcarbonyl, the aforementioned monocyclic and bicyclic heterocycles being linked, via a nitrogen or carbon atom, to Y1 in the formula (II), in the aforementioned monocyclic and bicyclic heterocycles a non-methino group directly linked to a nitrogen atom, oxygen or sulfur can be substituted with a fluorine atom, as well as a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom can be substituted with one or two fluorine atoms, the aforementioned monocyclic and bicyclic heterocycles, as well as the group 1- (C 1 -d) -4-piperidinylcarbonyl and 4- (C 1 -C 6 alkyl) -1-piperazinylcarbonyl can be substituted on the ring, one to four times, with hydroxy groups, C-alkyl? 6 or hydroxy-C 1 -C 3 alkyl, or, optionally additionally, once with a cycls-C 3 7 -alkyl group, hydroxycycloalkyl-C 3 7, cyclo-C 3-7 alkenyl, cyclo-C 3-7 alkylalkyl- C? -3, phenyl-C? -3 alkyl, pyridyl-C? _3 alkyl, C? -6-carbonyl alkyl, C? -6-carbonyl-C? _3 alkyl, hydroxy, alkoxy-? C? -6, amino, alkyl-C? -amino, di- (alkyl-C? _4) amino, phenylcarbonyl, pyridinylcarbonyl, alkoxy-C? -6-carbonyl, hydroxycarbonyl-carbonyl, alkoxy-C? -6- carbonyl-carbonyl, hydroxycarbonyl-C-alkyl ? 3, C 1 -C 6 alkoxy-carbonyl-C 1 -C 3 -alkyl, hydroxycarbonyl-C 1 -C 3 -carbonyl, C 1 -C 6 -alkoxy-C 1 -C -carbonyl, aminocarbonyl, C-alkyl? 4-aminocarbonyl, di- (C 1 -C 4) aminocarbonyl, aminosulfonyl, C 1 -4 aminosulfonyl alkyl, di- (C 4 alkyl) aminosulfonyl, C 1 -3 alkylsulfonyl, cyclo-C 3-7 alkylsulfonyl , aminocarbonyl-C? -3 alkyl, C? -4-aminocarbonyl-C? _3 alkyl, di- (C? -4) aminocarbonyl-C? -3 alkyl, hydroxy-aminocarbonyl-C-alkyl? -3, alkoxy-C? -3-aminocarbonyl-C? -3 alkyl or hydroxy- (C? _3 alkyl) -aminocarbonyl-C? -3 alkyl, with a cyclo-C3_7-carbonyl group, azacyclo -alkyl-C4_7-carbonyl, diazacyclo-C5_7-alkylcarbonyl or oxazacycloalkyl-C5-7-carbonyl optionally substituted on the ring with C -3alkyl, wherein the substituents may be the same or different and may be attached to a carbazole atom of the ring or a nitrogen atom of the ring, - the phenyl and pyridinyl radicals contained in the radicals defined above for R 4 to be mono-, di- or tri-substituted, for their part, with halogen atoms, with C 1 -C 3 -alkyl, C 2 -C 3 alkenyl, C 2-3 alkynyl, C 1 -C 3 -alkoxy, hydroxy, amino, alkyl-C? 4-amino, di- (alkyl-C? _4) -amino, amino-alkyl-C? _3, alkyl-C? _-amino-alkyl-C? -3, di- (alkyl-C? -) -amino-C? -3 alkyl, C? _4-carbonylamino alkyl, C? _ -carbonylamino-C? -3 alkyl, aminocarbonyl, C? _3-aminocarbonyl alkyl, alkyl-C? _4-aminocarbonyl, cyano, aminosulfonyl, alkyl-C? _ 4-aminosulfonyl, di- (alkyl-C? _) -aminosulf onyl, alkyl-C? -3-thio, alkyl-C? -3-sulfinyl or alkyl-C? -3-sulfonyl, the substituents being the same or different, or also, when Y1 represents the carbon atom, the hydroxycarbonyl, aminomethyl, alkyl-C? 4-aminomethyl or di- (alkyl-C? -) -aminomethyl group, R5 a hydrogen atom or a hydroxy group, a C 4 -alkyl radical, wherein an unbranched alkyl radical can be substituted, in the α-position, with a phenyl, pyridinyl, diazinyl, amino, alkyl-C ?4-amino, di- (C alqu-alkyl) -amino group , 4-alkyl-C? ~ 4-l-piperazinyl or 4-morpholinyl, a-C6-6-carbonyl, cyano or aminocarbonyl group or also, when Y1 represents a nitrogen atom, a pair of free electrons, or, when Y1 represents the carbon atom, also the fluorine atom, or R4 together with R5 and Y1 a cycloaliphatic ring of 4 to 7 members, in which a methylene group may be replaced by a group -NH-, -N (alkyl) C? _) -, - N (C3_4 alkenyl) -, -N (C3_ alkynyl), -N (cyclo-C3-7 alkyl) -, -N (C3_7 cycloalkyl- C3_3 alkyl) -, -N (hydroxycarbonyl-C-alkyl) ? -3) - or -N (C6-6-carbonyl-alkoxy-alkyl) C1-3) - a hydrogen atom bound to a nitrogen atom in one of the groups mentioned above for R4 may be replaced by a protective radical, R6 and R7, which may be the same or different, in each case an hydrogen, an alkyl-C group or also, when Y 1 represents a carbon atom, the fluorine atom, an amino group, alkyl-C-amino or di- (alkyl-C? _) -amino, being able to be linked together the two C 1 -4 alkyl groups with formation of a ring and R 8 and R 9, which may be the same or different, in each case a hydrogen atom or a C 1 -C 3 alkyl group, where, if not mentioned otherwise In the same way, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above can be straight-chain or branched, each methino group contained in the radicals mentioned above can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 ato fluorine groups and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be linked together under the formation of a 4 to 7 membered heterocyclic ring, saturated or unsaturated , all aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above may be mono-, di- or tri-substituted further with halogen, with cyano or hydroxy groups, and the substituents may be the same or different and for the protective radicals mentioned in the foregoing definitions and below are to be understood the usual protective groups of the chemistry of the peptides, in particular a phenylalkoxycarbonyl group having 1 to 3 carbon atoms in the alkoxy part, optionally substituted in the phenyl nucleus with a halogen atom, with a nitro or phenyl group, with one or two methoxy groups, for example the group b encyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-methoxy-benzyloxycarbonyl, 2-chloro-benzyloxycarbonyl, 3-chloro-benzyloxycarbonyl, 4-chloro-benzyloxycarbonyl, 4-biphenylyl-a, -dimethyl-benzyloxycarbonyl or 3, 5-dimethoxy-α, α-dimethyl-benzyloxycarbonyl, an alkoxycarbonyl group with in total 1 to 5 carbon atoms in the alkyl part, for example the methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl group, 1- methylpropoxycarbonyl, * 2-methylpropoxycarbonyl or tere. -butyloxycarbonyl, the allyloxycarbonyl group, 2,2,2-trichloro- (1,1-dimethylethoxy) carbonyl or 9-fluorenylmethoxycarbonyl or the formyl, acetyl or trifluoroacetyl group. In the above definitions and those listed below is to be understood by a group replaced in position? a group substituted in terminal positionby a halogen atom a fluorine, chlorine, bromine or iodine atom and by a double or triple bond isolated from a heteroatom a double or triple bond that is linked to a heteroatom through at least one saturated carbon atom. A second embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q and R1 are defined as mentioned above in the first and R2 mean the hydrogen atom, a phenylmethyl group or a C2_7 alkyl group, which in position? may be substituted with a group C3_7-cycloalkyl, C3_7-cycloalkenyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, alkyl-C6- amino, di- (C6_6 alkyl) -amino, alkenyl- C3_6-amino, di- (C3_6 alkenyl) amino, C3-6-amino alkynyl, di- (C3-6 alkynyl) amino, hydroxycarbonyl, C6_6-carbonyl alkoxy, aminocarbonyl, aminocarbonylamino, C-alkyl? -6-carbonylamino, alkenyl-C2_6-carbonylamino, alkynyl-C2_6 ~ carbonylamino, 4-morpholinyl, [bis- (2-hydroxyeth-yl)] amino, 4- (alkyl-C6-6) -1-piperazinyl or 4- (? -hydroxy-alkyl-C2_) -1-piperazinyl, a phenyl or pyridinyl group, the phenyl, pyridinyl and diazinyl groups mentioned in the groups defined above for R2 or contained as substituents being mono-, di- or tri-substituted additionally in the carbon framework with halogen, with C 1 -C 3 -alkyl, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 3 -alkoxy, hydroxy, amino, C 1 -C 3 -alkylamino, di- (C-alkyl) groups ? -3) -amino, amino-alkyl-C? -3, alkyl-C? _3-amino-alkyl-C ? _3, di- (C 1 -C 3 alkyl) -amino-C 1 -C 3 alkyl, C 1 -C 3 alkylcarbonylamino, C 1 -C 3 alkylcarbonylamino C 1 -C 3 alkyl, aminocarbonyl, C-alkyl? 3-aminocarbonyl, di- (C 1 -C 3 alkyl) -aminocarbonyl, cyano, aminosulfonyl, C 1 -C 3 alkyl aminosulfonyl, di- (C 1 -C 3 alkyl) -aminosulfonyl, C 1 -C 3 alkyl, alkyl -C? _3-sulfinyl or alkyl-C? -3-sulfonyl, and the substituents may be the same or different, R3 the hydrogen atom or a C? -3 alkyl group substituted with a phenyl or pyridinyl group, and may be attached the C3-alkyl group with an alkyl group contained in R2 or with a phenyl or pyridyl ring contained in R2, under the inclusion of the nitrogen atom to which R2 and R3 are attached, under the formation of a ring of 4- 7 members, or R and R3, together with the included nitrogen atom, a radical of the general formula where Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the numbers 0, 1 or 2, oqyr, when Y1 represents the nitrogen atom, the numbers 1 or 2, R4 the hydrogen atom, an amino group, alkyl-C? _4-amino, di- (alkyl-C? _4) -amino, alkyl-C? -6, a group C3_7-cycloalkyl, C3_7-cycloalkenyl, C2- amino-alkyl, C4-4alkylamino-C2- alkyl, di- (C4-4alkylamino) -C2_7alkyl, aminoiminomethyl , aminocarbonyl amino, alkyl-C? -. 4-aminocarbonylamino, di- (alkyl-C? _4) -aminocarbonylamino, alkyl-C? _4-aminocarbonyl-alkyl-C? -4-amino, di- (C-4 alkyl) ) -aminocarbonyl-alkyl-C? _4-amino, phenylaminocarbonylamino, aminocarbonyl, alkyl-C? _4-aminocarbonyl, di- (alkyl-C? _4) -aminocarbonyl, aminocarbonyl-C? -3 alkyl, alkyl-C? 4-aminocarbonyl-C 1 -C 3 alkyl, di- (C 1 -C 4 alkyl) -aminocarbonyl-C 1 -C 3 alkyl, aminocarbonylamino-C 1 -C 1 alkyl 3, C6-C6-alkoxycarbonyl, C3_6-alkenoxycarbonyl, C3_6-carbonyl alkyloxy, C6-alkoxy -6-carbonyl-C3-alkyl, C3-6-alkenoxy-carbonyl-alkyl- C_3, C-6-alkyloxy-carbonyl-C-3 alkyl or hydroxycarbonyl-C-3 alkyl, a phenyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl, pyridylcarbonyl or phenylcarbonyl group, which in each case can be mono -, di- or tri-substituted additionally in the carbon framework with halogen, with C 1 -C 3 -alkyl, C 2 -C 3 alkenyl, C 2 -3 alkynyl, C 1 -C 3 alkoxy, hydroxy, amino, C-alkyl groups? _-amino, di- (alkyl-C_4) -amino, amino-alkyl-C? -3, alkyl-C? _-amino-alkyl-C? _3, di- (alkyl-C? -4) -amino- C 1 -C 3 alkyl, C 4 alkylcarbonylamino, C 4 alkylcarbonylamino-C 1 -3 alkylaminocarbonyl, C 1 -4 alkyl aminocarbonyl, di- (C 1 -C 4 alkyl) -aminocarbonyl, cyano, aminosulfonyl, alkyl-Ci- -aminosulfonyl, di- (C 1 -C 4 alkyl) -aminosulfonyl, C 1 -thio alkyl, C 1 -4 -sulfinyl or C 1 -4 alkylsulfonyl, and being able the substituents to be equal or different ntes, a heterocycle selected from an azacycloalkyl group of 4 to 10 members, an oxa-za-, thiaza- and diaza-cycloalkyl group "of 6 to 10 members, as well as an azabicycloalkyl group of 6 to 10 members, a group l- alkyl-4-piperidinicarbonyl or 4-alkyl-1-piperazinylcarbonyl, the above-mentioned monocyclic and bicyclic heterocycle being linked, via a nitrogen or carbon atom, to Y1 in formula (II), in monocyclic heterocycles and bicyclics mentioned above a methine group not directly bonded with a nitrogen, oxygen or sulfur atom may be substituted with a fluorine atom, as well as a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom may be substituted with one or two fluorine atoms, the aforementioned monocyclic and bicyclic heterocycles, as well as the l- (alkyl-C? -β) -4-piperidinylcarbonyl and 4- (alkyl-Cx-e) -1-piperazinylcarbonyl groups they can be substituted in the ring, one to four times, with C 1 -C 6 alkyl groups, or, optionally additionally, once with a C 37 cycloalkyl group, C 7 cycloalkenyl group, C 3-7 cycloalkyl C3-alkyl, phenyl-C3-alkyl, pyridyl-C3-alkyl, C6-alkyl-carbonyl, hydroxy, C6-C6-alkoxy, amino, C-amino-alkylamino, - (C 1 -C 4 alkyl) amino, phenylcarbonyl, pyridinylcarbonyl, hydroxycarbonyl, hydroxycarbonyl-C 1 -C 3 alkyl, C 1 -C 6 alkoxycarbonyl, C 1 -C 5 alkoxycarbonyl-C 1 -C 3 alkyl, aminocarbonyl, alkyl-C? _4-aminocarbonyl, di- (alkyl-C? -4) aminocarbonyl or alkyl-C? 3-sulfonyl, with a cyclo-C3_7-carbonyl, azacyclo-C4_7-carbonyl, diazacycloalkyl group -C_7-carbonyl or oxazacycloalkyl-C5-carbonyl optionally substituted on the ring with C? -3 alkyl, the substituents being the same or different and being able to be attached to a ring carbon atom or a ring nitrogen atom , being able the phenyl and pyridinyl radicals contained in the r Additions defined above for R4 be mono-, di- or tri-substituted, on the other hand, with halogen atoms, with C-3 alkyl, C2_3 alkenyl, C2_3 alkynyl, C3_3 alkoxy, hydroxy, amino, C 1 -C 4 alkyl groups -amino, di- (alkyl-C? _4) -amino, amino-alkyl-C? _3, alkyl-C? -4-amino-alkyl-C? _3, di- (alkyl-C? _4) -amino- C 1 -C 3 -alkyl, C 1 -carbonylamino, C 1 -4 -carbonylamino-C 1 -C 3 alkyl, aminocarbonyl, C 1 -C 3 -aminocarbonyl, di-alkyl-C 4 -aminocarbonyl , cyano, aminosulfonyl, C 1 -4-aminosulfonyl-alkyl, di- (C 1 -C 4 alkyl) -aminosulfonyl, C 1 -3-thio alkyl, C 1 -C 3 -sulfinyl or C 1 -C 3 alkyl sulfonyl, the substituents being the same or different, or also, when Y1 represents the carbon atom, the hydroxycarbonyl, aminomethyl, alkyl-C? -4-aminomethyl or di- (alkyl-C? _) -aminomethyl group, R5 a hydrogen atom, a C 1 -4 alkyl radical, wherein an unbranched alkyl radical may be substituted, in the α-position, with a phenyl, pyridinyl, diazinyl, amino, alkyl-C 4 -amino, -di- (alkyl) group uil-C? _4) -amino, 4-alkyl-C? _-l-piperazinyl or 4-morpholinyl, a C6-C6-alkoxy, cyano or aminocarbonyl group or also, when Y1 represents a nitrogen atom, a pair of free electrons, or, when Y1 represents the carbon atom, also the fluorine atom, or R4, together with R5 and Y1 a cycloaliphatic ring of 4 to 7 members, in which a methylene group can be replaced by a group -NH-, -N (C-alkyl) -, -N (C3-4 alkenyl) -, -N (C3- alkynyl) - , -N (cyclo-C3-7-cycloalkyl) - or -N (C3-7-cycloalkyl-C -3-alkyl) -, 'a hydrogen atom may be attached to a nitrogen atom in one of the groups above mentioned for R 4 are replaced by a protective radical, R 6 and R 7, which may be the same or different, in each case a hydrogen atom, a C 1 -4 alkyl group or also, when Y 1 represents a carbon atom, the fluorine, an alkyl-C? -4-amino group or di- (alkyl-C? _4) -amino, the two C-4-alkyl groups being able to be linked together with formation of a ring and R8 and R9, which they may be the same or different, in each case a hydrogen atom or an alkyl-C? _3 group, where, if not otherwise mentioned, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above may be straight chain or branched, each methino group contained in the radicals mentioned above can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom may be linked together under the formation of a saturated or unsaturated 4- to 7-membered heterocyclic ring, all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above may be mono-, di- or tri-substituted additionally with halogen, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as as hydrates of salts, in particular their salts physiologically compatible with acids or "inorganic bases" cos or organic A third embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q, R2 and R3 are defined as mentioned above in the first or second embodiment and R1 means a heterocyclic aza, diaza, triaza or thiaza of 5 to 7 members, unsaturated once or twice, wherein the above-mentioned heterocycles are linked through a carbon or nitrogen atom, or are linked in a spirocyclic way through a carbon atom and a nitrogen atom, through a carbon atom and an oxygen atom or through a carbon atom and a sulfur atom, contain one or two carbonyl groups contiguous to a nitrogen atom, they may be substituted on a carbon atom with a phenyl, pyridinyl, diazinyl, thienyl, pyrrolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl or 1- (C 1 -4 alkyl) -pyrazolyl group, and where a double olefinic linkage of one of the above-mentioned unsaturated heterocycles may be fused with a ring of phenyl, naphthyl, pyridine, diazine, thienyl or quinoline, or with a ring of lH-quinolin-2-one optionally substituted on the nitrogen atom with a methyl group, wherein the phenyl, pyridinyl, diazinyl, thienyl, pyrrolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl or 1- (alkyl-C? -) -pyrazolyl groups contained in R1, as well as the heterocycles condensed with benzo, pyrido and diazino can esatr mono-, di- or trisubstituted in the carbon framework, additionally, with halogen, with alkyl-C6-6 groups, cyclo-C3_7-alkyl, cyclo-alkenyl-C3-7, alkoxy -C? _6, 'hydroxycarbonyl, C6_6-carbonyl alkoxy, cyano, hydroxy, amino, alkyl-C? _4-amino, di-alkyl-C? _4 amino, alkyl-C? _4-carbonylamino or alkyl-C? -carbonyl, wherein the substituents may be the same or different, wherein, if not otherwise mentioned, all radicals preceded mentioned under R 1 or the alkyl, alkenyl and alkynyl groups contained in R 1 can be straight-chain or branched, each methine group contained, in the abovementioned radicals it can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be bonded together under the formation of a 4- to 7-membered heterocyclic ring "*, saturated or unsaturated, and all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined under R1 can be mono-, di- or tri-substituted additionally with halogen, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. The present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q, R2 and R3 are defined as mentioned above in the first or second embodiment and R 1 means a 5- or 7-membered heterocycle diaza or triaza, unsaturated once, wherein the above-mentioned heterocycles are linked through a nitrogen atom, or are linked in a spirocyclic form "through an carbon and a nitrogen atom or through a carbon atom and an oxygen atom, ~ contain a carbonyl group contiguous to a nitrogen atom, can be further substituted on a carbon atom through a phenyl group, and wherein an olefinic double bond of one of the above-mentioned unsaturated heterocycles may be condensed with a phenyl, thienyl or quinoline ring, wherein the phenyl groups contained in R1, as well as the heterocycles condensed with benzo can be mono-, di- or tri-substituted in the carbon framework additionally with halogen, with methyl, methoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, alkyl-C? -amino groups, di- ( alkyl-C? -) -amino, acetylamino, acetyl, hydroxycarbonyl, C3-carbonyl alkoxy, -cyano, difluoromethoxy or trifluoromethoxy, wherein the substituents may be the same or different, but are preferably unsubstituted or are monosubstituted with an atom of halogen, with a methyl or methoxy group, wherein, if not otherwise mentioned, all the alkyl groups mentioned or contained in the radicals defined above under R 1 can be straight-chain or branched, each methino group contained in the radicals previously defined can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, its tautomers, its isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. A fifth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q, R2 and R3 are defined as mentioned above in the first or second embodiment and R1 means a 1,3-tetrahydro-l, 3-benzodiazepin-2-on-3-yl, 3,4-dihydro-1,3-quinazoline-2-on-group. 3- ilo, 5-phenyl-2,4-dihydro-l, 2,4-triazol-3-on-2-yl, 1,3-dihydro-imidazo [4, 5-c] quinolin-2-on- 3-yl, 1,3-dihydro-napht [1,2-d] imidazol-2-on-3-yl, 1,3-dihydro-benzimidazol-2-on-3-yl, 4-phenyl-1, 3-dihydro-imidazol-2-on-l.-yl, -3,4-dihydro-1-thieno [3,2-d] pyrimidin-2-on-3-yl or 3,4-dihydro-H- thieno [3, 4-d] pyrimidin-2-on-3-yl, wherein the heterocycles mentioned above under R 1 may be monosubstituted in the carbon framework additionally with a methoxy group, all the aromatic and heteroaromatic radicals mentioned or contained in the radicals above 'defined under R1' may be mono-, di- or tri-substituted additionally with halogen atoms, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases A sixth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, R1, R2 and R3 are defined as mentioned above in the first, second, third, fourth or fifth embodiment and signify (a) D, E, independently of one another, a methino group or the nitrogen atom and G a methino group substituted with the group Ra, M a methino group substituted with the group Rb, Q a methino group substituted with the group Rc, being able to mean one or two of the groups after G, M and Q in each case also a nitrogen atom, or (b) D and E, in each case, a methine group, could mean one of the groups D and E also a nitrogen atom, and G, M and Q in each case a nitrogen atom, wherein Ra, Rb and Rc, independently of each other, represents in each case a hydrogen atom or halogen, an alkyl-C? _4, group. C2-4 alkenyl, C2_ alkynyl, C3_6 cycloalkyl, C3-6 cycloalkenyl, cyano, hydroxy, hydroxy-C4-4alkyl, C3-4 hydroxy-alkenyl, C3-4 hydroxy-alkynyl , C 1 -4 alkoxy, C 1 -4 alkoxy-C 4 alkoxy, C 3-4 alkoxy-C 3-4 alkenyl, C 1 alkoxy-C 3 alkynyl, thiohydroxy, C 4 alkyl 4 thio, amino, alkyl-C? -amino, alkenyl-C3_4-amino, alkynyl-C3_-amino, di- (alkyl-C? _4) -amino, di- (alkenyl-C3_) -amino, di- (alkynyl) -C3_4) -amino, amino-alkyl-C? _4, alkyl-C? _3-amino-alkyl-C? -4, di- (alkyl-C? _3) -amino-alkyl-C? _4, amino-alkenyl -C3-, C3-4 alkyl-C3-amino-alkenyl, di- (C3-3 alkyl) -amino-C3- alkenyl, C3_4 amino-alkynyl, C3-amino-3-amino- C 3-4 alkynyl, di- (C 1 -C 4 alkyl) -amino-C 3-4 alkynyl, hydroxycarbonyl, phenylcarbonyl, pyridylcarbonyl, C 1 -C 4 alkylcarbonyl, formyl, C 4 -C 4 alkoxycarbonyl, alkenoxy -C3_4-carbonyl, C3_4-alkyloxycarbonyl, aminocarbonyl, alkyl-C4-4 aminocarbonyl, alkenyl-C3_4-aminocarbonyl, alkynyl-C3-aminocarbonyl, di- (alkyl-C? _ 4) -aminocarbonyl, di- (alkenyl-C3_) -aminocarbonyl, di- (C3-4 alkynyl) -aminocarbonyl, formylamino, alkyl-C? _ -cark-J-haloylamino, f-oryl-alkyl-C-4-amino, formyl-alkenyl -C3-amino, C3-4-amino-alkynyl-amino, alkyl-C? -carbonyl-alkyl-C? -amino, alkyl-C? _4-carbonyl-C3-4-alkenyl-amino, alkyl-C ? -4-carbonyl-alkynyl-C3_-amino, alkyl-C-sulfonyl, alkenyl-C2_4-sulfonyl, alkynyl-C2_4-sulfonyl, alkyl-C? _-Sulphonyl, alkenyl- C2_4-sulfinyl, alkynyl-C2_4- sulfinyl, C 1 -4-sulfonylamino alkyl, C 1 -4 alkylsulfonyl-C 1 alkylamino, C 1 alkylsulfonyl alkenyl C 3 amino, alkyl C 4 -sulfonyl- C3-amino alkynyl, aminosulfonyl, C 1 aminosulfonyl alkyl, di- (C 1 -4 alkyl) -aminosulfonyl, C 3 -4 alkenyl-aminosulfonyl, di- (C 3-4 alkenyl) -aminosulfonyl, C 3-4 alkynyl -aminosulfonyl or di- (C 3-4 alkynyl) -aminosulfonyl, with the provisos that, insofar as none of the groups D, E, G, M and Q represents a nitrogen atom, (i) Ra does not mean ahydrogen atom, when Rb, as well as Rc represent in each case an alkyl-C? _4 group, (ii) Rc does not mean a hydrogen atom, when Ra, as well as Rb represent in each case an alkyl-C? _4 group (iii) Ra does not adopt the terms of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoryl or trifluoromethyl group, when Rc represents a C-alkyl-, alkenyl-C2_4 or alkynyl-C2_ and Rb group represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, (iv) Rc does not take the meanings of a hydrogen, fluorine, chlorine, bromine or iodine atom or of a difluoro or trifluoromethyl group, when Ra represents a group alkyl-C? _4, C2_4 alkenyl or C2_4 alkynyl and Rb represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, wherein, if not otherwise mentioned, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the The aforementioned radicals for Ra, R and Rc can be straight-chain or branched, each methino group contained in the above-mentioned radicals can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each group Methyl can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be linked together under the formation of a 4 to 7 membered heterocyclic ring, saturated or unsaturated, the double and triple bonds of the C3-4 alkenyl or C3-alkynyl groups contained in the groups defined above for Ra, Rb and Rc are isolated from heteroatoms optionally also nests in these groups, and all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above may be mono-, di- or tri-substituted further with halogen, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. A seventh embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, R1, R2 and R3 are defined as mentioned above in the first, second, third, fourth or fifth embodiment and signify (a) D, E, independently of one another, a methine group or the nitrogen atom and G a methino group substituted with the group Ra, M a methine group substituted with the group Rb, Q a methine group substituted with the group Rc, where one or two of the groups G, M and Q may each also denote a nitrogen atom, or (b) D and E, in each case, a methino group, which may mean one of groups D and E also a nitrogen atom, and G, M and Q in each case a nitrogen atom, wherein Ra, Rb and Rc, independently of one another, each represent a hydrogen or halogen atom, an alkyl-C? _, alkenyl-C2_4, alkynyl-C2_4, cyclo-C3-6 alkyl, cycloalkyl group enyl-C3_6, cyano, hydroxy, hydroxy-C-2alkyl, hydroxy-C3-alkenyl, hydroxy-alkynyl-Cs, C-alkoxy, C4-alkoxy-C4-alkyl, amino, alkyl -C-amino, C 3-4 alkenyl-amino, C 3-4 alkynyl, di- (C 4 alkyl) -amino, di- (C 3-4 alkenyl) -amino, di- (C 3-4 alkynyl) - amino, amino-C-2-alkyl, C 1 -C 3 -alkylamino-C? _2 alkyl, di- (C--3 alkyl) -amino-C? -2-alkyl, C3-amino-alkenyl, alkyl -C3-amino-C3-alkenyl, di- (C3-3 alkyl) -amino-C3-alkenyl, C3-amino-alkynyl, C3-C3-amino-alkynyl-C3 alkyl, di- ( C3-alkyl) -amino-C3-alkynyl, hydroxycarbonyl, C, -C4-alkylcarbonyl, formyl, C4-C4-alkoxy, aminocarbonyl, C, -C4-aminocarbonyl, di- (C4-alkyl) -aminocarbonyl, formylamino, alkyl-C? _4-carbonylamino, f ormyl-alkyl-C? _4-amino, alkyl-C? _4-carbonyl-alkyl-C? _4-amino, alkyl-C? _-sulphonyl, alkyl -C? -4-sulfinyl, alkyl-C? 4-sulfonylamino, alkyl-C? _4-sulf onyl-alkyl-C? _4-amino, aminosulfonyl, alkyl-C? _4-aminosulfonyl or di- (alkyl-C? _4) -am inosulfonyl, with the conditions that, to the extent >; in which none of the groups D, E, G, M and Q represents a nitrogen atom, (i) Ra does not mean a hydrogen atom, when Rb, as well as Rc represent in each case a C-4 alkyl group (ii) Rc does not mean a hydrogen atom, when Ra, as well as Rb represent in each case a C-4 alkyl group, (iii) Ra does not take the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or a difluoro or trifluoromethyl group, when Rc represents a C alquilo -4 -4 alkyl, C 2-4 alkenyl or C 2-4 alkynyl group and R b represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, ( iv) Rc does not assume the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoro or trifluoromethyl group, when Ra represents a C-alkyl-, C2-4-alkenyl or C2-4 alkynyl and Rb group represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, wherein, if not otherwise mentioned, all alkyl, alkenyl and alkynyl groups When the radicals mentioned above for Ra, Rb and Rc are linear or branched, each methino group contained in the radicals mentioned above may be substituted with a fluorine atom, each methylene group may be substituted with up to 2 atoms. of fluorine and each methyl group can be substituted with up to 3 fluorine atoms, as well as dds alkyl and alkenyl groups attached to a nitrogen atom can be attached to each other under the formation of a 4 to 7 membered heterocyclic ring, saturated or unsaturated, the double and triple bonds of the alkenyl-C3_4 or alkynyl-C3_4 groups contained in the groups defined above for Ra, Rb and Rc are isolated from heteroatoms optionally also contained in these groups, their tautomers, their isomers, their diastereomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiological salts Logically compatible with inorganic or organic acids or bases. An eighth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, R1, R2 and R3 are defined as mentioned above in the first, second, third, fourth or fifth embodiment and signify (a) D, E, independently of one another, a methino group or the nitrogen atom and G a methino group substituted with the group R, M a methine group substituted with the group Rb, Q a methine group substituted with the group Rc, where one or two of the groups G, M and Q may also each denote a nitrogen atom, or (b) D and E, in each case, a methino group, which may mean one from groups D and E also a nitrogen atom, and G, M and Q in each case a nitrogen atom, wherein Ra, R and Rc, independently of each other, each represent a hydrogen or halogen atom, an alkyl-C? -, alkenyl-C2_4, alkynyl-C2-4, cyclo-alkyl-C3-6 / cyclo-alken group ilo-C3_6, cyano, hydroxy, hydroxy-C? -2-alkyl, C alco-4 alkoxy, amino, C--4-amino-alkyl, di- (C alqu-4-alkyl) -amino, amino-alkyl- C_2, alkyl-C? -3-amino-C? _2 alkyl, di- (C? -3 alkyl) -amino-C? -2 alkyl, hydroxycarbonyl, C? _4-carbonyl alkyl, formyl, alkoxy -C? _4-carbonyl, aminocarbonyl, alkyl-C? _4-aminocarbonyl, di- (alkyl-C? _4) -aminocarbonyl, formylamino, alkyl-C? _4-carbonylamino, formyl-alkyl-C? -4-amino or alkyl-C? -4-carbonyl-C1-4-alkyl-amino, with the provisos that, insofar as none of the groups D, E, G, M and Q represents a nitrogen atom, (i) Ra does not means a hydrogen atom, when Rb, as well as Rc represent in each case a C-4 alkyl group, (ii) Rc does not mean a hydrogen atom, when Ra, as well as Rb represent in each case a C-alkyl group ? -, (iii) Ra does not assume the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoro or trifluoromethyl group, when Rc represents an alkyl-C group ? _, C2- alkenyl or C2-4 alkynyl and Rb represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, (iv) Rc does not assume the meanings of a hydrogen, fluorine, chlorine, bromine or iodine atom or of a difluoro or trifluoromethyl group, when Ra represents a C 1 -4 alkyl, C 2-4 alkenyl or C 2-4 alkynyl group and R represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, wherein, if it was not mentioned otherwise, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above for R, Rb and Rc can be straight chain or branched, each methino group contained in the radicals mentioned above can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be attached to each other under formation of a 4 to 7 membered heterocyclic ring, saturated or unsaturated, its tautomers, its isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiological salts compatible with inorganic or organic acids or bases. A ninth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, R1, R2 and R3 are defined as mentioned above in the first, second, third, fourth or fifth embodiment and signify (a) D, E, independently of one another, a methine group or the nitrogen atom and G a methino group substituted with the group Ra, M a methine group substituted with the group Rb, Q a methine group substituted with the group Rc, where one or two of the groups G, M and Q may each also denote a nitrogen atom, or (b) D and E, in each case, a methino group, which may mean one of groups D and E also a nitrogen atom, and G, M and Q signify in each case a nitrogen atom, where R a, R b and R c, independently of each other, represent a hydrogen atom or halogen, a group methyl, difluoromethyl, trifluoromethyl, ethyl, vinyl, ethynyl, cyano, hydro oxy, methoxy, difluoromethoxy, trifluoromethoxy, amino, methylamino or dimethylamine, with the provisos that, insofar as none of the groups D, E, G, M and Q represents a nitrogen atom, (i) Ra does not mean a hydrogen atom, when Rb, as well as Rc represent in each case a methyl or ethyl group, (ii) Rc does not mean a hydrogen atom, when Ra, as well as Rb represent in each case a methyl or ethyl group, (iii) Ra does not assume the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoro- or trifluoromethyl group, when R represents a methyl, ethyl, vinyl or ethynyl group and Rb represents an atom of chlorine or bromine, an amino, methylamino or hydroxy group, (iv) Rc does not take the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoro- or trifluoromethyl group, when Ra represents a group methyl, ethyl, vinyl or ethynyl and R represents a chlorine or bromine atom, an amino, methylamino or hydro oxy, its tautomers, its isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. A tenth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q and R1 are defined as mentioned above in the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment ^ and R2 represents the hydrogen atom, or a phenylmethyl group or a C2-7 alkyl group, which in the? position can be substituted with a cyclo-C3-7-alkyl group, C3_7-cycloalkenyl, phenyl, pyridinyl, hydroxy, amino, alkyl-C6-amino, di- (C6-alkyl) -amino, hydroxycarbonyl, C6-C6-alkoxy, aminocarbonyl, aminocarbonylamino, alkyl-C? -6-amino, 4-morpholinyl, wherein the phenyl and pyridinyl radicals mentioned in the groups defined above for R2 or contained as substituents may be mono-, di- or tri-substituted additionally in the carbon framework with halogen, with C 1 -C 3 -alkyl, C 1 -C 3 -alkoxy, hydroxy, amino, C 1 -C 3 -alkylamino, di- (C 3 -alkyl) -amino, C 1 -3 amino-alkyl, alkyl-C? -3-amino-C? -3 alkyl, 'di- (C? -3 alkyl) -amino-C? -3 alkyl, C? -3-carbonylamino alkyl, C-alkyl? _3-carbonyl-C 1 -C 3 -amino, aminocarbonyl, C 1 -C 3 -aminocarbonyl or di- (C 1 -C 3 alkyl) -aminocarbonyl, and the substituents can be the same or different, R 3 represents the hydrogen * or an alkyl-C group -3 or R2 and R3, together with the included nitrogen atom, a radical of the formula where Y1 represents the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the numbers 0 or 1, oqyr, when Y1 represents the atom of nitrogen, the numbers 1 or 2, R4 the hydrogen atom, an amino group, alkyl-C? -4-amino, di- (alkyl-C? _4) -amino, alkyl-C? _6, a cyclo- C3-7alkyl or C3_7alkenyl-cycloalkyl optionally substituted with a hydroxycarbonyl, C6-6alkoxycarbonyl, hydroxycarbonyl-C3-3alkyl or C6-6alkoxy -6-carbonyl-C3-alkyl group , an amino-C2- alkyl, C4-4alkylamino-C2_7alkyl, di- (C- 4alkylamino) -alkyl-C2_7alkyl, alkyl-C-4-aminocarbonyl, di- ( alkyl-C? _4) -aminocarbonyl, aminocarbonyl-C-3 alkyl, alkyl-Ci- -aminocarbonyl-C? _3 alkyl, di- (C? -4 alkyl) -aminocarbonyl-C? -3 alkyl, aminocarbonylamino-C 1 -C 3 -alkyl, -alkoxy-C 6 -carbonyl, alkoxy-C 6 -carbonyl-C 1 -3 -alkyl or hydroxycarbonyl-C-3 -alkyl, a group phenyl, pyridinyl or diazinyl, which in each case can be substituted with a halogen, with a C-3-alkyl, C-3-alkoxy, hydroxy, amino, alkyl-C? -4-amino, di- ( alkyl-C? _4) -amino, amino-C? -3 alkyl, C? -4-amino-C-C3 alkyl, di- (C? _4 alkyl) -amino-C-alkyl? -3, a heterocycle chosen from an azacycloalkyl group of 4 to 7 members, an oxaza group, S, S-dioxotiaza and diazacycloalkyl of 6 to 7 members, and an azabicycloalkyl group of 7 to 9 members, the monocyclic and bicyclic heterocycles being bound above mentioned, through a nitrogen or carbon atom, to Y1 in the formula (II), in the aforementioned monocyclic and bicyclic heterocycles a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom can be substituted with one or two fluorine atoms and the aforementioned monocyclic and bicyclic heterocycles may be substituted, once or twice, with hi groups droxy, C 1 -C 3 -alkyl or hydroxyalkyl-C 3 -3, or once with a benzyl group, cyclo-C 3-6 alkyl, hydroxycyclo-C 3-6 alkyl, cyclo-C 3-6 alkyl-C 3 alkyl, alkyl C 4 -carbonyl, C 1 -C 4 alkylcarbonyl C 3 alkyl, hydroxy, C 1 alkoxy, amino, alkyiCamino, di- (C 4 alkyl) amino, alkoxy-C? -3-carbonyl, hydroxycarbonyl-carbonyl, alkoxy-C? _3-carbonyl-carbonyl, hydroxycarbonyl-C -3-alkyl, C3-alkoxy-carbonyl-C? _3 alkyl, hydroxycarbonyl-C-alkyl ? -3-carbonyl, alkoxy-C? _3-carbonyl-alkyl-C? -3-carbonyl, aminosulfonyl, alkyl-C? -4-aminosulfonyl, di- (C4-alkyl) -aminosulfonyl, alkyl-C1_3- sulfonyl, cycloalkyl-C3-7-sulfonyl, aminocarbonyl-C3-3alkyl, alkyl-C4-4aminocarbonyl-C3-alkyl, di- (C3-4alkyl) -aminocarbonyl-alkyl- C _ 3, hydroxyaminocarbonyl-C 1 -C 3 -alkyl, C 1 -C 3 -aminocarbonyl-C 1 -C 3 -alkyl or hydroxy- (C 1 -C 3 alkyl) -aminocarbonyl-C 1 -C 3 alkyl, or else, when Y 1 represents the carbon atom, the hydroxycarbonyl group, aminomethyl, quil-C? _ 4-aminomethyl or di- (alkyl-C? 4) -aminomethyl, R5 a hydrogen atom, an alkyl radical-C? _3 or, when Y1 represents a nitrogen atom, also a pair of electrons free, R6 and R7, which may be the same or different, in each case a hydrogen atom, a C3-alkyl group or also, when Y1 represents a carbon atom, an amino group, alkyl-C? _3-amino or di- (alkyl-C? -3) -amino, the two C-C3-alkyl groups being able to be linked together with formation of one ring and R8 and R9, which may be the same or different, represent in each case a hydrogen atom or a C-3 alkyl group, wherein, if not otherwise mentioned, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above may be straight chain or branched, each group methino contained in the above-mentioned radicals can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom may be linked together under the formation of a saturated or unsaturated 4- to 7-membered heterocyclic ring, all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above may they may be mono-, di- or tri-substituted additionally with halogen, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers ,. their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. An eleventh embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q and R1 are defined as mentioned above in the first, second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment, and R2 represents the hydrogen atom, or a phenylmethyl group or a C2_7 alkyl group, which in position? may be substituted with a group C3_7-alkyl-cycloalkenyl-C3_7 cycloalkyl, phenyl, pyridinyl, hydroxy, amino, alkyl-C? -6-amino, di- (alkyl-Ci-β) -amino, hydroxycarbonyl, alkoxy -C? _6-carbonyl, aminocarbonyl, aminocarbonylamino, alkyl-C? _6-amino, 4-morpholinyl, wherein the phenyl and pyridinyl radicals mentioned in the groups defined above for R2 or contained as substituents may be mono-, di- or further tri-substituted in the carbon framework with halogen, with C 1 -C 3 alkyl, C 1 -C 3 alkoxy, hydroxy, amino, C 1 -C 3 alkylamino, di- (C 1 -C 3 alkyl) amino, amino-C 1 -C 3 -alkyl, C 1 -C 3 -alkylamino-C 3 -alkyl, di- (C 1 -C 3 alkyl) -amino-C 1 -C 3 -alkyl, C 1 -C 3 -carbonylamino , C 1 -C 3 alkylcarbonyl-C 1 -C 3 -amino, aminocarbonyl, C 1 -C 3 -aminocarbonyl or di- (C 1 -C 3 alkyl) -aminocarbonyl, and the substituents may be the same or different, R 3 represents the hydrogen atom vo a C-3-alkyl group or R2 and R3, together with the nitrogen atom included, a radical of the general formula in which Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the numbers 0 or 1, oqyr, when Y1 represents the atom of nitrogen, the numbers 1 or 2, R4 the hydrogen atom, an amino group, alkyl-C? _4-amino, di- (alkyl-C? _4) -alkylamino, alkyl-C? _6, cyclo-alkyl-C3 -, C3_7-cyclo-alkenyl, C2_7-amino-alkyl, C-4-amino-C2_7-alkyl, di- (C 1 -4 -alkylamino) - C2_7-alkyl, C-4 alkyl- aminocarbonyl, di- (C 1 -4 alkyl) -aminocarbonyl, aminocarbonyl-C 1 -C 3 alkyl, C 1 alkyl 4-aminocarbonyl-C 1 -C 3 alkyl, di- (C 1 -C 4 alkyl) -aminocarbonyl-C 1 -C 3 alkyl, C 1 -C 3 aminocarbonylamino, C 1 -C 6 alkoxy 6-car-bonyl, alkoxy-C? -6-carbonyl-C? _3-alkyl or hydroxy-carbonyl-C? -3 alkyl, a phenyl, pyridinyl or diazinyl group, which in each case can be substituted with a halogen, with a -3-C-alkyl group, -3-C-alkoxy, hydroxy, amino, alkyl-C? 4-amino, di- (alkyl-C? 4) -amino, amino-alkyl-C? -3, alkyl-C-amino-alkyl-C? -3, di- (alkyl-C? _4) -amino -alkyl-C? _3, a heterocycle selected from an azacycloalkyl group of 4 to 7 members, an oxaza- and diaza-cycloalkyl group of 6 to 7 members and an azabicycloalkyl group of 7 to 9 members, the monocyclic and bicyclic heterocycles being bound above mentioned, through a nitrogen or carbon atom, to Y1 in the formula (II), in the aforementioned monocyclic and bicyclic heterocycles a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom can be substituted with one or two fluorine atoms and - the above-mentioned monocyclic and bicyclic heterocycles may be substituted once or several times, for example one to three times, with C 1 -C 3 -alkyl groups, or once with a benzyl, cycloalkyl group -C3_6, cyclo-alkyl-C3_6 ~ alkyl-C? -3, alkyl-C? -4-carbonyl, hydroxy, alkoxy-C? _4, amin or, C 1 -4-amino alkyl, di- (C 4 alkyl) -amino, hydroxycarbonyl, C 1 -C 3 -alkoxy, hydroxycarbonyl-carbonyl, C 1 -C 3 -carbonylcarbonyl, hydroxycarbonyl-alkyl- C? -3, alkoxy-C? _3-carbonyl-C? _3 alkyl or C-sulphonyl-alkyl, or else, when Y1 represents the carbon atom, the hydroxycarbonyl, aminomethyl, alkyl-C? -4-aminomethyl group or di- (alkyl-C? _4) -aminomethyl, R5 a hydrogen atom, a C-alkyl radical -3 or, when Y1 represents a nitrogen atom, also a pair of free electrons, R6 and R7, which can they are the same or different, in each case a hydrogen atom, a C-3 alkyl group or also, when Y 1 represents a carbon atom, an alkyl-C? -3 amino group or di- (alkyl-C? -3) -amino, the two C-3-alkyl groups being able to be linked together with the formation of a ring and R 8 and R 9, which may be the same or different, represent in each case a hydrogen atom or a C-alkyl group? 3, where, if not mentioned otherwise, t All the alkyl, alkenyl and alkynyl groups mentioned or contained in the aforementioned radicals can be straight chain or branched, each methino group contained in the radicals mentioned above can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be linked together low, formation of a 4 to 7 membered heterocyclic ring, saturated or unsaturated, all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above may be mono-, di- or tri-substituted additionally with halogen, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. A twelfth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q and R1 are defined as mentioned above in the first , second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment, and R2 represents the hydrogen atom, or a phenylmethyl group or a C2_7 alkyl group, which in position? can be substituted with a phenyl, amin, C 1 -C 6 -amino, di- (C 1 -C 6 alkyl) amino group, wherein the aforementioned phenyl and phenylmethyl groups can be mono- or disubstituted further in a aromatic carbon atom with halogen, with C alquilo _3 alkyl, C alco _3 alkoxy, C amino _3 amino-alkyl, C-_3-amino-C-_3 alkyl or di- (C--alkyl? -3) -amino-C-3 alkyl, and the substituents may be the same or different, R 3 represents the hydrogen atom or a C-3 alkyl group or R 2 and R 3, together with the included nitrogen atom, a radical of the general formula in which Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the numbers 0 or 1, oqyr, when Y1 represents the atom of nitrogen, the numbers 1 or 2, R4 the hydrogen atom, an amino group, alkyl C? -4-amino, di- (C? _4 alkyl) -alkylamino, C? _6 alkyl, a C3_7 cycloalkyl group or C3_7 cycloalkenyl optionally substituted with a hydroxycarbonyl group, C? -6-carbonyl alkoxy , hydroxycarbonyl-C? -3 alkyl or C? -6-carbonyl-C? _3 alkyl, an amino-C2_7 alkyl group, C? _-amino-C2_7 alkyl, di- (C? -4-amino alkyl) -alkyl C2_7, C6-C6-alkoxy, C-6-alkoxy-C3-alkyl or hydroxycarbonyl-C3-3alkyl, a phenyl or pyridyl group, which in each case can be substituted with a halogen, with an alkyl group -C? -3, alkoxy-C? _3, amino, alkyl-C? -amino, di- (alkyl-C? _) -amino, a heterocycle chosen from an azacycloalkyl group of 6 to 7 members, a group S , S-dioxothiaza and diazacycloalkyl of 6 to 7 members, and an azabicycloalkyl group of 7 to 9 members, the aforementioned monocyclic and bicyclic heterocycles being linked, through a nitrogen or carbon atom, to Y1 in the formula (II) ), in monocyclic heterocycles Above mentioned bicyclic and a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom can be substituted with one or two fluorine atoms and the aforementioned monocyclic and bicyclic heterocycles can be substituted one or two. sometimes with a hydroxy group, C-alkyl -3 * or hydroxy-C-alkyl-3, with a benzyl group, cyclo-C3_6 alkyl, hydroxy-C3_6-cycloalkyl, cyclo-C3-6 alkyl-alkyl -C? _3, alkyl-C? -3-carbonyl-C? -3 alkyl, amino, alkyl-C? _4-amino or di- (C? _4 alkyl) -amino, hydroxycarbonyl-carbonyl, alkoxy- C6-carbonylcarbonyl, hydroxycarbonyl-alkyl-C3-carbonyl, alkoxy-C3-carbonyl-alkyl-C3-carbonyl, aminosulfonyl, alkyl-C4-aminosulfonyl, di- ( alkyl-C? _4) -aminosulfonyl, cycloalkyl-C3_7-sulfonyl, aminocarbonyl-C? -3 alkyl, alkyl-C? -aminocarbonyl-C? -3 alkyl, di- (C? -4 alkyl) ) -aminocarbonyl-C-3-alkyl, hydroxy-aminocarbonyl-C-3-alkyl, C 1 -3-aminocarbonyl-C 1 -C 3 -alkyl or hydroxy- (C 1 -C 3 alkyl) -aminocarbonyl-C 1 -C 3 -alkyl , or also, when Y1 represents the carbon atom, the hydroxycarbonyl, aminomethyl, alkyl-C? 4-aminomethyl or di- (alkyl-C? 4) -aminomethyl group, R5 a hydrogen atom or, when Y1 represents a Nitrogen atom, also a couple of free electrons, R6 and R7, which may be the same or different, in each case a hydrogen atom, a C-3 alkyl group or also, when Y1 represents a carbon atom, an alkyl-C-3 group amino or di- (alkyl-C? _3) -amino, the two C-3-alkyl groups being able to be linked together with formation of one ring and R8 and R9, which may be the same or different, represent in each case a hydrogen atom or a C3_3 alkyl group, their tautomers, their isomers, their diastereomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with acids or inorganic or organic bases. A thirteenth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q and R1 are defined as mentioned above in the first , second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment, and R2 represents a phenylmethyl group or a C2- alkyl group, which in position? it can be substituted with a phenyl, amino, alkyl-C6- amino-amino, di- (C6-6 alkyl) amino group, wherein the aforementioned phenyl and phenylmethyl groups can be substituted on an aromatic carbon atom with an amino-C 1 -C 3 -alkyl group, Cs-amino-alkyl-Cx-s alkyl or di- (C 1 -C 3 alkyl) -amino-C 1 -C 3 alkyl, R 3 represents the hydrogen atom or an alkyl group -C? _3 or R2 and R3 / together with the included nitrogen atom, a radical of the general formula where R6 and R7 in each case mean a hydrogen atom or a dimethylamino group, R8 and R9 in each case the hydrogen atom, and (a) Y1 the carbon atom, qyr the numbers 0 or 1, R4 the atom of hydrogen, a phenyl, pyridinyl or pyrimidinyl group, which in each case may be substituted with a halogen, with an amino, methylamino, dimethylamino, methyl or methoxy group, a hydroxy, 2-diethylamino-ethyl, amino, ethylamino, dimethylamino group , diethylamino, pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-l-yl-pyrrolidin-1-yl yl 2-methoxycarbonyl-pyrrolidin-l-2-hydroxycarbonyl-, piperidin-1-yl, 4, 4-dimethylpiperidine -l-yl, 4-amino-4-methyl-piperidin-1-yl, 2-hydroxycarbonyl-piperidin-1-yl, 2-methoxycarbonyl-piperidin-1-yl, 4-hydroxymethyl-piperidin-1-yl, 4 - (1-hydroxycyclopropyl) -piperidin-1-yl, 4-amino-piperidin-1-yl, 4-methylamino-piperidin-1-yl, 4-dimethylamino-piperidin-1-yl, 4-hydroxy-4-methyl -piperidin-1-yl, 4-hydroxy-4-ethyl-piperidin-1-yl, -hydroxy-4-trifluorome til-piperidin-1-yl, 4-hydroxy-4-hydroxymethyl-piperidin-1-yl, 3-amino-piperidin-1-yl, 3-methylamino-piperidin-1-yl, 3-dimethylamino-piperidin-1- ilo, 3-hydroxy-piperidin-1-yl, 4-hydroxy-piperidin-1-yl, 4-hydroxycarbonylmethyl-piperidin-1-yl, 4-ethoxycarbonylmethyl-piperidin-1-yl, perhydro-azepin-1-yl, perhydro-1, 4-diazepin-1-yl, 4-methyl-perhydro-l, 4-diazepin-1-yl, l-methyl-piperidin-4-yl, piperidin-4-yl, l-ethylpiperidin-4 yl, 1- (2-hydroxyethyl) piperidin-4-yl, l-cyclopropyl-piperidin-yl-4, 1-cyclopropylmethyl-piperidin-4-yl-1-methylsulfonyl-piperidin-yl-4, l-etilsulfonil- piperidin-4-yl, 1-isopropylsulfonyl-piperidin-4-yl, l-cycle? ropilsulfonil-piperidin-4-yl, 4-hydroxy-1-methylsulfonyl-piperidin-4-yl 1-aminosulfonyl-piperidin-4- yl, 1- (methylaminosulphonyl) -piperidin-4-yl, 1- (dimethylaminosulfonyl) yl-l-ethoxycarbonylmethyl-piperidin-4 -piperidin-4-yl, 1-hidroxicarbonilmeti1-piperidin-4-, l- (2 -hydroxycarbonylethyl) -piperidin-4-yl, 1- (2-ethoxycarbonylethyl) -piperi din-4-yl, 1- (3-hydroxycarbonyl-propionyl) -piperidin-4-yl, 1- (3-ethoxycarbonyl-propionyl) -piperidin-4-yl, 1- (hydroxycarbamoyl-methyl) -piperidin-4- ilo, 1- (hydroxy-methyl-carbamoyl-methyl) -piperidin-4-yl, 1- (methoxy-arbamoyl-methyl) -piperidin-4-yl, l-oxalyl-piperidin-4-yl, l-ethoxyoxalyl-piperidin- 4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 4-cyclopropylmethyl-piperazin-1-yl, 4-ethyl-piperazin-1-yl, 4- (2-hydroxyethyl) -piperazin- 1-yl, piperazin-methylsulfonyl-l-yl 4-yl 4-aminosulfonyl-piperazin-1-yl piperazin-1-4-cyclopropyl-piperazin-1-yl,,, 4- (methylaminosulfonyl), 4- (dimethylaminosulfonyl ) -piperazin-1-yl, 4-hydroxycarbonylmethyl-piperazin yl-l-yl 4-ethoxycarbonylmethyl-piperazin-l-yl -piperazine-1-, 4- (2-hidroxicarboniletil), 4- (2-ethoxycarbonylethyl) - piperazin-1-yl, 4- (3-hydroxycarbonyl-propionyl) -piperazin-1-yl, 4- (3-ethoxycarbonyl-propionyl) -piperazin-1-yl, 4- (hydroxycarbamoyl) -methyl-piperazin-1- ilo, 4- (hydroxy-methyl-carbamoyl) -methyl-piperazin-1-yl, 4 - (methoxycarbamoyl) -methyl-piperazin-1-yl, 1,2-dimethyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, 3, 4, 5-trimethyl-piperazin-1-yl, 3 , 5-dimethyl-piperazin-1-yl, 3, 3, 4-trimethyl-piperazin-1-yl, 3, 3-dimethyl-piperazin-1-yl, 3, 3, 4, 5, 5-pentylmethyl- piperazin-1-yl, 3,3,5,5-tetramethyl-piperazin-1-yl, 3,3,3-trifluoro-2-oxo-propyl) -piperazin-1-yl, morpholin-4-yl, 1 , 1-dioxo-l? -thiomorpholin-4-yl, tetrahydropyran-4-yl, 4,4-difluoro-piperidin-1-yl, 8-methyl-8-aza-bicyclo [3.2.1] oct-3-yl, 8-aza-bicyclo [3.2.1] oct-3-yl, azetidin-1-yl, 1- (methoxycarbonylmethyl) -piperidin-4-yl, 1- (ethoxycarbonylmethyl) -piperidin-4-yl, 4- (ethoxycarbonylmethyl) -piperazin-1 -yl, l-hydroxycarbonylmethyl-piperidin-4-yl or 4-hydroxycarbonylmethyl-piperazin-1-yl, and R 5 a hydrogen atom, or (b) Y 1 a nitrogen atom, q and r the numbers 1 or 2, R 4 the hydrogen atom, a phenyl, pyridinyl or pyrimidinyl group, which in each case may be substituted with a halogen, with an amino, methylamino, dimethylamino, methyl or methoxy group, a methyl, ethyl, isopropyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-hydroxycarbonylmethyl-cyclohexyl, 4-ethoxycarbonylmethyl-cyclohexyl, cyclopropylmethyl, 2-diethylamino-propyl, 1-quinuclidin-3-yl, tetrahydropyran-4-yl, l-piperidin-4-yl, l-methyl-piperidin-4- ilo, l-ethyl-piperidin-4-yl, 1- (2-hydroxyethyl) -piperidin-4-yl, 1-methylsulfonyl-piperidin-4-yl, l-aminosulfonyl-piperidin-4-yl, 1- (methylaminosulfonyl) -piperidin-4-yl, 1- (dimethylaminosulfonyl) -piperidin-4-yl, l-hydroxycarbonylmethyl-piperidin-4-yl, l-ethoxycarbonylmethyl-piperidin-4-yl, 1- (2-hydroxycarbonylethyl) ) -piperidin-4-yl, * l- (2-ethoxycarbonylethyl) -piperidin-4-yl, 1- (3-hydroxycarbonyl-propionyl) -piperidin-4-yl, 1- (3-ethoxycarbonyl-propionyl) -piperidine -4-yl, 1- (hydroxycarbamoyl-methyl) -piperidin-4-yl, 1- (hydroxy-methyl-carbamoyl-methyl) -piperidin-4-yl, 1- (methoxycarbamoyl-methyl) -piperidin-4-yl , l-cyclopropyl-piperidin-4-yl, 1-cyclopropylmethyl-piperidin-4-yl, l-hydroxycarbonylmethyl-piperidin-4-yl or l-ethoxycarbonylmethyl-piperidin-4-yl and R5 represents a pair of free electrons, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. A fourteenth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A, X, D, E, G, M, Q and R1 are defined as mentioned above in the first , second, third, fourth, fifth, sixth, seventh, eighth or ninth embodiment, and R2 represents a phenylmethyl group or a C2_7-alkyl group, which in position? it can be substituted with a phenyl, amino, alkyl-C6- amino-amino, di- (C6-6 alkyl) amino group, wherein the aforementioned phenyl and phenylmethyl groups can be substituted on an aromatic carbon atom with an amino-C 1 -C 3 -alkyl group, C 1 -C 3 -alkylamino-C 1 -C 3 alkyl or di- (C 1 -C 3 alkyl) -amino-C 1 -C 3 alkyl, R 3 represents the hydrogen atom or an alkyl group-C3 -3 or R2 and R3, together with the included nitrogen atom, a radical of the general formula where R6 and R7 in each case mean a hydrogen atom or a dimethylamino group, R8 and R9 in each case the hydrogen atom, and (a) Y1 the carbon atom, qyr the numbers 0 or 1, R4 the atom of hydrogen, a phenyl, pyridinyl or pyrimidinyl group, which in each case may be substituted with a halogen, with an amino, methylamino, dimethylamino, methyl or methoxy group, a hydroxy, 2-diethylamino-ethyl, amino, methylamino, dimethylamino group , diethylamino, pyrrolidin-1-yl, piperidin-1-yl, 4-amino-piperidin-1-yl, 4-methylamino-piperidin-1-yl, 4-dimethylamino-piperidin-1-yl, 3-amino-piperidin -1-yl, 3-methylamino-piperidin-1-yl, 3-dimethylamino-piperidin-1-yl, perhydro-azepin-1-yl, perhydro-1,4-diazepin-1-yl, 4-methyl-perhydro -l, 4-diazepin-1-yl, l-methyl-piperidin-4-yl, piperidin-4-yl, l-ethylpiperidin-4-yl, l-cyclopropyl-piperidin-4-yl, l-cyclopropylmethyl-piperidin -4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 4-cyclopropylmethyl-piperazin-1-yl, 4-ethyl-pip Ezin-1-yl, 4-cyclopropyl-piperazin-1-yl, 1,2-dimethyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, 3, 4, 5-trimethyl-piperazin-1- ilo, 3, 5-dimethyl-piperazin-1-yl, 3, 3, 4-trimethyl-piperazin-1-yl, 3, 3-dimethyl-piperazin-1-yl, 3, 3, 4, 5, 5- pentamethyl-piperazin-1-yl, 3,3,5,5-tetramethyl-piperazin-1-yl, morpholin-4-yl, 4-difluoro-piperidin-1-yl, 8-methyl-8-aza-bicyclo [3.2.1] oct-3-yl, 8-aza-bicyclo [3.2.1] oct-3-yl, azetidin-1-yl, 1- (methoxycarbonylmethyl) -piperidin-4-yl, 1- (ethoxycarbonylmethyl) -piperidin-4-yl, 4- (ethoxycarbonylmethyl) -piperazin-1-yl, l-hydroxycarbonylmethyl-piperidin-4-yl or 4-hydroxycarbonylmethyl-piperazin-1-yl, and R 5 a hydrogen atom, or (b) Y 1 a nitrogen atom, q and r the numbers 1 or 2, R 4 the hydrogen atom, a phenyl, pyridinyl or pyrimidinyl group, which in each case can be substituted with a halogen, with an amino group, methylamino, dimethylamino, methyl or methoxy, a methyl, ethyl, isoproyl, cyclopropyl, cyclopropylmethyl, 2-diethylamino-propyl, l-quinuclidin-3-yl, l-piperidin-4-yl group, l- methyl-piperidin-4-yl, 1-ethyl-piperidin-4-yl, l-cyclopropyl-piperidin-4-yl, 1-cyclopropylmethyl-piperidin-4-yl, 1-hydroxycarbonylmethyl-piperidin-4-yl or l- ethoxycarbonylmethyl-piperidin-4-yl and R5 represents a pair of free electrons, their tautomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with acids or inorganic or organic bases. A fifteenth embodiment of the present invention consists of the compounds of the general formula (I) above, in which D, E, G, M, Q, R1, R2 and R3 are defined, as mentioned above in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth or thirteenth embodiment and A and X represent in each case an oxygen atom, its tautomers, its isomers, its diastereomers , its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. A sixteenth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A and X represent in each case an oxygen atom, R1 means a group 1, 3, 4, 5-tetrahydro -l, 3-benzodiazepin-2-on-3-yl, 3,4-dihydro-l-yl-quinazolin-2-on-3-yl, 5-phenyl-2,4-dihydro-l, 2-triazole -3-on-2-yl, 1,3-dihydro-imidazo [4, 5-c] quinolin-2-on-3-yl, 1,3-dihydro-napht [1,2-d] imidazole-2 -on-3-yl, 1,3-dihydro-benzimidazol-2-on-3-yl, 4-phenyl-1,3-dihydro-imidazol-2-on-l-yl, -3,4-dihydro- I-thieno [3,2-d] pyrimidin-2-on-3-yl or 3,4-dihydro-Ify-thieno [3,4-d] pyrimidin-2-on-3-yl, and R2 and R3 are defined as mentioned above in the first or second embodiment, wherein the heterocycles mentioned above under R1 may be monosubstituted in the carbon framework additionally with a methoxy group, and wherein all the aromatic and heteroaromatic radicals mentioned or contain The radicals defined above under Rl and the parts of the molecule can be mono-, di- or tri-substituted additionally with halogen atoms, with cyano or hydroxy groups, and the substituents can be the same or different, and wherein in these and in all the embodiments mentioned above, an extraordinary importance is given in each case to the compounds in which D and E represent in each case a methino group, G represents a methino group substituted with the group Ra, M represents a methino group substituted with the group Rb, Q represents a methino group substituted with the group Rc and Ra, Rb and Rc, independently of each other, each representing a hydrogen or halogen atom, a C-alkyl group 4, C2_4 alkenyl, C2_4 alkynyl, C3_6 cycloalkyl, C3_6 cycloalkenyl, cyano, hydroxy, hydroxy-C2_2alkyl, C3-hydroxy-alkenyl, C3-hydroxy-alkynyl, alkoxy- C? _4, C1-4 alkoxy-C1-2 alkyl, amino, alkyl-C? _4-amino , alkenyl-C3-amino, C3-4 alkynyl-amino, di- (C3-4 alkyl) -amino, di- (C3-4 alkenyl) -amino, di- (C3-4 alkynyl) -amino, amino-alkyl-C? _2, alkyl-C? _3-amino-alkyl-C? _2, di- (alkyl-C? -3) -amino-alkyl-C? _2, amino-alkenyl-C3, alkyl-C? _3-amino-alkenyl-C3, di- (C3-alkyl) -amino-alkenyl-C3, amino-alkynyl-C3, alkyl-C ~ 3-amino-alkynyl-C3, di- (alkyl) -C? -3) -amino-C3-alkynyl, hydroxycarbonyl, C4-alkylcarbonyl, formyl, C4-4alkoxycarbonyl, aminocarbonyl, C3-4alkylaminocarbonyl, di- (C-alkyl) ? -4) -aminocarbonyl, formylamino, alkyl-C? _ -carbonylamino, formyl-alkyl-C1-amino, alkyl-C? -4-carbonyl-alkyl-C? -amino, alkyl-C? _-Sulfonyl, alkyl-C? _4-sulfinyl, alkyl-C? _4-sulfonylamino, alkyl-C? _-sulphonyl-alkyl-C? -4-amino, aminosulfonyl, alkyl-C? -4-aminosulfonyl or di- (alkyl) -C? _) -aminosulfonyl, wherein the alkyl, alkenyl and alkynyl groups mentioned or contained in the definitions of the radicals Ra, Rb and Rc can be straight chain or branched, each methino group contained in these radicals can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, and the double and triple bonds of the alkenyl-C3-4 or alkynyl-C3- groups 4 contained in the groups defined above for Ra, Rb and Rc are isolated from heteroatoms eventually also contained in these groups, they are given a very particular extraordinary importance to the compounds, in which D and E in each case represent a methino group, G represents a methino group substituted with e The group Ra, M represents a methine group substituted with the group Rb, Q represents a methino group substituted with the group Rc and Ra, Rb and Rc, independently of each other, represent in each case a hydrogen or halogen atom, a group C 4 -alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, cyano, hydroxy, hydroxyalkyl, C 4 alkoxy, amino, alkyl, C 4 -4 amino, di- (C 1 -4 alkyl) -amino, C 1 -C 2 amino-alkyl, C 1 -C 3 alkylamino-C 2 alkyl, di- (C 1 -C 3 alkyl) amino-C 1 -C 2 -alkyl, hydroxycarbonyl, C 1 -4 -carbonyl, formyl, C 1 -4 -alkoxycarbonyl, aminocarbonyl, C 1 -C 4 -aminocarbonyl, di- (C 1 -4 alkyl) - aminocarbonyl, formylamino, alkyl-C? -4-carbonylamino, formyl-alkyl-C? _4-amino or alkyl-C? -4-carbonyl-C1_4-amino-alkyl, wherein the alkyl, alkenyl and alkynyl groups mentioned or contained in the definitions of the radicals Ra, Rb and Rc can be straight chain or branched and each methine group contained in these r additives may be substituted with a fluorine atom, each methylene group may be substituted with up to 2 fluorine atoms, and each methyl group may be substituted with up to 3 fluorine atoms, and very special importance is attached to the compounds, wherein D and E in each case represent a methino group, G represents a methino group substituted with the group Ra, M represents a methino group substituted with the group R, Q represents a methino group substituted with the group Rc and R, Rb and Rc, independently of one another, represent a hydrogen or halogen atom, a methyl, difluoromethyl, trifluoromethyl, ethyl, vinyl, ethynyl, cyano, hydroxy, methoxy, difluoromomethoxy, trifluoromethoxy, amino, methylamino or dimethylamino group, their tautomers, its isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with acids or inorganic or organic bases. A seventeenth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A and X in each case mean an oxygen atom, R 1 is defined as above under the fifth embodiment, D and E represent in each case a methino group, G represents a methino group substituted with the group Ra, M represents a methino group substituted with the group R, Q represents a methino group substituted with the group Rc and Ra, Rb and Rc, independently one of the other, represent a hydrogen or halogen atom, a methyl, difluoromethyl, trifluoromethyl, ethyl, vinyl, ethynyl, cyano, hydroxy, methoxy, difluoromethoxy, trifluoromethoxy, amino, methylamino or dimethylamino group, and wherein in these and in all the embodiments mentioned above are given an extraordinary importance in each case to the compounds in which R2 and R3 are defined as above under the tenth or und Eighth embodiment, particular importance is attached to the compounds, in which R2 and R3 are defined as above under the twelfth embodiment, and a very particular importance is given to the compounds, in which R2 and R3 are defined as before in the thirteenth embodiment, its tautomers, its isomers, its diastereomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic acids or bases or organic A eighteenth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A and X in each case mean an oxygen atom, D and E in each case mean a methino group, G means a methino group substituted with the group Ra, M means a methino group substituted with the group Rb, Q means a methino group substituted with the group Rc, Ra, Rb and Rc, independently of one another, each meaning a hydrogen atom or halogen, a C-3-alkyl, trifluoromethyl, cyano, hydroxy, methoxy, trifluoromethoxy, amino, methylamino or dimethylamino group, R1 means a 5- to 7-membered heterocycle diaza, once unsaturated, linked to the piperidine ring in formula (I) through a nitrogen atom, wherein the above-mentioned heterocycle contains a carbonyl group contiguous with a carbon atom. nitrogen and the carbonyl group is preferably bonded with two nitrogen atoms, just as the olefinic double bond of the heterocycle is fused with a phenyl or thienyl ring and the phenyl and thienyl rings may be mono-, di- or trisubstituted with carbon atoms. halogen, with methyl, methoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, alkyl-C-3-amino, di- (C 1 -C 3) -amino, acetylamino, acetyl, cyano, difluoromethoxy or trifluoromethoxy groups, wherein substituents may be the same or different, but is preferably monosubstituted with a halogen atom, with a methyl or methoxy group, and for R 1 there may be mentioned, for example, a 1, 3, 4, 5-tetrahydro-l, 3- group benz odiazepin-2-on-3-yl, 3,4-dihydro-lH-quinazolin-2-on-3-yl, 5-phenyl-2,4-dihydro-1,2,4-triazole-3-onyl 2-yl, 1,3-dihydro-imidazo [4, 5-c] quinolin-2-on-3-yl, 1,3-dihydro-napht [1,2-d] imidazol-2-on-3- ilo, 1, 3-dihydro-benzimidazol-2-on-3-yl, 4-phenyl-l, 3-dihydro-imidazol-2-on-l-yl, 3,4-dihydro-lyl-thieno [3, 2- d] pyrimidin-2-on-3-yl or 3,4-dihydroxy-thieno [3,4- d] pyrimidin-2-on-3-yl, which at an unsaturated carbon atom of the The aromatic or heteroaromatic part is mono-, di- or tri-substituted with halogen atoms, with cyano or hydroxy groups, and the substituents may be the same or different, but preferably it is not substituted, R2 and R3 / together with the nitrogen included, a radical of the general formula Y1 the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, mean the numbers 0, 1 or 2, ascending the sum of q and 1, 2 or 3, qyr, when Y1 represents the nitrogen atom, means the numbers 1 or 2, ascending the sum of qyra 2 or 3, R4 the hydrogen atom, an amino group, alkyl C? _4-amino, di- (C? _4 alkyl) -alkylamino, C? -6 alkyl, a C3_7 cycloalkyl group optionally substituted with a hydroxycarbonyl group, C? _6-carbonyl alkoxy, hydroxycarbonyl-C3 alkyl or C6-C6-alkoxy-C3-3alkyl, an amino-C2_7alkyl group, C4-4alkylamino-C2_alkyl, di- (C4-4alkynyl) alkyl- C2_7alkyl, C6-6alkoxy carbonyl, C6-C6-alkoxy-C3-3alkyl or hydroxycarbonyl-C3-3alkyl, a phenyl or pyridyl group, which in each case can be substituted with a halogen atom, with a C3-C3-alkyl group alkoxy-C? -3, amino, alkyl-C? _4-amino or di- (alkyl-C? _4) -amino, a heterocycle selected from an azacycloalkyl group or S, S-dioxothiaza from 5 to 7 members and a 6 to 7 membered diazacycloalkyl group, wherein the aforementioned heterocycles are linked to Y1 in the formula (II) through a nitrogen atom or a carbon atom and with one or two hydroxy groups, C-alkyl? or hydroxy-alkyl-C? _3, with a cyclo-alkyl group -C3_6, hydroxy-cycloalkyl-C3_6, cycloalkyl-Cs-β-a-alkyl-Ci-s, alkyl-C? -3-carbonyl-C? -3 alkyl, amino, alkyl-C? _4-amino , di- (alkyl-C? -4) -amino, hydroxycarbonyl-carbonyl, alkoxy-C? -3-carbonyl-carbonyl, hydroxycarbonyl-alkyl-C? -3-carbonyl, C3-carbonyl-alkyl-C alkoxy? -3-carbonyl, aminosulfonyl, alkyl-C? _4-aminosulfonyl, di- (alkyl-C? _4) -aminosulfonyl, cyclo-C3_7-sulfonyl-alkyl, aminocarbonyl-C? _3 alkyl, alkyl-C? _4- aminocarbonyl-C 1 -C 3 -alkyl, di- (C 1 -4 -alkyl) -aminocarbonyl-C 1 -C 3 -alkyl, hydroxyaminocarbonyl-C 3 -alkyl, C 1 -C 3 alkylaminocarbonyl-C 1 -C 3 -alkyl or hydroxy- (alkyl-C? _3) -aminocarbonyl-alkyl C? -3 R5 means a hydrogen atom or, when Y1 represents a nitrogen atom, also means a pair of free electrons, and R6, R7, R8 and R9, which may be the same or different, represent in each case an atom of hydrogen or a C? -3 alkyl group, its tautomers, its isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. A nineteenth embodiment of the present invention consists of the compounds of the general formula (I) above, in which A and X in each case mean an oxygen atom, D and E in each case mean a methino group, G means a methino group substituted with the group Ra, M means a methino group substituted with the group Rb, Q means a methino group substituted with the group Rc, Ra, Rb and Rc, independently of one another, each meaning a hydrogen atom or halogen, a C? _3 alkyl, trifluoromethyl, cyano, hydroxy, methoxy, trifluoromethoxy, amino, methylamino or dimethylamino group, R1 means a 5- to 7-membered heterocycle diaza, unsaturated once, bound to the piperidine ring in the formula (I) through a nitrogen atom, wherein the above-mentioned heterocycle contains a carbonyl group contiguous to a nitrogen atom and the carbonyl group is preferably linked with two nitrogen atoms , just as the olefinic double bond of the heterocycle is fused with a phenyl or thienyl ring and the phenyl and thienyl rings can be mono-, di- or trisubstituted with halogen atoms, with methyl, methoxy, difluoromethyl, trifluoromethyl, hydroxy groups , amino, alkyl-C? _3-amino, di- (alkyl-C? -3) -amino, acetylamino, acetyl, cyano, difluoromethoxy or trifluoromethoxy, wherein the substituents may be the same or different, but preferably is monosubstituted with a halogen atom, with a methyl or methoxy group, and for R 1 there may be mentioned, for example, a 1,3,4,5-tetrahydro-1,3-benzodiazepin-2-on-3-yl group, 3,4 -dihydro-l, -quinazolin-2-on-3-yl, 5-phenyl-2,4-dihydro-1,2,4-triazol-3-on-2-yl, 1,3-dihydro-imidazo [4] , 5-c] quinolin-2-on-3-yl, 1,3-dihydro-napht [1,2-d] imidazol-2-on-3-yl, 1,3-dihydro-benzimidazole-2-on -3-yl, "4-phenyl-l, 3-dihydro-imidazol-2-on-l-yl, 3,4-dihydro-lH-thieno [3,2-d] pyrimidin-2-on-3-- ilo or 3, 4-dihydro-lH-t ieno [3,4-d] pyrimidin-2-on-3-yl, which at an unsaturated carbon atom of the aromatic or heteroarctic part is mono-, di- or tri-substituted with halogen atoms, with cyano groups or hydroxy, and the substituents may be the same or different, but preferably not substituted, R2 and R3, together with the included nitrogen atom, a radical of the general formula where Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, mean the numbers 0, 1 or 2, ascending the sum of qyral, 2 or 3, qyr, when Y1 represents the nitrogen atom, means the numbers 1 or 2, ascending the sum of qyra 2 or 3, R4 means the hydrogen atom, an amino group, alkyl-C? -4- amino, di- (alkyl-C? -) -alkylamino, alkyl-C? _6, cyclo-C3-7-alkyl, amino-C2_7-amino, alkyl-C? -4-amino-C2_7-alkyl, di- ( alkyl-C? -4-amino) -alkyl-C2-7, alkoxy-C6-carbonyl, alkoxy-C6-carbonyl-C3-3alkyl or hydroxycarbonyl-C3-3alkyl, a. a phenyl or pyridyl group, which in each case may be substituted with a halogen atom, with a C 1 -C 3 -alkyl, C 3 -alkoxy, amino, C 1 -4 amino or di- (alkyl- C? _4) -amino, a heterocycle chosen from an azacycloalkyl group of 5-7 members and a diazacycloalkyl group of from 6 to 7 members, wherein the above-mentioned heterocycles are linked to Y1 in formula (II) through a Nitrogen atom or a carbon atom and can be substituted with an alkylC, -3, cyclo-C3-6 alkyl, cyclo-C3_6-alkyl-C_3, -amino, C4-amino-alkyl or di- (alkyl-C? _4) -amino, R5 means a hydrogen atom or, when Y1 represents a nitrogen atom, also means a pair of free electrons, and R6, R7, R8 and R9, which may be the same or different, in each case, they represent a hydrogen atom or a C3_3 alkyl group, their tautomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. As very particularly preferred compounds of the general formula • (I) above, for example, the following compounds can be mentioned its enantiomers, its diastereoisomers and its salts.

The compounds of the general formula (I) are prepared according to methods known in principle. The following processes have been particularly proven for the preparation of the compounds of the general formula (I) according to the invention: (a) for the preparation of the compounds of the general formula (I), in which all the radicals are defined as mentioned at the beginning: reaction of piperidines of the general formula wherein R1 is defined as mentioned at the beginning, with carbonic acid derivatives of the general formula in which Yi and Y2 mean nucleophilic groups, which may be the same or different, preferably the cine atom, the p-nitrophenoxy or tricomethoxy group, in case A represents the oxygen atom, or the cine atom, if A means the sulfur atom, and with compounds of the general formula wherein X, D, E, G, M and Q are defined as mentioned at the beginning and Zi represents a protecting group for a carboxy group, for example an alkyl-C6-6 or benzyl group, the alkyl groups being linear or branched and the benzyl group being able to be substituted with one or two methoxy groups. The methyl, ethyl, tere group is preferred for Z. -butyl or benzyl. Before carrying out the reaction, the carboxylic acid functions, primary or secondary amino functions or hydroxy functions, optionally present in the radical R 1 of a compound of formula (III) and / or in a compound of formula (V), can be protected by suitable protective radicals, and the optionally used protective radicals are again separated, after carrying out the reaction, by methods customary for the expert. In a first step, the compounds of the general formula (III) are reacted with the carbonic acid derivatives of the general formula (IV), for example in dicomethane, THF, pyridine or mixtures thereof, at a temperature between -20 and 50 ° C in the presence of a base, for example triethylamine, pyridine or ethyldiisopropylamine. The intermediate step, which results therefrom, can be purified or reacted further without purification. The reaction of this intermediate step with compounds of the general formula (V) is also carried out in one of the aforementioned solvents, and at one of the aforementioned temperatures, in the presence of a base, such as triethylamine or pyridine, with or without the addition of an activation reagent, such as, p. ex. , 4-dimethylaminopyridine. For activation, the compounds of the general formula (V) can also be deprotonated by a metal hydride, such as, e.g. ex. , NaH or KH, in this case the presence of the base or activation reagent may be waived. (b) For the preparation of compounds of the general formula (I), in which all the radicals are defined as mentioned at the beginning: coupling of a carboxylic acid of the general formula wherein all radicals are defined as mentioned at the beginning, with an amine of the general formula HNR2R3, wherein R2 and R3 are defined as mentioned at the beginning. Before carrying out the reaction, the carboxylic acid functions, primary or secondary amino functions or hydroxy functions, optionally present in a compound of formula (VI) and / or in the radicals R2 and R3 of the amine of formula HNR2R3, can be protected by suitable protective radicals, and the optionally used protective radicals are again separated, after carrying out the reaction, according to methods customary for the expert. The coupling is preferably carried out using known methods of peptide chemistry (see, eg, Houben-Weyl, Methoden der Organischen Chemie, volume 15/2), using, for example, carbodiimides, such as, eg. ex. dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or ethyl- (3-dimethyl-amino-propyl) -carbodiimide, O- (lif-benzotriazol-l-yl) -N, N-N1, N '-tetramethyluronium hexafluorophosphate (HBTU) ) or tetrafluoroborate 0- (1H-benzotriazole-1-yl) -N, N-N ', N'-tetramethyluronium (TBT) or l-benzotriazol-1-yl-oxy-tris- (dimethylamino) -phosphonium hexafluorophosphate (BOP). By the addition of 1-hydroxybenzotriazole (HOBt) or 3-hydroxy-4-oxo-3,4-dihydro-l, 2,3-benzotriazine (HOObt) can increase the speed of the reaction. The couplings are usually carried out with equimolar proportions of the coupling components, as well as the coupling reagent in solvents, such as dichloromethane, tetrahydrofuran, acetonitrile, dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (? MP) or mixtures based on these and at temperatures between -30 and +30 ° C, preferably between -20 and +25 ° C. Insofar as necessary, N-ethyldiisopropylamine (Hünig's base) is preferred as additional auxiliary base. As another coupling method for the synthesis of compounds of the general formula (I), the so-called "anhydride process" is used (see, also: M. Bodanszky, "Peptide Chemistry", Springer Publishing 1988, pp. -; 58 / 59 M. Bodanszky, "Principies of Peptide Synthesis", Springer Publishing 1984, pp. 21-27). The "mixed anhydride process" is preferred in the variant according to Vaughan (JR Vaughan Jr., J. / Amer. Chem. Soc. 7_3, 3547 (1951)), in which, with the use of isobutyl ester of chlorocarbonic acid in presence of bases, such as 4-methylmorpholine or 4-ethylmorpholine, the mixed anhydride is obtained from the carboxylic acid of the general formula (VIII) to be coupled and the monoisobutyl ester of carbonic acid. The preparation of this mixed anhydride and the coupling with the amines of the general formula HNR2R3 is carried out in a single-vessel process, using the aforementioned solvents and at temperatures between -20 ° C and + 25 ° C, preferably between 0 ° C and +25 ° C. (c) For the preparation of compounds of the general formula (I), in which all the radicals are defined as mentioned at the beginning: coupling a compound of the general formula with an amine of the general formula HNR2R3, in which all the radicals are defined as mentioned at the beginning and Nu means a leaving group, for example a halogen atom, such as the chlorine, bromine or iodine atom, a group alkylsulfonyl having 1 to 10 carbon atoms in the alkyl part, a phenylsulfonyloxy or naphthylsulfonyloxy group mono-, di- or trisubstituted optionally with chlorine or bromine atoms, with methyl or nitro groups, the substituents being the same or different, a group 1H-imidazol-1-yl, a li? -pyrazol-1-yl group optionally substituted on the carbon framework with one or two methyl groups, a 1H-1,2,4-triazol-1-yl group, 1H -1, 2, 3-triazol-1-yl, 1 H-1, 2, 3, 4-tetrazol-1-yl, a vinyl, propargyl, p-nitrophenyl, 2,4-dinitrophenyl, trichlorophenyl, pentachlorophenyl, pentafluorophenyl group , pyranyl or pyridinyl, a dimethylaminyloxy group, 2 (1H) -oxopyridin-1-yl-oxy, 2,5-dioxopyrrolidin-1-yloxy, phthalimidyloxy, Ify-benzo-triazol-1-yloxy or azido. Before carrying out the reaction, the carboxylic acid functions, primary or secondary amino functions or hydroxy functions, optionally present in a compound of formula (VII) and / or in the radicals R2 and R3 of the amine of formula HNR2R3, can be protected by suitable protective radicals, and the protective radicals optionally used are again separated, after carrying out the reaction, according to methods customary for the expert. The reaction is carried out under Schotten-Baumann or Einhorn conditions, said components are reacted in the presence of at least one equivalent of an auxiliary base, at temperatures between -50 ° C and + 120 ° C, preferably between -10 ° C and + 30 ° C, and possibly in the presence of solvents. Suitable auxiliary bases are preferably alkali and alkaline earth metal hydroxides, for example sodium hydroxide, potassium hydroxide or barium hydroxide, alkali metal carbonates, e.g. ex. Sodium carbonate, potassium carbonate or cesium carbonate, alkali metal acetates, p. ex. sodium or potassium acetate, as well as tertiary amines, for example pyridine, 2,4,6-trimethylpyridine, quinoline, triethylamine, N-ethyldiisopropylamine, N-ethyldicyclohexylamine, 1,4-di-azabicyclo [2, 2, 2] octane or 1,8-diaza-bicyclo [5, 4, 0] undec-7-ene, as solvents, for example, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, dimethylformamide, dimethylacetamide, N-methylpyrrolidone or mixtures thereof. same; if alkali metal or alkaline earth metal hydroxides, carbonates to alkali metal acetates are used as auxiliary bases, water can also be added as a co-solvent to the reaction mixture. The novel compounds of the general formula (I) according to the invention contain one or more centers of chirality. If, for example, two centers of chirality are present, then the compounds can be manifested in the form of two pairs of diastereomeric antipodes. The invention encompasses the individual isomers, as well as their mixtures. The separation of the respective diastereoisomers is achieved by virtue of their different physico-chemical properties, eg by fractional crystallization from suitable solvents, by high-pressure liquid chromatography or column chromatography, using chiral stationary phases or , preferably, achiral. The separation of the racemates falling under the general formula (I) is achieved, for example, by HPLC in suitable chiral stationary phases (eg Chiral AGP, Chiralpak AD). Racemates, which contain a basic or acidic function, can also be separated by the optically active diastereomeric salts which are formed in the reaction with an optically active acid, for example (+) - or (-) - tartaric acid, (+) - or (-) - diacetyltartaric acid, (+) - or (-) - monomethyl tartrate or (+) - or (-) - camphorsulfonic acid. or berin with an optically active base, for example with (R) - (+) - 1-phenylethylamine, (S) - (-) -1-phenylethylamine or (S) -brucine. According to a usual process for the separation of isomers, the racemate of a compound of the general formula (I) is reacted with one of the above-described optically active acids or bases in an equimolar amount in a solvent, and the optically active, diastereomeric salts , crystalline, obtained are separated taking advantage of their different solubility. This reaction can be carried out in all types of solvents, as long as they have a sufficient difference in relation to the solubility of the salts. Preferably, methanol, ethanol or mixtures thereof are used, for example in the 50:50 volume ratio. Thereafter, each of the optically active salts is dissolved in water, neutralized carefully with a base, such as sodium carbonate or potassium carbonate., or with a suitable acid, for example with dilute hydrochloric acid or aqueous methanesulfonic acid and, thereby, the corresponding free compound is obtained in the (+) or (-) form. In each case only the (R) or (S) -enantiomer or a mixture of two optically active diastereomeric compounds, which fall under the general formula (I), is also obtained by carrying out the above-described syntheses in each case with a component of the reaction with suitable (R) or (S) configuration. In the case that the group X in compounds of the general formula (V) represents the oxygen atom, the hydroxycarboxylic acids required for the synthesis of the general formula can be obtained from compounds of the general formula D, E, G, M and Q being defined in the two formulas as mentioned at the beginning. By diazotization of compounds of the general formula (IX) with a suitable diazotization reagent, preferably sodium nitrite in an acidic medium, the compounds of the general formula can be obtained (VIII). By using pure compounds for the enantiomers, the corresponding pure hydroxycarboxylic acid compounds are obtained with respect to the enantiomers, the reaction proceeding with retention of the configuration. An alternative access to compounds of the general formula (VIII) consists in the reaction of aldehydes of the general formula (X) with N-acetylglycine an acetanhydride as a solvent in the presence of alkali metal acetate, preferably sodium or potassium acetate at a temperature suitable, preferably at 80-130 ° C.

The resulting azalactones of primary form are hydrolyzed, without isolation, to give the compounds of the general formula (XI). By subsequent reaction in the presence of aqueous mineral acids, such as sulfuric, phosphoric or hydrochloric acid, but preferably hydrochloric acid, compounds of the general formula (XII) are obtained. These are then transformed with suitable reducing agents into the compounds of the general formula (VIII).

(XII) As reducing agents, alkali metal borohydrides, such as sodium or potassium borohydride, can be used. Other reducing agents represent chlorodialkylborane, such as chlorodicyclohexylborane. If chiral chlorodialkylboranes are used, such as. p. ex. B-chlorodiisopinocanphenylborane, the compounds of the general formula (VIII) can be isolated in pure form as regards the enantiomers. Another access to compounds of the general formula (VIII) consists of the alkylation of the compound (XIII) with aryl- or heteroaryl-methyl halides of the general formula in which Hal means a chlorine, bromine or iodine atom, and -D, E, G, Q and E are defined as mentioned at the beginning, in analogy to methods known from the literature (Michael T. Crimmins, Kyle A Emmitte and Jason D. Katz, Org. Lett.2, 2165-2167 [2000]). The resulting diastereomeric products can then be separated with the aid of physical-chemical methods, preferably with the aid of chromatographic methods or by recrystallization. The hydrolytic separation of the chiral auxiliary agent and the separation of the benzyl carrier group also opens an access to pure hydroxycarboxylic compounds with respect to the enantiomers of the general formula (V). The further reaction of compounds of the general formula (VIII) to give compounds of the general formula (V) is carried out in an alcoholic medium, preferably in methanol or ethanol, in the presence of a suitable acid, such as hydrochloric acid. The reaction can be effected, alternatively, by reaction in alcoholic solvents, preferably methanol, with thionyl chloride. In case the group X in compounds of the general formula (V) represents the sulfur atom, thiocarboxylic acids, required for the synthesis, of the general formula in which D, E, G, M and Q are defined as mentioned at the beginning and Zi represents a protecting group described under process (a) for a carboxy group, from compounds of the general formula (V), wherein X represents the oxygen atom. By a Mitsunobu reaction of the compounds of the general formula (V) with alkylthio-C? -6-carboxylic acids, the alkyl chain being linear or branched, but preferably representing the methyl group, the corresponding acid esters are obtained alkylthiocarboxylics of these compounds. These can be hydrolyzed, according to known methods, to give the compounds of the general formula (XV) (Bert Strijtveen and Richard M. Kellogg, J. Org. Chem. 51, 3664-3671 [1986]). All the compounds of the general formula (I), which contain primary or secondary amino functions, hydroxy or hydroxycarbonyl are obtained, preferably from precursors provided with protective groups. Suitable protective groups for amino functions include, for example, a benzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 4-nitro-benzyloxycarbonyl, 4-methoxy-benzyloxycarbonyl, 2-chloro-benzyloxycarbonyl, 3-chloro-benzyloxycarbonyl, 4-chloro- benzyloxycarbonyl, 4-biphenylyl-α, α-dimethyl-benzyloxycarbonyl or 3,5-dimethoxy-α, α-dimethyl-benzyloxycarbonyl, an alkoxycarbonyl group having a total of 1 to 5 carbon atoms in the alkyl part, for example the methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, 1-methylpropoxycarbonyl, 2-methylpropoxycarbonyl or tere group. -butyloxycarbonyl, the allyloxycarbonyl group, 2,2,2-trichloro- (1,1-dimethylethoxy) carbonyl or 9-fluorenylmethoxycarbonyl or a formyl, -acetyl or trifluoroacetyl group. Suitable protective groups for hydroxy functions are, for example, a trimethylsilyl, triethylsilyl, triisopropyl, tere group. -butyldimethylsilyl or tert-butyldiphenylisilyl, a tere group. -butyl, benzyl, 4-methoxybenzyl or 3,4-dimethoxybenzyl. As a protective group for functions * hydroxycarbonyl is, for example, an alkyl group with a total of 1 to 5 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, tere. -butyl, allyl, 2, 2, 2-trichloroethyl, benzyl or 4-methoxybenzyl. The compounds of the general formula (I) obtained, insofar as they contain basic functions, can be converted, in particular for pharmaceutical applications, into their physiologically compatible salts with inorganic or organic acids. As acids, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, succinic acid are suitable. , lactic acid, mandelic acid, malic acid, citric acid, tartaric acid or maleic acid. In addition, the novel compounds of the formula (I), if they contain a carboxylic acid function, can be converted into their salts by addition with inorganic or organic bases, in particular for the pharmaceutical application, in their salts by physiological addition. compatible Suitable bases are, for example, sodium hydroxide, potassium hydroxide, ammonia, cyclohexylamine, dicyclohexylamine, ethanolamine, diethanolamine and triethanolamine. The present invention relates to racemates, insofar as the compounds of the general formula (I) have only one element of chirality. However, the application also covers the pairs of individual diastereomeric antipodes or their mixtures, which occur when more than one element of chirality is present in the compounds of the general formula (I), as well as the individual optically active enantiomers, from which the aforementioned racemates can be constituted. Also, the compounds according to the invention, including their salts, in which one or more hydrogen atoms, for example one, two, three, four or five hydrogen atoms are exchanged with deuterium, are covered by the object of this invention. The new compounds of the general formula (I) and their physiologically compatible salts have valuable pharmacological properties that are attributed to their selective CGRP antagonist properties. Another object of the invention are medicaments containing these compounds, their use and their preparation. The aforementioned new compounds and their physiologically compatible salts possess CGRP antagonistic properties and show good affinities in studies of CGRP receptor binding. The compounds present antagonist properties of CGRP in the pharmacological test systems described below. For the detection of the affinity of the aforementioned compounds for human CGRP receptors and their antagonistic properties, the following tests were carried out: A. Binding studies with SK-N-MC cells (expressing the human CGRP receptor) SK-N-MC cells are cultured in "Dulbecco's modified Eagle medium". The medium is removed from confluent cultures. The cells are washed twice with PBS buffer (Gibco 041-04190 M), detached by the addition of PBS buffer, mixed with 0.02% EDTA, and isolated by centrifugation. After resuspension in 20 ml of "balanced salt solution - Balanced Salts Solution" [BSS (in mM): NaCl 120, KCl 5.4, NaHC03 16.2, MgSO4 0.8, NaHP04 1.0, CaCl2 1 , 8, D-glucose 5.5, HEPES 30, pH 7.40] cells are centrifuged twice at 100 xg and resuspended in BSS. After determining the number of cells, they are homogenized with the aid of an Ultra-Turrax and centrifuged for 10 minutes at 3000 x g. The supernatant is discarded and the pellet is recentrifuged in Tris buffer (10 mM Tris, 50 mM NaCl, 5 mM MgCl2, 1 mM EDTA, pH 7.40), enriched with 1% bovine serum albumin and 0% bacitracin., 1%, and resuspended (1 ml / 1000000 cells). The homogenate is frozen at -80 ° C. The membrane preparations are stable under these conditions for more than 6 weeks. After thawing, the homogenate is diluted in the ratio 1:10 with assay buffer (50 mM Tris, 150 mM NaCl, 5 mM MgCl 2, 1 mM EDTA, pH 7.4-0) and homogenized for 30 seconds with an Ultra-Turrax 230 μl of the homogenate are incubated for 180 minutes at room temperature with 50 pM of peptides related to the 125 I-iodotyrosyl-calcitonin gene (Amersham) and increasing concentrations of the test substances in one volume total of 250 μl The incubation is terminated by rapid filtration through glass fiber filters GF / B treated with polyethylenimine (0.1%) by a cell harvester.The radioactivity bound to the protein is determined with the aid of A Gamma counter As a non-specific binding, the bound radioactivity is defined after the presence of 1 μM of human CGRP-alpha during incubation The analysis of the concentration-union curves is carried out with the help of an adaptation of the non-linear curve susten The compounds mentioned at the beginning show in the test described IC50 values; 10000 nM. B. Antagonism of CGRP in SK-N-MC cells SK-N-MC cells (1 million cells) are washed twice with 250 μl of incubation buffer (Hanks HEPES, 1 mM 3-isobutyl-1-methylxanthine, 1% BSA, pH 7.4) and preincubated at 37 ° C for 15 minutes. After the addition of CGRP (10 μl) as an agonist in increasing concentrations (1011 to 106 M) or, additionally, of substance in 3 to 4 different concentrations, it is incubated again for 15 minutes. Next, intracellular cAMP is extracted by the addition of 20 μl of 1M HCl and centrifugation (2000 x g, 4 ° C for 15 minutes). The supernatants are frozen in liquid nitrogen and stored at 20 ° C. The cAMP contents of the samples are determined by radioimmunoassay (Amersham signature) and the pA2 values of antagonist action substances are calculated graphically. The compounds according to the invention show in the in vitro test model described antagonist properties of CGRP in a dose range between 1012 and 105 M. By virtue of their pharmacological properties, the compounds according to the invention and their salts with physiologically compatible acids they are suitable, therefore, for the acute and prophylactic treatment of headaches, in particular migraine or headache in accumulations. In addition, the compounds according to the invention also positively influence the following diseases: non-insulin-dependent diabetes mellitus ("NIDDM"), complex regional pain syndrome (CRPS1), cardiovascular diseases, tolerance to morphine, dipepsias caused by the toxin of Clostridium, skin diseases, in particular thermal and radiation-conditioned skin lesions, including solar erythema, inflammatory diseases p. ex. inflammatory diseases of the joints (arthritis), neurogenic inflammations of the oral mucosa, inflammatory diseases of the lungs, allergic rhinitis, asthma, diseases that are accompanied by a disproportionate widening of the vessels and reduced hyperemia of the tissues conditioned by this, p . ex. shock and sepsis. In addition, the compounds according to the invention show a calming effect of pain states in general. The symptomatology of menopausal hot flashes, caused by a widening of the vessels and by an increased hemorrhage, of estrogen-deficient women, as well as of prostate carcinoma patients treated with gormones, is favorably influenced in an preventive and therapeutic way by the antagonists of CGRP of the present application, this therapeutic approach being distinguished before hormone replacement by few side effects. The dosage necessary to achieve a corresponding effect rises, conveniently in the case of intravenous or subcutaneous administration, to 0.0001 to 3 mg / kg of body weight, preferably to 0.01 to 1 mg / kg of body weight and, in the case of oral, nasal or inhalation administration, at 0.01 to 10 mg / kg of body weight, preferably at 0.1 to 10 mg / kg of body weight, in each case 1 to 3 times a day. To the extent that treatment with CGRP antagonists and / or CGRP release inhibitors is carried out as a complement to a usual hormonal substitution, a reduction of the aforementioned dosages is advised, and the dosage can then be increased to 1/5 of the lower limits indicated above up to 1/1 of the upper limits indicated above. The compounds prepared according to the invention can be applied alone or, optionally, in combination with other active substances for the treatment of migraine intravenously, subcutaneously, intramuscularly, intrarectally, intranasally, by inhalation, transdermally or orally, being particularly suitable aerosol formulations for inhalation. The combinations can be administered simultaneously or sequentially. Classes of imaginable active ingredients as participants in the combination are, p. ex. antiemetics, prokinetics, neuroleptics, antidepressants, neurokinin antagonists, angiotensin receptor blockers (angiotensin II antagonists), iNOS inhibitors, AMPA antagonists, ahticonvulsants, histamine Hl receptor antagonists, antimuscarinics, beta blockers, agonists and antagonists a , ergotalcaloids, weak analgesics, non-steroidal antiphlogistics, corticosteroids, calcium anatagonists, 5-HT? B /? D agonists or other anti-migraine agents, which, together with one or more usual inert carrier substances and / or diluents , p. ex. with corn starch, lactose, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerin, water / sorbitol, water / polyethylene glycol, "propylene glycol, .alcohol Cetylstearyl, carboxymethylcellulose or fat-containing substances, such as hard fat or their mixtures, can be incorporated into customary galenic preparations, such as tablets, dragees, pads, powders, suspensions, solutions, dosing aerosols or suppositories. mentioned, therefore, as other active substances, for example the non-steroidal antiphlogistics Aceclofenac, Acemetacin, acetylsalicylic acid, Azathioprine, Diclofenac, Diflunisal, Fenbufen, Fenoprofen, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Leflunomide, Lornoxicam, mefenamic acid, Naproxen, phenylbutazone, Piroxicam, Sulfasalazin, Zomepirac or its pharmacological salts therapeutically compatible and meloxicam and other selective inhibitors C0X2, such as, for example, rofecoxib and celecoxib. In addition, ergotamine, dihydroergotamine, Metoclopramid, Domperidone, Diphenhydramine, Cyclizine, Promethazine, Chloropromazine, Vigabatrin, Timolol, Isometheptene, Pizotifen, Botox, Gabapentin, Topira at, Riboflavin, Montelukast, Lisinopril, Prochloroperazine, dexamethasone, Flunarizine, dextropropoxyphene, Meperidine can be used. , Metoprolol, Propranolol, Nadolol, Atenolol, Clonidine, Indoramine, Carbamazepine, Phenytoin, Valproat, Amitriptyline, Lidocaine or Diltiazem and other agonists of 5-HTIB / ID, such as, p. ex. To otriptan, Avitriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan and Zolmitriptan. The dose for these active substances amounts in this case, conveniently, to 1/5 of the lowest dosage usually recommended up to 1/1. of the dosage normally recommended, ie for example 20 to 100 mg of Sumatriptan. Another object of the invention is the use of the compounds according to the invention as valuable adjuvants for the production and purification (affinity chromatography) of antibodies as well as, after suitable radioactive labeling, for example by titration of suitable precursors, for example by catalytic hydrogenation with tritium or replacement of halogen atoms by tritium, in RIA and ELISA assays and as diagnostic or analytical adjuvants in neurotransmitter research. Experimental part For prepared compounds, as a general rule, IR, H-NMR and / or mass spectra are present. If not stated otherwise, the Rf values are determined using plates prepared from CCD of silica gel 60 F254 (E. Merck, Darmstadt, article no. 1.05714) without saturation of the chamber. The Rf values determined under the name Polygram were tested using sheets prepared from CCD Polygram SIL G / UV2s4 (coated with 0.2 mm silica gel) from the firm Macherey-Nagel (Duren, article number 805 021). The Rf values determined under the name Polygram-Alox are checked using sheets prepared from CCD Polygram Alox N / UV25 (coated with 0.2 mm aluminum oxide) from the firm Macherey-Nagel (Duren, article number 802 021) . The indicated ratios in the eluting agents refer to volume units of the respective solvents. The volume units indicated in the case of NH3 refer to a conventional solution of NH3 in water. If not otherwise indicated, the solutions of acids, bases and salts used in the treatments of the reaction solutions are aqueous systems of the indicated concentrations. For chromatographic purifications, silica gel from Millipore (MATREX®, 35-70 μm) is used. For the chromatographic purifications, rust is used, from the company ICN Biomedicals (Esch ege, article number 02090). According to the manufacturer's data, the required activity stage is created before use. The HPLC data indicated are measured with the parameters collected below: Method A: Analytical Column: Column Zorbax (Agilent Technologies), SB (stable link) - C18; 3.5 μm; 4.6 x 75 mm; Column temperature: 30 ° C; flow rate: 0.8 mL / min; injection volume: 5 μL; detection at 254 nm Method B: Analytical column: Waters Symmetry C18; 3.5 μm; 4.6 x 75 mm; Column temperature: 30 ° C; flow rate: 0.8 mL / min; injection volume: 5 μL; detection at 254 nm Method C: Analytical Column: Zorbax column (Agilent Technologies), Bonus-RP C14; 3.5 μm; 4.6 x 75 mm; Column temperature: 30 ° C; flow rate: 0.8 L / min; injection volume: 5 μL; detection at 254 nm Method D: Analytical Column: Zorbax Column - (Agilent Technologies), SB (stable link) - C18; 3.5 μm; 4.6 x 75 mm; Column temperature: 30 ° C; flow rate: 0.8 mL / min; injection volume: 5 μL; detection at 254 nm Method E: Analytical Column: Column Zorbax (Agilent Technologies), SB (stable link) - C18; -3.5 μm; 4.6 x 75 mm; Column temperature: 30 ° C; flow rate: 1.6 mL / min; injection volume: 5 μL; detection at 254 nm étPdo F: Analytical column: Waters Symmetry C8; 5 μm; 4, 6 x 150 mm; column temperature: 25 ° C; flow rate: 1.3 mL / min; injection volume: 5 μL; detection at 254 nm In the case of preparative HPLC purifications, the same gradients that were used in the calculation of the analytical data by HPLC are generally used. The collection of the products is done with mass control, the fractions containing product are collected and lyophilized. In the event that more precise configuration data are missing, it remains open whether they are pure enantiomers or if a partial or even total racemization has been initiated. The following abbreviations are used in the test descriptions in the test descriptions: Boc tere ..- butoxycarbonyl Cyc cyclohexane DCM dichloromethane DIPE diisopropyl ether DMF N, N-dimethylformamide EtOAc ethyl ester of acetic acid EtOH ethanol Fmoc 9-fluorenylmethoxycarbonyl semiconc. semi-concentrated HATU O- (7-azabenzotriazol-1-yl) -?,?,? 'hexafluorophosphate ,? ' -tetramethyluronium HCl hydrochloric acid HOAc acetic acid HOBt 1-hydroxybenzotriazole-hydrate i. empty in vacuo (in vacuo) KOH potassium hydroxide conc. concentrate LiOH lithium hydroxide MeOH methanol NaOAc sodium acetate NaCl sodium chloride NaOH sodium hydroxide n.c. untested PE petroleum ester TA ambient temperature TBME. tere. -butyl methyl ether TBTU O- (benzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium trifluoroacetic acid trifluoroacetic acid THF tetrahydrofuran Example 1 Ester (R) -1- (3,4-dibromo-benzyl) - 2- (4- (l-Methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl of 4- (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1- Acrylic A mixture based on 22.1 g (83.7 mmol) of 3,4-dibromobenzaldehyde, 14.7 g (126 mmol) of N-acetylglycine and 10.3 g (126 mmol) of NaOAc in 100 mL of acetanhydride was heated for 1.5 h to 118 ° C (internal temperature). After the reaction was complete, the reaction mixture was cooled to about 100 ° C and then mixed in portions with 20 g of ice (exothermic reaction), keeping the internal temperature below 120 ° C. it was heated for another 2 h to 95 ° C, then it was added to a mixture of 240 mL of water and 120 mL of toluene and stirring was continued for 1 h at RT The precipitate was filtered with suction, washed in each case with 50 mL of toluene and water and dried overnight at 40 ° C in the circulating air oven Yield: 20.8 g (69% of the theory) ESI-MS: (M + H) + = 362 / 364/366 (2 Br) Rf = 0.19 (silica gel, EtOAc / MeOH / NH3 90: 10: 1) Ib 3- (3,4-dibromo-phenyl) -2-oxo-propionic acid A solution of 11.98 g (32.82 mmol) of acid (Z, E) -2-acetylamino-3- (3, -dibromo-phenyl) -acrylic acid in 90 mL of N-methyl-2-pyrrolidinone were added with 125 mL of ice-cold 4 M HCl, and then the The reaction mixture was heated at reflux for 2 h. The reaction solution, cooled to 40 ° C, was poured into 450 mL of water, and the resulting suspension was mixed with 300 mL of toluene and stirring was continued overnight. The organic phase was extracted with water until a precipitate formed between the phases. This was filtered with suction, the phases were separated, the toluene phase was concentrated to half, mixed again with water and the resulting precipitate was filtered with suction. This was then combined with the first precipitate and dried at 50 ° C in the circulating air oven. Yield: 5.73 g (54% of theory) ESI-MS: (M + H) + = 319/321/323 (2 Br) Rf = 0.17 (silica gel, EtOAc / MeOH / NH3 80: 20: 2) le (R) -3- (3,4-dibromo-phenyl) -2-hydroxy-propionic acid To a solution, cooled to -35 ° C, of 5.1 g (15.8 mmol) of 3- (3,4-dibromo-phenyl) -2-oxo-propionic acid and 2.2 mL (15.8 mmol) of triethylamine in 20 mL of THF was added dropwise, within 30 min. solution of 6.1 g (19.0 mmol) of (IR) -B-chlorodiisopinocamphanylborane in 40 mL of THF, and the reaction mixture was maintained for 1 h at this temperature. The reaction solution was carefully mixed with 30 mL of 1 M NaOH (exothermic) and 30 mL of TBME, stirring was continued for 15 min, the organic phase was separated, and this was then extracted with 25 mL of water and 15 mL of water. 1 M NaOH. The combined aqueous phases were acidified with 2 M HCl, extracted three times, in each case with 40 mL of TBME and the combined organic phases were dried over Na 2 SO. After separating the drying agent and the solvent, the residue was purified by chromatography (silica gel, EtOAc / MeOH / NH3 70: 30: 3). Yield: 3.2 g (63% of the theory) ESI-MS: (M + H) + = 321/323/325 (2 Br) * Retention time (HPLC): 7.0 min (method A) ld Ethyl ester of (R) -3- (3,4-dibromo-phenyl) -2-hydroxy-propionic acid To a solution, cooled to 0 ° C, of 3.2 g (9.9 mmol) of acid (R ) -3- (3,4-dibromo-phenyl) -2-hydroxy-propionic acid in 40 mL of dry EtOH was added dropwise 0.8 mL (10.9 mmol) of thionyl chloride and the reaction mixture was added. continued stirring for 1 h at RT. The reaction solution was concentrated i. aq., the residue was mixed with 30 mL of DCM and filtered from the insoluble precipitate. After removing the solvent, the product was obtained in the form of a viscous oil, which was reacted further without purification. Yield: 3.1 g (88% of the theory) ESI-MS: (M + H) + = 351/353/355 (2 Br) Retention time (HPLC): 8.1 min (method A) le Chloride of 4- (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carbonyl To a solution, cooled to 0 ° C, of 2.5 g ( 10.2 mmol) of 3-piperidin-4-yl-1,3,4,5-tetrahydro-l, 3-benzodiazepin-2-one and 2.6 mL (14.9 mmol) of ethyldiisopropylamine in 75 mL of DCM was added 6.0 g (12.1 mmol) of phosgene (20 weight percent in toluene) and the reaction mixture was continued stirring for 30 min at this temperature. The reaction solution * was heated to RT, concentrated i. empty up to approx. 50 mL, it was filtered on silica gel, it was washed with 200 mL of DCM / EtOAc (1: 1) and the combined organic filtrates were again concentrated i. empty The residue was mixed with stirring with DIPE, filtered with suction and dried i. empty Yield: 2.4 g (77% of theory) Rf = 0.43 (silica gel, DCM / EtOAc 1: 1) lf Ester (R) -2- (3,4-dibromo-phenyl) -1- 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid ethoxycarbonyl. To a solution, cooled to 0 ° C, of 2 90 g (8.24 mmol) of (R) -3- (3,4-dibromo-phenyl) -2-hydroxy-propionic acid ethyl ester in 50 mL of dry THF were added portionwise 362 mg (al 55 % in mineral oil, 9.06 mmol) of NaH and stirring was continued for another 30 min at this temperature, forming a dark brown suspension. Then, 2.15 g (6.99 mmol) of 4- (2-oxo-1,2,4,5,5-tetrahydro-1,3-benzodiazepin-3-yl) chloride were added in portions under cooling. piperidin-1-carbonyl, and the reaction mixture was stirred for 2 h at RT. It was mixed with 50 L of half-saturated solution of NaHCO 3, extracted twice, in each case with 50 mL of EtOAc, the combined organic phases were washed with 50 mL of saturated NaCl solution and the organic phase was filtered over Na 2 SO. After removing the solvent, the residue was purified by chromatography (silica gel, EtOAc / Cyc 3: 1). Yield: 3.64 g (84% of the theory) ESI-MS: (M + H) + = 622/624/626 (2 Br) Retention time (HPLC): 10.0 min (method A) lg Ester (R) -l-carboxy-2- (3,4-dibromo-phenyl) -ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid To a solution of 3.64 g (5.83 mmol) of ester (R) -2- (3,4-dibromo-phenyl) -1-ethoxycarbonyl-ethyl 4- (2- oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 70 mL of THF was added, at RT, a solution of 210 mg (9.0 mmol) of LiOH * H20 in 40 L of water and the reaction mixture was stirred for 7 h at RT. He concentrated i. vac., the residue was taken up in 100 mL of water, mixed with stirring with 1 M HCl until the acid reaction, the precipitate was separated by filtration and dried in a vacuum oven at 50 ° C. The product was reacted further without purification. Yield: 3.36 g (97% of the theory) ESI-MS: '(M + H) + = 594/596/598 (2'Br) Retention time (HPLC): 8.5 min (method A) l Ester (R) -1- (3,4-dibromo-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl acid of 4 - (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 80 mg (0.13 mmol) of ester (R) -l 4- (2-Oxo-1,2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1 -carboxy-2- (3,4-dibromo-phenyl) -ethyl acid carboxylic acid, 43.2 mg (0.13 mmol) of TBTU and 37 μL (0.27 mmol) of triethylamine in 1.5 mL of DMF was stirred for 1 h at RT. The addition of 24.9 mg (0.134 mmol) of 1- (1-methyl-piperidin-4-yl) -piperazine was then carried out and the reaction mixture was then stirred overnight at RT. The reaction solution was filtered through an injection filter and purified, without further treatment, directly through HPLC. The fractions containing the product were combined and lyophilized. Yield: 87.6 mg (87% of the theory) ESI-MS: (M + H) + = 759/761/763 (2 Br) Retention time (HPLC): 5.0 min (method A) Analogously, the following compounds from each in each case 80 mg of (R) -2- (3,4-dibromo-phenyl) -1-hydroxycarbonyl-ethyl ester of 4- (2-oxo-l, 2,4, 5- tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and the corresponding amount of amine: Analogously the following compounds can be prepared from ester (R) -2- (3,4-dibromo-phenyl) ) -1- 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid hydroxycarbonyl and the corresponding amount of amine: EXAMPLE 19 4- (2-Oxo) -ethyl (R) -1- (3,4-dibromo-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl ester -l, 2, 4, 5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 125 mg (0.15 mmol) of ester (R) -1- (3, 4 -dibromo-benzyl) -2- [4- (1-tert.-butoxycarbonyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl acid 4- (2-oxo-l, 2 , 4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 20 mL of 2 M HCl was stirred at RT for 16 h. The reaction mixture was lyophilized, precipitating the product in the form of the bis-hydrochloride salt. Yield: 110 mg (91% of the theory) ESI-MS: (M + H) + = 745/747/749 (2 Br) Retention time (HPLC): 5.4 min (method A) Example 20 Ester ( R) -1- (3,4-dibromo-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl 4- (2-oxo-1,2) -ethyl ester , 4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 79 mg (0.09 mmol) of 4- (l-. {(R) -3- (3,4-dibromo-phenyl) -2- [4- (2- (2-tert -butyl) -butyl ester) oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carbonyloxy] -propionyl.} - piperidin-4-yl) -piperazine-1-carboxylic acid in 15 mL of 2 M HCl was stirred at RT for 16 h.

The reaction mixture was lyophilized, precipitating the product in the form of the bis-hydrochloride salt. Yield: 76 mg (100% theory) ESI-MS: (M + H) + = 745/747/749 (2 Br) Retention time (HPLC): 5.7 min (method A) Example 21 Ester ( R) -1- (3,4-dichloro-benzyl) -2- [4- (l-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl acid 4- (2 -oxo- 1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 21a 2-Acetylamino-3- (3,4-dichloro-phenyl) -acrylic acid A mixture based on 20.0 g (112 mmol) of 3,4-dichlorobenzaldehyde, 19.7 g (168 mmol) of N- acetylglycine and 13.8 g (168 mmol) of NaOAc in 80 mL of acetanhydride was heated for 5 h to 120 ° C (oil bath temperature). After the reaction was complete, the reaction mixture was cooled by an ice bath and then slowly mixed with 60 mL of water (slightly exothermic reaction). The reaction mixture was heated for another 1.5 h to 80 ° C, cooled somewhat, then added to a mixture of 400 mL of water and 200 mL of toluene and stirring was continued overnight at RT. The precipitate was filtered off with suction, followed by washing with toluene and water, and then diethyl ether was added and filtering with suction. Yield: 21.0 g (68% of the theory) ESI-MS: (M + H) + = 274/276/278 (2 Cl) Rf = 0.16 (silica gel, DCM / MeOH / NH3 80: 20: 2) 21b 3- (3, -Dichloro-phenyl) -2-oxo-propionic acid To a suspension of 21.0 g (76.6 mmol) of 2-acetylamino-3- (3,4-dichloro) phenyl) -acrylic acid in 100 mL of N-methyl-2-pyrrolidinone was added 140 mL of ice-cold 4M HCl, and then the reaction mixture was heated at reflux for 4 h at a temperature of the oil bath. 125 ° C. The cooled reaction solution was poured onto a cooled mixture based on 350 mL of water and 120 mL of toluene. The phases were separated, the aqueous phase was extracted again with toluene, the combined organic phases were extracted with water, filtered over Na 2 SO 4 and concentrated i. empty The residue was taken up in 1 M NaOH and washed twice with diethyl ether. The aqueous phase was acidified with 2M HCl and extracted three times with EtOAc. The combined organic phases were filtered over Na2SO4 and concentrated i. empty The residue was mixed with diethyl ether, filtered with suction and dried in the vacuum drying oven. Yield: 8.20 g (46% of the theory) ESI-MS: (M + H) + = 231/233/235 (2 Cl) Rf = 0.11 (silica gel, DCM / MeOH / Cyc / NH3 70: 15 ': 15: 2) 21c (R) -3- (3,4-dichloro-phenyl) -2-hydroxy-propionic acid To a solution, cooled to -35 ° C, of 8.0 g (34 , 3 mmol) of 3- (3,4-dichloro-phenyl) -2-oxo-propionic acid and 5.2 mL (38.0 mmol) of triethylamine in 40 mL of THF was added dropwise in the space 30 min, a solution of 12.2 g (38.0 mmol) of (1R) -B-chlorodiisopinocanphenylborane in 20 mL of THF, and the reaction mixture was kept for 1 h at this temperature. The cooling bath was removed and the reaction solution was stirred for 4 h at RT. Then, the reaction solution was carefully mixed, at 5-10 ° C, with 50 mL of 1 M NaOH (exothermic) and 30 mL of TBME and stirring was continued for 15 min. The organic phase was separated, and extracted with 25 mL of water and 15 mL of 1 M NaOH. The combined aqueous phases were acidified with 2 M HCl and extracted three times, in each case with 40 mL of TBME. The combined organic phases were dried over Na 2 SO 4 and concentrated i. empty The residue was dissolved in 80 mL of boiling water and filtered with suction on Celite. The filtrate was saturated with NaCl and extracted three times with EtOAc. The combined organic phases were filtered over Na 2 SO 4 and concentrated again i. empty The crude product was reacted further without purification. Yield: 3.9 g (48% of theory) ESI-MS: (M + H) + = 233/235/327 (2 * C1) Retention time (HPLC): 6.8 min (method A) Rf = 0.87 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 21d Ethyl ester of (R) -3- (3,4-dichloro-phenyl) -2-hydroxy-propionic acid To a solution of 3.5 g (14.9 mmol) of acid (R) -3- (3,4-dichloro-phenyl) -2-hydroxy-propionic acid in 50 mL of EtOH was added 50 mL of ethanolic HCl and the reaction mixture was continued stirring for 4 h at RT. The reaction solution was concentrated i. vac., the residue was mixed with DCM, extracted with 15% K2C03 solution and the organic phase was dried over Na2SO4. After separating the drying agent and the solvent, the product was obtained in the form of an oil, which was reacted further without purification. Yield: 2.6 g (66% of the theory) ESI-MS: (M + H) + = 263/265/267 (2 Cl) Rf = 0.91 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 21e Ester (R) -2- (3,4-dichloro-phenyl) -1-ethoxycarbonyl ethyl 4- (2-oxo-l, 2,4,5-tetrahydro- 1, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid To a solution, cooled to 0 ° C, of 2.6 g (9.9 mmol) ethyl ester of (R) -3- (3, 4-dichloro-phenyl) -2-hydroxy-propionic acid in 50 mL of THF were added in portions 450 mg (55% in mineral oil, 10.3 mmol) of NaH and stirring was continued for another 30 min at this temperature. Subsequently, 3.7 g (11.9 mmol) of 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) chloride were added in portions under cooling. piperidin-1-carbonyl and the reaction mixture was stirred overnight at RT. The reaction solution was concentrated i.vac., The residue was mixed with DCM, the organic phase was separated, this was washed with 10% citric acid solution and 15% K2C03 solution and dried over Na2SO4. After removing the drying agent and the solvent, the product was obtained in the form of an oil, which was reacted without further purification. Yield: 5.2 g (98% of theory) ESI-MS: (M + H) + = 534/536/538 (2 Cl) Rf = 0.77 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 21f 1-carboxy (R) -2- (3,4-dichloro-phenyl) -ethyl ester of 4- (2-oxo-l, 2, 4, 5-tetrahydro- 1, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid To a solution of 5.2 g (9.7 mmol) of ester (R) -2- (3,4-dichloro-phenyl) -1- 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid ethoxycarbonyl ethyl ester in 30 mL of THF was added, at RT, . solution of 348 mg (14.5 mmol) of lithium hydroxide in 10 mL of water and the reaction mixture was stirred overnight at RT, concentrated i.vac, the residue was taken up in 15% K2CO3 solution and the aqueous phase was washed three times with EtOAc The aqueous phase was mixed, with stirring, with 5 M HCl until the acid reaction and extracted to exhaustion with DCM The combined organic phases were filtered over Na 2 SO and the solvent was removed i. The residue was taken up in isopropanol and the precipitate was filtered off, the filtrate was concentrated i.vac, the residue was purified by chromatography (silica gel, gradient DCM / MeOH / NH3 10: 0: 0 to 75: 25: 5), the corresponding fractions were combined, the solvent was removed, and the residue was mixed with diethyl ether and filtered off Yield: 2.2 g (45% of theory) ESI-MS: (M + H ) + = 506/508/510 (2 Cl) Rf = 0.51 (silica gel, DCM / MeOH / Cyc / NH3) 70: 15: 15: 2) 21g Ester (R) -1- (3,4-dichloro-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] - 2-oxo-ethyl- of 4- (2-oxo-l, 2,4,5-tetrahydro-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 80 mg (0.16 mmol) of ester 1-Carboxy- (R) -2- (3,4-dichloro-phenyl) -ethyl 4- (2-oxo-1, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid, 58 mg (0.18 mmol) of TBTU and 25 μL (0.18 mmol) of triethylamine in 2 mL of DMF was stirred for 10 min at RT. The addition of 33 mg (0.18 mmol) of 1- (1-methyl-piperidin-4-yl) -piperazine was then carried out and the reaction mixture was then stirred overnight at RT. The reaction solution was filtered through an injection filter and purified, without further treatment, directly through HPLC. The fractions containing the product were combined and lyophilized. Yield: 35.0 mg (33% of theory) ESI-MS: (M + H) + = 671/673/675 (2 Cl) Retention time (HPLC): 5.3 min (method A) The following compounds were prepared analogously, in each case from 80 mg (Examples 22 to 24) or in each case from 160 mg (Examples 25 to 27) of 4- (2-carboxy (R) -2- (3,4-dichloro-phenyl) -ethyl ester) -oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and the corresponding amount of amine: Example 28 Ester (R) -1- (3,4-dichloro-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl 4- (2- oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 30 mg (0.04 mmol) of ester (R) -l- (3, -dichloro-benzyl) -2- [4- (1-tert-butoxycarbonyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl acid 4- (2-oxo-l, 2 , 4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 25) in 5 mL of 4 M HCl was stirred at RT overnight. The reaction mixture was lyophilized, precipitating the product as an HCl salt. Yield: 18 mg (66% of theory) ESI-MS: (M + H) + = 657/659/661 (2 Cl) Rf = 0.33 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) Example 29 (R) -1- (3,4-dichloro-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl acid ester 4- (2-oxo-l, 2,4,5-tetrahydro-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 35 mg (0.05 mmol) of tere-butyl ester of 4- (l- { (R) -3- (3,4-dichloro-phenyl) -2- [4- (2- oxo-1,2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carbonyloxy] -propionyl.} - piperidin-4-yl) -piperazine-1-carboxylic acid (Example 26) in 5 mL of 4 M HCl was stirred at RT overnight. The reaction mixture was lyophilized, precipitating the product as an HCl salt. Yield: 24 mg (75% of the theory) ESI-MS: (M + H) + = 657/659/661 (2 Cl) Rf = 0.30 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) Example 30 (R) -2-4, 4'-bipiperidinyl-l-yl-1- (3,4-dichloro-benzyl) -2-oxo-ethyl ester of 4- ( 2-oxo-l, 2,4,5,5-tetrahydro-benzodiazepin-3-yl) -piperidine-1-carboxylic acid tert.-butyl ester of 1 '- acid. { (R) -3- (3,4-dichloro-phenyl) -2- [4- (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1 -carbonyloxy] -propionyl} -4, 4'-bipiperidinyl-1-carboxylic acid (Example 27) in 5 mL of 4 M HCl was stirred at RT overnight. The reaction mixture was lyophilized, precipitating the product as an HCl salt. Yield: 16 mg (58% of theory) ESI-MS: (M + H) + = 656/658/660 (2 Cl) Example 31 Ester (R) -1- (4-chloro-3,5-dimethyl) -benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl acid 4- (2-oxo-l, 2,4, 5- tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 31a 5-bromo-2-chloro-l, 3-dimethylbenzene 40.0 g (200 mmol) of 4-bromo-2,6-dimethylamine in 100 mL of semiconc. HCl. 0 ° C was mixed with 15, -2 g (220 mmol) of NaN02 in 90 mL of water, stirring was continued for 20 min, mixed with a solution based on 21.7 g (220 mmol) of CuCl in water. 90 mL of semiconc. HCl. and stirred for 2 h at 70 ° C and for 15 h at RT. After the reaction was complete, the reaction mixture was poured into 200 L of water and extracted with TBME. The organic phases were combined, extracted with 2 M NaOH until the organic phase became colorless and then the combined organic phases were dried over Na 2 SO 4. After separating the drying agent and the solvent, the residue was purified by chromatography (silica gel, Cyc / DCM 1: 1). Yield: 30.7 g (70% of theory) ESI-MS: (M + H) + = 218/220/222 (Br, Cl) Rf = 0.84 (silica gel, Cyc / DCM 1: 1 ) 31b 2-Acetylamino-3- (4-chloro-3,5-dimethyl-phenyl) -acrylic acid methyl ester Under a nitrogen atmosphere, 30.0 g (136.7 mmol) of 5-bromo-2 were mixed. -chloro-l, 3-dimethylbenzene, 24.0 g (164.0 mmol) of 2-acetylamino-acrylic acid methyl ester in 420 mL of triethylamine and 200 mL of acetonitrile with 3.4 g (10.9 mmol) of tri-o-tolyl-phosphane and 2.4 g (10.9 mmol) of Pd (OAc) 2 and stirred for 18 h at 80 ° C. The precipitate was filtered with suction, the filtrate was concentrated i. vac., mixed with 800 mL of DCM and 800 mL of water, and the organic phase was separated and dried over Na2SO4. After removing the drying agent and the solvent, the residue was mixed with EtOAc, filtered with suction and dried i. empty Yield: 29.4 g (76% of theory) ESI-MS: (M + H) + = 282/284 (Cl) Retention time (HPLC-MS): 7.8 min (method A) 31c Acid 3 - (4-Chloro-3,5-dimethyl-phenyl) -2-oxo-propionic acid 29.4 g (105 mmol) of 2-acetylamino-3- (4-chloro-3,5-dimethylphenyl) methyl ester Acrylic in 330 mL of N-methyl-2-pyrrolidinone was mixed with 500 mL of cooled 4 M HCl, and stirred for 6 h at reflux and for 16 h at RT. After the reaction was completed, the reaction mixture was poured into 1650 mL of water, stirring was continued for 1 h, filtered with suction - and the crystals were dried at 50 ° C in the vacuum drying oven. The product was recrystallized from toluene. Yield: 12.3 g (52% of theory) ESI-MS: '(M + H) + = 225/227 (Cl) Retention time (HPLC-MS): 7.9 min (method A) 31d Acid (R) -3- (4-Chloro-3,5-dimethyl-phenyl) -2-hydroxy-propionic acid 12.3 g (54.4 mmol) of 3- (4-chloro-3,5-dimethyl) acid phenyl) -2-oxo-propionic acid in 130 mL of THF and 7.6 mL (54.4 mmol) of triethylamine were mixed at -35 ° C with a solution of 21.0 g (65.3 mmol) of (1R) -B-chlorodiisopinocampheylborane in 65 mL of THF in the space of 30 min. and stirring was continued for 2 h at this temperature. After the reaction was complete, the reaction mixture was made alkaline at 0 ° C with 50 L of 1 M NaOH. (exothermic), stirring was continued for 3 h, mixed with 30 mL of TBME and the phases were separated. The organic phase was washed with 50 mL of water and 30 mL of 1 M NaOH. The combined aqueous phases were acidified with 2 M HCl and extracted with TBME. The organic phases were dried over Na 2 SO 4 and concentrated i. empty The product was reacted further without purification. Yield: 12.5 g (100% of the theory) ESI-MS: (M + H) + = 227/229 (Cl) Retention time (HPLC-MS): 7.1 min (method A) 31e Methyl ester of (R) -3- (4-Chloro-3,5-dimethyl-phenyl) -2-hydroxy-propionic acid To a solution, cooled to 0 ° C, of 12.45 g (54.4 mmol) of acid . (R) -3- (4-Chloro-3,5-dimethyl-phenyl) -2-hydroxy-propionic acid in 300 mL of MeOH was added dropwise 4.4 mL (59.9 mmol) of S0C12 and the mixture of reaction was continued stirring for 1 h at RT. The reaction solution was concentrated i. empty and the residue was purified by chromatography (silica gel, Cyc / EtOAc 4: 1). Yield: 10.1 g (76% of the theory) ESI-MS: (M + NH4) + = 260/262 (Cl) Retention time (HPLC-MS): 8.1 min (method A) 31f Ester ( R) -2- (4-chloro-3,5-dimethyl-phenyl) -1-methoxycarbonyl-ethyl 4- (2-oxo-l, 2, 4,5-tetrahydro-1,3-benzodiazepin-3) -yl) -piperidine-1-carboxylic acid. Under a nitrogen atmosphere, 1.0 g (8.2 mmol) of 4-dimethylaminopyridine in 30 mL of pyridine were mixed with 1.7 g (8.2 mmol) of 4-ester. Chloroformic acid nitrophenyl ester, stirred for 40 min at RT, then 2.0 g (8.2 mmol) of (R) -3- (4-chloro-3,5-dimethyl-phenyl) methyl ester were added. -2-hydroxy-propionic acid, was stirred again for 20 min at RT and then mixed with 2.0 g (8.2 mmol) of 3-piperidin-4-yl-1, 3, 5- tetrahydro-1,3-benzodiazepin-2-one and the reaction mixture was stirred for 20 h at RT. He concentrated i. vac., the residue was taken up in EtOAc, washed with 10% KHS04 solution and saturated NaHCO3 solution and the organic phase was dried over Na2SO4. After separating the drying agent and the solvent, the residue was purified by chromatography (silica gel, Cyc / EtOAc 1: 1 to 1: 2). Yield: 2.16 g (51% of the theory) ESI-MS: (M + H) + = 514/516 (Cl) Retention time (HPLC-MS): 10.1 min (method A) 31g Ester ( R) -l-carboxy-2- (4-chloro-3,5-dimethyl-phenyl) -ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3) -yl) -piperidine-1-carboxylic acid To a solution of 2.15 g (4.18 mmol) of ester (R) -2- (4-chloro-3,5-dimethyl-phenyl) -1-methoxycarbonyl-ethyl of 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin- 3-yl) -piperidine-1-carboxylic acid in 60 mL of THF was added a solution of 150 mg (0.60 mmol) of LiOH in 30 L of water and the reaction mixture was stirred for 1 h at RT. He concentrated i. vac., the residue was taken up in 100 mL of water, acidified with 1 M HCl, the precipitate was filtered and dried in the vacuum drying oven at 40 ° C. Yield: 2.05 g (98% of theory) ESI-MS: (M + H) + = 500/502 (Cl) Retention time (HPLC-MS): 8.8 min (method A) 31 h Ester (R) -1- (4-Chloro-3,5-dimethyl-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl from 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 80 mg (0.16 mmol) of ester (R) -2- (2-Oxo-1,2,4,5,5-tetrahydro-benzodiazepin-3-yl) -piperidyi-1-carboxylic acid (4-chloro-3, 5-dimethyl-phenyl) -ethyl ester; 51 mg (0.16 mmol) of TBTU and 28 μL (0.20 mmol) of triethylamine in 1.5 mL of DMF were stirred for 1 h at RT. The addition of 30 mg (0.16 mmol) of 1-methyl-4- (piperidin-4-yl) -piperazine was then carried out and the reaction mixture was then stirred for 16 h at RT. The reaction solution was filtered through an injection filter and purified, without further treatment, directly through HPLC. The fractions containing the product were combined and lyophilized. Yield: 18 mg (17% of theory) ESI-MS: (M + H) + = 665/667 (Cl) Retention time (HPLC-MS): 5.6 min (method A) The following were similarly prepared compounds, in each case from 80 mg (Examples 32 to 34) or in each case from 140 mg (Examples 35 and 36) of ester (R) -l-carboxy-2- (4-chloro-3, 4- (2-Oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 5-dimethyl-phenyl) and the corresponding amount of amine: EXAMPLE 37 Ester (R) -1- (4-Chloro-3,5-dimethyl-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl 4-ethyl ester (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 64.0 mg (0.09 mmol) of 4- (1- (R) -3- (4-chloro-3,5-dimethyl-phenyl) -2-tert-butyl ester. - [4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carbonyloxy] -propionyl.} - piperidin-4-yl) -piperazin -1-carboxylic acid (Example 35) in 5 mL of 2 M HCl was stirred at RT overnight. The reaction mixture was lyophilized, precipitating the product in the form of the bis-hydrochloride salt. Yield: 61.2 mg (99% of the theory) ESI-MS: (M + H) + = 651/653 (Cl) Retention time (HPLC-MS): 5.9 min (method A) Example 38 Ester (R) ) -1- (4-Chloro-3, 5-dimethyl-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl 4- (2-oxo-) 1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 59 mg (0.08 mmol) ester (R) -l- (4-chloro-3,5-dimethyl-benzyl) -2- [4- (1-tert.-butoxycarbonyl-piperidin-4-) il) -piperazin-1-yl] -2-oxo-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 36) in 5 mL of 2 M HCl was stirred at RT overnight. The reaction mixture was lyophilized, precipitating the product as a bis-hydrochloride salt. Yield: 55.7 mg (57% of the theory) ESI-MS: (M + H) + = 651/653 (Cl) Retention time (HPLC-MS): 5.5 min (method A) Example 39 Ester (R) -1- (3, 5-dimethyl-benzyl) -2- [4- (l-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl acid 4- ( 2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 39a Ester (R) -l-carboxy-2- (3, 5-dimethyl-phenyl) -ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-) il) -piperidine-1-carboxylic acid 500 mg (1.0 mmol) 1-carboxy (R) -2- (4-chloro-3,5-dimethyl-phenyl) -ethyl ester of 4- (2- oxo-l, 2, 5-tetrahydro-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 31g) in 20 mL of MeOH were mixed with 100 mg of 10% Pd / C and 2 mL of triethylamine and they were hydrogenated for 10 days at RT and 3 bar. After the reaction was complete, the reaction mixture was concentrated i.vac., The residue was taken up in 25 mL of water, acidified with 1 M HCl, the precipitate was filtered with suction and dried in the vacuum drying oven at 40 ° C. Yield: 418 mg (90% of the theory) ESI-MS: (M + H) + = 466 Retention time (HPLC-MS): 8.3 min (method A) 39b Ester (R) -I- (3 , 5-dimethyl-benzyl) -2- 4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl acid 4- (2-oxo-l, 2, 4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 50 mg (0.16 mmol) of ester (R) -l-carboxy-2- (3, 5) 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid dimethyl-phenyl) -ethyl ester, 35 mg (0.11 mmol) of TBTU and 19 μL (0.13 mmol) of triethylamine in 1 mL of DMF was stirred for 1 h at RT.

The addition of 20 mg (0.11 mmol) of 1- (1-methyl-piperidin-4-yl) -piperazine was then carried out and the reaction mixture stirred for 16 h at RT The reaction solution was filtered through an injection filter and purified, without further treatment, directly through HPLC The fractions containing the product were pooled and lyophilized Yield: 33 mg 49% of the theory) ESI-MS: (M + H) + = 631 Retention time (HPLC-MS): 5.3 min (method A) The following compounds were prepared analogously, in each case from 50 mg (Examples 40 and 41) or in each case from 80 mg (Examples 42 and 43) of ester (R) -l-carboxy-2- (3, 5-dimethyl-phenyl) -ethyl 4- (2 -oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and the corresponding amount of amine: Example 44 4- (2-Oxo) -ethyl (R) -1- (3,5-dimethyl-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl ester -l, 2, 4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 45 mg (0.06 mmol) ester (R) -1- (3, 5-dimethyl-benzyl) -2- [4- (1-tert.-butoxy-carbonyl-piperidin-4-yl) 4- (2-Oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid -piperazin-1-yl] -2-oxo-ethyl ester (Example 42) in 10 mL of 2 M HCl was stirred at RT overnight. The reaction mixture was lyophilized. The crude product was collected in 1 mL of DMF, it was made basic with 0.6 mL of saturated K2C03 solution and purified by chromatography through HPLC. Yield: 26.8 mg (69% of theory) ESI-MS: (M + H) + = 617 Retention time (HPLC-MS): 5.4 min (method A) Example 45 Ester (R) -2 - [4,4 '] bipiperidinyl-l-yl-l- (3, 5-dimethyl-benzyl) -2-oxo-ethyl 4- (2-oxo-l, 2, 4, 5-tetrahydro-1) , 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 0O-Q? H A solution of 101 mg (0.14 mmol) of tert.-butyl ester of 1 '- acid. { (R) -3- (3, 5-dimethyl-phenyl) -2- [4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1 -carbonyloxy] -propionyl} -4, -bipiperidinyl-1-carboxylic acid (Example 43) in 10 mL of 2M HCl was stirred at RT overnight. The reaction mixture was lyophilized. The crude product was taken up in 1 mL of DMF, basified with 0.6 mL of saturated K2C03 solution and purified by HPLC chromatography. Yield: 18.7 mg (22% of theory) ESI-MS: (M + H) + = 616 Retention time (HPLC-MS): 6.5 min (method A) Example 46 Ester (R) -1 - (3, 5-Bis-trifluoromethyl-benzyl) -2- [4- (1-methyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl 4- (2-oxo) -l, 2,4, 5-tetrahydro-l, 3-benzodiazepin-3-yl) - trifluoromethyl-phenyl) acrylic Under a nitrogen atmosphere, 50.0 g (171 mmol) of 3,5-bis- (trifluoromethyl) -bromobenzene, 25.0 g (171 mmol) of 2-acetylamino- Acrylic in 475 mL of triethylamine and 250 mL of acetonitrile with 3.9 g (12.4 mmol) of tri-o-tolyl-phosphane and 2.8 g (12.5 mmol) of Pd (0Ac) 2 and stirred for 18 h at 80 ° C. After the reaction was complete, the reaction mixture was concentrated i. empty up to approx. 200 mL, was combined with 400 L of EtOAc and 400 mL of water, the precipitate was filtered with suction and the phases were separated. The organic phase was dried over Na 2 SO, mixed with activated charcoal, filtered and concentrated to dryness. The residue was mixed with stirring with DIPE, filtered with suction and dried i. empty Yield: 19.5 g (32% of the theory) ESI-MS: (M + H) + = 356 Rf = 0.76 (silica gel, PE / EtOAc 1: 1) 46b Acid 3- (3, 5 -bis-trifluoromethyl-phenyl) -2-oxo-propionic acid 19.5 g (54.9 mmol) of 2-acetylamino-3- (3,5-bis-trifluoromethyl-phenyl) -acrylic acid methyl ester in 100mL of 1,4-dioxane was heated to a bath temperature of 100 ° C, mixed with 100 mL of 4 M HCl and stirred for 8 h at a bath temperature of 100 ° C. The reaction mixture was concentrated i. vacuum, the crystals were filtered with suction, washed with water and dried in the drying oven at 50 ° C. Yield: 16.1 g (98% of the theory) ESI-MS: (MH) "= 299 Rf = 0.18 (silica gel, EtOAc) 46c (R) -3- (3,5-bis-) acid trifluoromethyl-phenyl) -2-hydroxy-propionic acid 16.1 g (53.6 mmol) of 3- (3,5-bis-trifluoromethyl-phenyl) -2-oxo-propionic acid in 9.5 g (70.0 mmol) of triethylamine and 100 mL of THF were mixed "at -35 ° C with a solution based on 26.0 g (81.1 mmol) of (1R) -B-chlorodiisopinocampheylborane in 40 mL of THF in the 30 min and stirring was continued for 1 h at this temperature and overnight at RT. After the reaction was complete, the reaction mixture was made basic at 0 ° C with 160 mL of 1 M NaOH, se. continued stirring for 15 min, mixed with 100 mL of TBME and the phases separated. The organic phase was washed with 50 mL of water and 50 mL of 1 M NaOH. The combined aqueous phases were acidified with. 4 M HCl, were extracted to exhaustion with TBME and the combined organic phases were dried over Na 2 SO, filtered with suction on activated carbon and concentrated i. empty The product was reacted further without purification. Yield: 12.5 g (77% of the theory) ESI-MS: (MH) "= 301 Rf = 0.45 (silica gel, EtOAc) 46d (R) -3- (3, 5) methyl ester -bis-trifluoromethyl-phenyl) -2-hydroxy-propionic acid 12.5 g (41.4 mmol) of (R) -3- (3,5-bis-trifluoromethyl-phenyl) -2-hydroxy-propionic acid in 150 mL of methanolic HCl (1.25 M) was stirred for 4 h at RT and then i.vac was concentrated The residue was taken up in EtOAc and washed with saturated NaHCO 3 solution, the organic phase was dried over Na 2 SO 4, it was filtered with suction on activated charcoal and concentrated i.vac.The residue was mixed with stirring with PE, filtered with suction and concentrated i.vac.The product was further reacted without purification Yield: 11.4 g (87 g. % of theory) ESI-MS: (M + H) + = 316 Rf = 0, 80 (silica gel, PE / EtOAc 1: 1) 46e Ester (R) -2- (3,5-bis-trifluoromethyl-phenyl) -1-methoxycarbonyl-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Analogously to Example 31f, from 6.0 g (8.2 mmol) of methyl ester of acid (R) -3- (3,5-bis-trifluoromethyl-phenyl) -2-hydroxy-propionic acid and 5.13 g (20.9 mmol) of 3-piperidin-4-yl-1,3,4,5-tetrahydro- 1, 3-benzodiazepin-2-one, the product could be obtained. Purification was carried out by chromatography (silica gel, gradient PE / EtOAc 1: 1 to 1: 9). Yield: 5.1 g (46% of the theory) ESI-MS: (M + H) + = 588 Rf = 0.63 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 46f Ester (R) -2- (3,5-bis-trifluoromethyl-phenyl) -1-carboxylic acid 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3- benzodiazepln-3-yl) -piperidine-1-carboxylic acid To a solution of 5.0 g (8.5 mmol) of ester (R) -2- (3,5-bis-triflupromethyl-phenyl) -1-methoxycarbonyl- Ethyl 4- (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benz diazepin-3-yl) -piperidine-1-carboxylic acid in 50 mL of water was added a solution of 307 mg ( 12.8 mmol) of LiOH in 5 mL of water and the reaction mixture was stirred overnight at RT. He concentrated i. aq., the residue was taken up in water, acidified with 1 M HCl, the precipitate was separated by filtration and dried in the drying oven at 40 ° C. Yield: 4.5 g (92% of the theory) ESI-MS: (M + H) + = 574 Rf. = 0.32 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 46g Ester (R) -l- (3., 5-bis- trifluoromethyl-benzyl) -2- 4- (2- (1-methyl-piperidin-4-yl) - • piperazin-1-yl] -2-oxo-ethyl 4- (2-oxo-1, 2, 4, 5- -tetrahydro-1, 3-ben?: odiazepin- -3-: il) -piperidine-1-carboxylic acid A solution of 80 mg (0.14 mmol) of ester (R) -2- (3,5-bis-trifluoromethyl- phenyl) -1-carboxy-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-benzodiazepin-3-yl) -piperidine-1-carboxylic acid, 51 mg (0.16 mmol) of TBTU and 22 μL (0.16 mmol) of triethylamine in 1 mL of DMF was stirred for 1 hr. The addition of 29 mg (0.16 mmol) of 1- (1-methyl-piperidin-4-yl) -piperazine was then carried out and the reaction mixture was stirred overnight at RT. The reaction solution was filtered through an injection filter and purified, without further treatment, directly through HPLC.

The fractions containing the product were combined and lyophilized. Yield: 56 mg (54% of the theory) ESI-MS: (M + H) + = 739 Retention time (HPLC-MS): 5.8 min (method A). Analogously the following compounds were prepared, in each case from 80 mg (Examples 47 to 49) or in each case from 100 mg (Examples 50 to 53) of ester (R) -2- (3,5-bis-trifluoromethyl-phenyl) -1-carboxy - 4- (2-Oxo-l, 2,, 5-tetrahydro-benzodiazepin-3-yl) -piperidine-1-carboxylic acid ethyl ester and the corresponding amount of amine: Example Time Spectrum Performance of (%) HPLC retention masses (method) 47 49 739 6.5 min x Nyy > [M + Hf (A) Example 54: Ester (R) -1- (3,5-bis-trifluoromethyl-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) - Ethyl 4- (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 77 mg (0.09 mmol) of ester (R) -2- [4- (1-benzyl-piperidin-4-yl) -piperazin-1-yl] -1- (3, 5-bis- trifluoromethyl-benzyl) -2-oxo-ethyl of 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 51 ) in 10 mL of MeOH was mixed with 50 mg of 10% Pd / C and shaken for 3 h at RT and 3.5 kg / cm 2 of hydrogen. The catalyst was filtered with suction, the solvent was concentrated i. vac., and the residue was mixed with acetonitrile and water and lyophilized. Yield: 6 mg (70% of the theory) ESI-MS: (M + H) + = 725 Retention time (HPLC-MS): 5.7 min (method A) Example 55 Ester (R) '- l- (3, 5-Bis-trifluoromethyl-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl 4- (2-oxo-1,2,4, 5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 64 mg (0.08 mmol) of ester (R) -2- [4- (4-benzyl-piperazin-1-yl) -piperidin-1-yl] -1- (3, 5-bis- trifluoromethyl-benzyl) -2-oxo-ethyl 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 52) in 10 mL of MeOH was mixed with 50 mg of 10% Pd / C and shaken for 3 h at RT and 3.5 kg / cm 2 of hydrogen. The catalyst was filtered with suction, the solvent was concentrated i.vac., And the residue was mixed with acetonitrile and water and lyophilized. Yield: 43 mg (76% of theory) ESI-MS: (M + H) + = 725 Retention time (HPLC-MS): 5.7 min (method A) Example 56 Ester (R) -2-4 , 4 '-bipiperidinyl-l-yl-1- (3,5-bis-trifluoromethyl-benzyl) -2-oxo-2-ethyl of 4- (2-oxo-1,2,4,5,5-tetrahydro- l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 92 mg (0.11 mmol) of (R) -2- (1, -benzyl-4,4'-bipi? Eridinyl-1-yl) -l- (3,5-bis-trifluoromethyl) ester benzyl) -2-oxo-ethyl 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 53) in 10 mL of MeOH was mixed with 50 mg of 10% Pd / C and shaken for 3 h at RT and 3.5 kg / cm 2 of hydrogen. The catalyst was filtered with suction, the solvent was concentrated i.vac., And the residue was mixed with acetonitrile and water and lyophilized. Yield: 55 mg (67% of theory) ESI-MS: (M + H) + = 724 Retention time (HPLC-MS): 5.6 min (method A) Example 57 Ester (R) -1- ( 3, 5-bis-trifluoromethyl-benzyl) -2- (1 '-carboxymethyl-4,4'-bipiperidinyl-l-yl) -2-oxo-ethyl acid 4- (2-oxo-l, 2,4 , 5-tetrahydro-l, 3-benzodiazepin-3-yl) - To a solution of 35 mg (0.04 mmol) of ester (R) -1- (3,5-bis-trifluoromethyl-benzyl) -2- (1'-ethoxycarbonylmethyl-4,4'-bipiperidinyl-1-yl) ) -2- oxo-ethyl 4- (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 50) in 5 mL of THF was added a solution of 1.5 mg (0.06 mmol) of LiOH in 1 mL of water and the reaction solution was stirred overnight at RT. He concentrated i. vac., the residue was taken up in water, acidified with 1 N HCl, the precipitate was separated by filtration and dried in a vacuum oven at 40 ° C. Yield: 15 mg (44% of theory) ESI-MS: (M + H) + = 782 Rf = 0.41 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) Example 58 Ester (R) -1- (3, 5-dibromo-benzyl) -2- (4-dimethylamino-piperidin-1-yl) -2-oxo-ethyl of 4- (2-oxo-l, 2,, 5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 58a Acid (Z, E) -2-acetylamino-3- (3,5-dibromo-phenyl) -acrylic Analogously to Example la, from 35.0 g (133 mmol) of 3, 5-dibromo-benzaldehyde and 23.3 g (199 mmol) of N-acetyl-glycine, the product could be obtained. Yield: 29.2 g (61% of theory) Melting point 248-249 ° C ESI-MS (M + H) + = 362/364/366 (2 Br) Rf = 0.1 (silica gel, DCM / MeOH / AcOH 90: 10: 1) 58b 3- (3,5-dibromo-phenyl) -2-oxo-propionic acid Analogously to Example Ib, from 29.0 g (80.0 mmol) of (Z, E) -2-acetylamino-3- (3,5-dibromo-phenyl) -acrylic acid, the product could be obtained. Yield: 14.0 g (54% of the theory) ESI-MS (MH) "318/320/322 (2 Br) Rf = 0.4 (silica gel, DCM / MeOH / AcOH 90: 10: 1) 58c (R) -3- (3,5-dibromo-phenyl) -2-hydroxy-propionic acid Analogously to Example LE, from 12.0 g (37.3 mmol) of 3- (3, 5- dibromo-phenyl) -2-oxo-propionic acid and 15.1 g '(47.1 mmol) of (1R) -B-chlorodiisopinocanphenylborane, the product could be obtained Yield: 4.1 g (34% of the theory) ESI-MS (MH) ~ 321/323/325 (2 Br) 58d (R) -3- (3,5-dibromo-phenyl) -2-hydroxy-propionic acid methyl ester Analogously to Example 46d, from 4.0 g (12.4 mmol) of (R) -3- (3,5-dibromo-phenyl) -2-hydroxy-propionic acid, the product could be obtained, using methanolic HCl (6 M) for esterification. Yield: 4.0 g (96% of theory) Rf = 0.9 (silica gel, DCM / MeOH / AcOH .90: 10: 1) 58e Ester (R) -2- (3, 5-dibromo- 4- (2-oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid phenyl) -1-methoxycarbonyl ethyl ester Analogously to Example 31f, starting from of 3.40 g (10.06 mmol) of (R) -3- (3,5-dibromo-phenyl) -2-hydroxy-propionic acid methyl ester and 2.46 g (10.03 mmol) of 3 -piperidin-4-yl-l, 3, 4, 5-tetrahydro-l, 3-benzodiazepin-2-one, the product could be obtained. Performance: 2.0 g (33% of theory) ESI-MS (M + H) + = 608/610/612 (2 Br) Rf = 0.2 (silica gel, n-hexane / EtOAc 3: 7) Retention time (HPLC): 22.6 min ( method F) 58f 4- (2-Oxo-l, 2,, 5-tetrahydr? -l, 3-benzodiazepin) (R) -l-carboxy-2- (3,5-dibromo-phenyl) -ethyl ester -3-yl) -piperidine-1-carboxylic acid To a solution of 2.0 g (3.3 mmol) of (R) -2- (3,5-dibromo-phenyl) -1-methoxycarbonyl-ethyl acid ester 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 12.5 L of THF was added a solution of 118 mg (4.9 mmol ) of LiOH in 5 mL of water and the reaction mixture was stirred for 2 h at RT. The reaction mixture was concentrated i. vac., the residue was mixed with water and TBME and the aqueous phase was adjusted to pH 2-3 with conc. HCl. and extracted with DCM. The combined organic phases were washed with saturated NaCl solution, dried over Na 2 SO and concentrated to dryness i. empty Yield: 1.9 g (97% of the theory) ESI-MS (M + H) + = 594/596/598 (2 Br) Rf = 0.25 (silica gel, DCM / MeOH 9: 1) Time Retention (HPLC): 19.1 min (method F) 58g Ester (R) -1- (3, 5-dibromo-benzyl) -2- (4-dimethylamino-piperidin-1-yl) -2-oxo- Ethyl 4- (2-oxo-l, 2,, 5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 150 mg (0.25 mmol) of ester (R ) -l-carboxy-2- (3, 5-dibromo-phenyl) -ethyl 4- (2-oxo-1,2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine -1- 'carboxylic acid, 90 mg (0.28 mmol) of TBTU, 95 μL (0.55 mmol) of ethyldiisopropylamine and 38 mg (0.28 mmol) of HOBt in 6 mL of DMF were stirred for 90 min at RT . The addition of 42 mg (0.33 mmol) of 4-dimethylamino-piperidine was then carried out and the reaction mixture was stirred for 16 h at RT. The reaction solution was mixed with water, the organic phase was concentrated and the residue was purified by chromatography (silica gel, DCM / MeOH / NH3 95: 5: 0.5). Yield: 140 mg (79% of theory) ESI-MS (M + H) + = 704/706/708 (2 Br) Rf = 0.35 (silica gel, DCM / MeOH / NH3 90: 10: 1 ) Retention time (HPLC): 12.0 min (method F) The following compounds were similarly prepared from each in each case 150 mg ester (R) -l-carboxy-2- (3,5-dibromo-phenyl) ) - 4- (2-Oxo-1,2,4,5,5,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid amine ester: EXAMPLE 66 4- (2-Oxo) -ethyl (R) -1- (3,5-dibromo-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl ester -l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 300 mg (0.23 mmol) of 4- (l-. {(R) -3- (3,5-dibromo-phenyl) -2- [4H-fluoren-9-ylmethyl] 4-ester - (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carbonyloxy] -propionyl.} - piperidin-4-yl) -piperazin-1- carboxylic acid (Example 63) in 4 mL of piperidine was stirred at RT for 1 h. The reaction solution was concentrated to dryness and the residue was purified by chromatography (silica gel, gradient DCM to DCM / MeOH / NH3 90: 10: 1). Yield: 134 mg (79% of the theory) ESI-MS: (M + H) + = 745/747/749 (2 Br) Retention time (HPLC): 9.7 min (method F) Example 67 Ester (R) -1- (3,5-dibromo-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazine) 4- (2-oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid-1-yl) -ethyl ester To a solution of 180 mg (0.21 mmol) of ester (R) -1- (3,5-dibromo-benzyl) -2- [4- (1-tert-butoxycarbonyl-piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl ester of 4- (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 64) in 2 mL of water was added 1.8 mL of HCl (3.2 M) and the reaction mixture was stirred for 3 h at RT. It was mixed with 25 L of EtOAc and 20 L of 17% Na 2 CO 3 solution, the organic phase was separated, the aqueous phase was extracted again with 25 mL of EtOAc, and the combined organic phases were washed with 10 mL of saturated solution. of NaCl and dried over Na2SO4. After separating the drying agent and the solvent, the residue was suspended in diethyl ether, the organic phase was separated by decantation and the residue was dried. Yield: 130 mg (82% of theory) ESI-MS: (M + H) * = 745/747/749 (2 Br) Retention time (HPLC): 9.3 min (method F) Example 68: Ester (R) -2-4, 4'-bipiperidinyl-l-yl-1- (3,5-dibromo-benzyl) -2-oxo -2- Ethyl 4- (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 160 mg (0.19 mmol) of tert.-butyl ester of 1 '- acid. { (R) -3- (3, 5-dibromo-phenyl) -2- [4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1 -carbonyloxy] -propionyl} -4,4'-bipiperidinyl-1-carboxylic acid (Example 65) in 2 L of formic acid was stirred at RT for 1 h. The reaction solution was concentrated i.vac., The residue was taken up in DCM, the organic phase was washed with 10% Na2CO3 solution, filtered and concentrated to dryness. The residue was suspended in 10% NaOH, stirred for 1 h at RT, the precipitate was filtered, washed with a little water and diethylether and dried i.vac.

Yield: 86 mg (61% of the theory) ESI-MS: (M + H) * = 744/746/748 (2 Br) Retention time (HPLC): 12.6 min (method F) Example 69 Ester ( R) -1- (4-hydroxy-3, 5-dimethyl-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl acid 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 69a 2-benzyloxy-5-bromo-1,3-dimethylbenzene To a solution of 50.0 g (249 mmol) of 2,6-dimethyl-bromophenol in 500 mL of DMF was added 39.9 g (286 mmol) of K2C03 and stirring was continued for 20 min.

Then, 34.0 mL (286 mmol) of benzyl chloride were slowly added dropwise and the reaction mixture was stirred for 3 h at a bath temperature of 100 ° C. Once the reaction was finished, 500 mL of water was poured and extracted to exhaustion with EtOAc. The organic phases were combined, dried over Na2SO4 and concentrated i. empty Yield: quantitative GC-MS: (M *) = 290/292 (Br) Rf = 0.87 (silica gel, Cyc / EtOAc 3: 1) 69b 2-Acetylamino-3- (4-benzyloxy) methyl ester 3, 5-dimethyl-phenyl) -acrylic Under a nitrogen atmosphere, a mixture of 40.0 g (137 mmol) of 2-benzyloxy-5-bromo-1,3-dimethylbenzene and 24.1 g (165 g) was combined (165 mmol) of 2-acetylamino-acrylic acid methyl ester in 420 mL of triethylamine and 200 mL of acetonitrile with 3, 5 g (11.2 mmol) of tri-o-tolyl-phosphane and 2.5 g (11.1 mmol) of Pd (OAc) 2 were added and stirred for 18 h at 80 ° C. The precipitate was filtered with suction, the filtrate was concentrated i. empty and it was mixed with 800 mL of DCM and 800 mL of water. The organic phase was separated, filtered with suction over Na 2 SO 4, the solvent was removed i. vac., the residue was mixed with stirring with EtOAc, filtered with suction and dried i. empty Yield: 31.1 g (64% of the theory) ESI-MS: (M + H) * = 354 Retention time (HPLC-MS): 8.6 min (method A) 69c 3- (4-benzyloxy) acid -3,5-dimethyl-phenyl) -2-oxo-propionic acid 31.1 g (88.1 mmol) of 2-acetylamino-3- (4-benzyloxy-3,5-dimethyl-phenyl) - methyl ester - Acrylic in 150 mL of 1,4-dioxane were mixed with 125 mL of 4 M HCl, and stirred for 7 h under reflux and overnight at RT. The precipitate was filtered with suction, washed with water and dried at 45 ° C in the vacuum drying oven. Yield: 14.3 g (54% of theory)EI-MS: (M) * = 298 Retention time (HPLC-MS): 9.0 min (method A) 69d Acid (R) -3- (4-benzoyl-3, 5-dimethyl-phenyl) -2 -hydroxy-propionic Under a nitrogen atmosphere, a solution of 14.3 g (47.8 mmol) of 3- (4-benzyloxy-3,5-dimethyl-phenyl) -2-oxo-propionic acid and 8.3 mL (59.8 mmol) of triethylamine in 170 mL of THF was mixed at -35 ° C with a solution of 22.1 g (69.0 mmol) of (1R) -B-chlorodiisopinocampheylborane in 70 mL of THF in the space of 30 min. After the addition was complete, the cooling bath was removed and the reaction solution was stirred overnight at RT. The reaction mixture was made alkaline at 0 ° C with 70 mL of 1 M NaOH, mixed with 100 mL of TBME, stirring was continued for 15 min and the phases were separated. The organic phase was washed with 50 mL of water and three times, in each case with 50 mL of 1 M NaOH. The combined aqueous phases were acidified with half-cone HCl, extracted to exhaustion with EtOAc and the combined organic phases were dried over Na2S04. After removing the drying agent and the solvent, the residue was reacted further without purification. Yield: 14.0 g (98% of the theory) ESI-MS: (MH) "= 299 Retention time (HPLC-MS): 7.9 min (method A) 69e Methyl acid ester (R) -3 - (4-benzyloxy-3, 5-dimethyl-phenyl) -2-hydroxy-propionic To a solution, cooled to 0 ° C, of 14.0 g (23.3 mmol) of (R) -3- (4-benzoyl-3,5-dimethyl-phenyl) -2-hydroxy-propionic acid in 150 mL of MeOH was added dropwise 2.0 mL (27, 4 mmol) of S0C12 and the reaction mixture was continued stirring for 1 h at RT. The reaction solution was concentrated i. empty and the residue was purified by chromatography (silica gel, Cyc / EtOAc 3: 1). Performance: '5.7 g (78% -of theory) ESI-MS: (M + NH4) * = 332 Retention time (HPLC-MS): 9.1 min (method A) 69f Ester (R) -2- (4-benzyloxy-3, 5-dimethyl-phenyl) 4- (2-Oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid-1-methoxycarbonyl acid Under a nitrogen atmosphere, to a solution of 1.17 g (9.58 mmol) of 4-dimethylaminopyridine in 50 mL of pyridine were added 1.93 g (9.58 mmol) of 4-nitrophenyl ester of chloroformic acid, stirred for 1.5 h at RT, was mixed with 3.0 g (9.58 mmol) of (R) -3- (4-benzyloxy-3,5-dimethyl-phenyl) -2-hydroxy-propionic acid methyl ester and stirred for 20 min. TA. Then, 2.35 g (9.58 mmol) of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one was added and stirred for 20 h at RT . The reaction mixture was concentrated i. empty , the residue was taken up in EtOAc, the organic phase was washed with saturated solution of 10% KHS0 and saturated solution of NaHCO3, and dried over Na2SO4. After separating the drying agent and the solvent, the residue was purified by chromatography (silica gel, gradient Cyc / EtOAc 1: 1 to 1: 2). Yield: 3.21 g (57% of theory) 0 ESI-MS: (M + H) * = 586 Retention time (HPLC-MS): 10.4 min (method A) 69g Ester (R) -2 4- (2-Oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) - (4-benzyloxy-3,5-dimethyl-phenyl) -1-carboxy ethyl acid - ? iperidine-1-carboxylic acid A solution of 3.21 g (5.48 mmol) of 4- (4-benzyloxy-3,5-dimethyl-phenyl) -1-methoxycarbonyl-ethyl ester of 4- (4) -hydrate (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 80 mL of THF was added a solution of 200 mg (8.35 mmol) of LiOH in 40 mL of water and stirred for 1 h at RT. The reaction mixture was concentrated i. vac., the residue was taken up in 100 mL of water, acidified with 2 M HCl, the precipitate was filtered off with suction and dried in a vacuum drying oven at 40 ° C. Yield: quantitative ESI-MS: (M + H) * = 572 Retention time (HPLC-MS): 9.2 min (method A) 69h Ester (R) -2- (4-hydroxy-3,5-dimethyl) 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 3,72 g (6-phenyl) -1-carboxy-ethyl ester , 51 mmol) of (R) -2- (4-benzyloxy-3, 5-dimethyl-phenyl) -1-carboxy-ethyl ester of 4- (2-oxo-1,2,4,5,5-tetrahydro- 1, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 50 mL of DCM was mixed with 300 mg of 10% Pd / C and shaken at RT and 3 bar of hydrogen until the reaction was stopped. The catalyst was filtered with suction and the solvent was concentrated i. empty The residue was triturated with DIPE and filtered with suction. Yield: 2.41 g (77% of theory) ESI-MS: (M + H) * = 482 Retention time (HPLC-MS): 7.0 min (method A) 69i Ester (R) -1- (4-hydroxy-3, 5-dimethyl-benzyl) -2- [4- (4-Methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl 4- (2-oxo-l, 2, 4, 5-tetrahydro-l) , 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 70 mg (0.15 mmol) of ester (R) -2- (4-hydroxy-3,5-dimethyl-phenyl) -1- carboxy-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid, 51 mg (0.16 mmol) of TBTU and 26 μL (0.18 mmol) of triethylamine in 1 mL of DMF was stirred for 1 h at RT. The addition of 27 mg (0.15 mmol) of l-methyl-4-piperidin-4-yl-piperazine was then carried out and the reaction mixture was stirred for 16 h at RT. The reaction solution was filtered through an injection filter and purified, without further treatment, directly through HPLC. The fractions containing the product were pooled and lyophilized. Yield: 39 mg (42% of theory) ESI-MS: (M + H) * = 647 Retention time (HPLC-MS): 5.3 min (method A) The following compounds were prepared analogously, in each case from 70 mg (Examples 70 to 76) - or in each case from 100 mg (Examples 77 and 78) or from 400 mg (Example 79) of ester (R) -2- (4-hydroxy-3,5-dimethyl-phenyl) -1-carboxy 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid ethyl ester and the corresponding amount of amine: Example 80 Ester (R) -1- (4-hydroxy-3, 5-dimethyl-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl 4- ethyl (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 32 mg (0.04 mmol) of tert-butyl ester of 4- (l- { (R) -3- (4-hydroxy-3,5-dimethylphenyl) -2- [4 - (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carbonyloxy] -propionyl.} - piperidin-4-yl) -piperazin-1- carboxylic acid (Example 77) in 5 mL of 2 M HCl was stirred for 20 h-TA and then lyophilized, precipitating the product as bis-hydrochloride. Yield: quantitative ESI-MS: (M + H) * = 633 Retention time (HPLC-MS): 5.0 min (method A) Example 81 Ester (R) -1- (4-hydroxy-3, 5- dimethyl-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl ester of 4- (2-oxo-1,2,4,5,5-tetrahydro-l, 3) -benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 54 mg (0.08 mmol) of ester (R) -2- [4- (1-benzyl-piperidin-4-yl) -piperazin-1-yl] -1- (4-hydroxy-3, 4- (2-Oxo-1,2,4,5,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (5-dimethyl-benzyl) -2-oxo-ethyl ester (Example 78 ) in 5 mL of MeOH was mixed with 20 mg of 10% Pd / C and shaken at RT and 3 bar of hydrogen until the reaction was stopped. The catalyst was filtered with suction and the solvent was concentrated i. empty The residue was triturated with DIPE, filtered with suction "and dried under high vacuum Yield: 35.0 mg (74% of theory) ESI-MS: (M + H) * = 633 Retention time (HPLC-MS): 4.9 min (method A) Example 82 Ester (R) -1- (4-hydroxy-3, 5-dimethyl-benzyl) ) -2- (4-hydroxy-4- methyl- [1,4 '] bipiperidinyl-1'-yl) -2-oxo-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro) -l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 50 mg (0.09 mmol) of ester (R) -l- (4-hydroxy-3,5-dimethyl-benzyl) -2-oxo-2- (4-oxo-piperidin-1-yl) 4- (2-Oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid ethyl ester (Example 79) in 1.5 mL of DCM was mixed with 21 mg (0.18 mmol) of 4-methyl-piperidin-4-ol and 10.3 μl (0.19 mmol) of AcOH, it was cooled to 0 ° C and stirred for 2 h. Then 28 mg (0.19 mmol) of sodium triacetoxyborohydride was added and stirred overnight at 0 ° C. After removing the solvent, the residue was mixed with 2 mL of DMF and purified by HPLC. The fractions containing the product were pooled and lyophilized.

Yield: 25 mg (42% of theory) ESI-MS: (M + H) * = 662 Retention time (HPLC-MS): 2.90 min (method E) Example 83 Ester (R) -1- (4, 4-dimethyl- [1, 4 ' ] bipiperidinyl-1 '-yl) -1- (4-hydroxy-3, 5-dimethyl-benzyl) -2-oxo-ethyl of 4- (2-oxo-1, 2,4,5-tetrahydro-l) , 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Analogously to Example 82, from 50.0 mg (0.09 mmol) of ester (R) -1- (4-hydroxy-3,5-dimethyl-benzyl) -2-OXO-2- (4-oxo) 4- (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (piperidin-1-yl) (Example 79) and 31.0 mg (0.18 mmol) of 4,4-dimethylpiperidine, the product could be obtained. Yield: 18.3 mg (31% of theory) ESI-MS: (M + H) + = 660 Retention time (HPLC-MS): 3.2 min (method E) Example 84 Ester (R) -2- (4-amino-4-methyl- [1, 4 '] bipiperidinyl-1' -yl) -1- (4-hydroxy-3, 5-dimethyl-benzyl) -2-oxo-ethyl 4- (2-oxo-1, 2,4,5-tetrahydro) -l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 150 mg (0.27 mmol) of ester (R) -1- (4-hydroxy-3,5-dimethyl-benzyl) - 2-Oxo-2- (4-oxo-piperidin-1-yl) -ethyl acid 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine -1-carboxylic acid (Example 79) in 4 mL of DCM was mixed with 120 mg (0.53 mmol) of (4-methyl-piperidin-4-yl) -carbamic acid tert-butyl ester and 31 μl (0.degree. , 56 mmol) of AcOH, cooled to 0 ° C and stirred for 2 h. Then 85 mg (0.56 mmol) of sodium triacetoxyborohydride was added and stirred overnight at 0 ° C. Then, the reaction solution was mixed with 0.5 mL of TFA and stirred again overnight at RT. After removing the solvent, the residue was dissolved in 2 L of DMF and purified by HPLC. The fractions containing the product were combined and lyophilized, precipitating the product in the form of TFA salt. Yield: 94 mg (46% of theory) ESI-MS: (M + H) * = 661 Retention time (HPLC-MS): 2.50 min (method E) Example 85 Ester (R) -1- ( 4-amino-3, 5-dimethyl-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl 4- (2-oxo) -l, -2, 4, 5-tetrahydro-l, 3-benzodiazepin-3-yl) - 85a Methyl ester of (Z, E) -2-acetylamino-3- (4-amino-3,5-dimethyl) acid phenyl) -acrylic Under a nitrogen atmosphere, to a mixture based on 7.2 g (32.1 mmol) of Pd (OAc) 2 and 10.1 g (32.1 mmol) of tri-o-tolyl -phosphine in 1.2 L of triethylamine and 600 mL of acetonitrile, a solution of 90.0 g (441 mmol) of 4-bromo-2,6-dimethyl-phenylamine in 200 mL of acetonitrile was first added and then , drop was added a. drop a solution of 65.0 g (445 mmol) of 2-acetylamino-acrylic acid methyl ester in 200 mL of acetonitrile. After the addition was complete, it was stirred for 18 h at 80 ° C. To complete the reaction, the reaction mixture was again combined with 4.0 g (17.8 mmol) of Pd (OAc) 2 and 5.0 g (16.4 mmol) of tri-o-tolyl-phosphane and it remained another 5 h at 80 ° C. It concentrates i. empty until approx. 200 mL, the residue was mixed with 400 mL of EtOAc, the residue was filtered (A) and the organic phase was dried over Na2SO4. After separating the drying agent by filtration on activated carbon, the filtrate was concentrated by evaporation to approximately 100 mL, the precipitated substance was filtered off with suction, the mixture was washed with 30 mL of EtOAc and dried.

The residue A above was mixed with 1 L of DCM, with Na 2 SO and activated carbon and filtered on Celite. The filtrate was concentrated, the residue was mixed with 350 L of diethyl ether, the resulting precipitate was filtered off with suction and this was washed with 100 mL of diethyl ether and dried. The two product fractions met. Yield: 74.8 g (65% of the theory) ESI-MS: (M + H) * = 263 Rf = 0.51 (silica gel, EtOAc) 85b 3- (4-amino-3, 5- dimethyl-phenyl) -2-oxo-propionic A suspension of 74.0 g (282 mmol) of (Z, E) -2-acetylamino-3- (4-amino-3,5-dimethyl-phenyl) methyl ester ) -acrylic in 500 mL of 1,4-dioxane was heated to 100 ° C and mixed with 460 mL of 4 M HCl, forming a solution. It was heated for another 8 h at 100 ° C and the cooled solution was concentrated i. empty up to approx. 200 mL, crystallizing the product. It was filtered, the residue was washed with 50 mL of water and the product was dried at 50 ° C. Yield: 43.6 g (63% of the theory) ESI-MS: (M + H) * = 208 Rf = 0.68 (silica gel, PE / EtOAc 1: 1) 85c (R) -3- (4-Amino-3,5-dimethyl-phenyl) -2-hydroxy-propionic acid methyl ester Under a nitrogen atmosphere, a 20- , 0 g (82.1 mmol) of 3- (4-amino-3,5-dimethyl-phenyl) -2-oxo-propionic acid and 25.7 mL (189 mmol) of triethylamine in 400 mL of THF was cooled up to -35 ° C. Then a solution of 40.0 g (125 mmol) of (IR) -B-chlorodiisopinocanphenylborane in 100 mL of THF was added dropwise so that the temperature of the reaction was maintained between -35 ° C and -25 ° C. . The reaction mixture was kept for 1 h at this temperature, the cooling bath was removed and the reaction mixture was allowed to stir overnight at RT. THF concentrated i. vac., the residue was mixed with methanolic HCl (1.25 M) and stirred for 2 h at RT. He concentrated i. vac., and the residue was taken up in 2 M HCl and extracted to exhaustion with EtOAc. The aqueous phase was basified with NaOH semiconc. and extracted to exhaustion with EtOAc. The combined organic phases were dried over Na 2 SO 4, filtered by suction over active carbon and concentrated. The product could be obtained in the form of a brown oil. Yield: 8.3 g (45% of theory) ESI-MS: (M + H) * = 224 Rf = 0.46 (silica gel, PE / EtOAc 1: 1) 85d Ester (R) -2- 4- (2-Oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidin (4-amino-3, 5-dimethyl-phenyl) -1-methoxycarbonyl-ethyl acid -1-carboxylic acid Analogously to Example 31f, from 4.0 g (17.9 mmol) of (R) -3- (4-amino-3,5-dimethyl-phenyl) -2-hydroxymethyl ester -propionic and 4.8 g (19.6 mmol) of 3-piperidin-4-yl-1,3,4,5-tetrahydro-l, 3-benzodiazepin-2-one, the product could be obtained. Yield: 3.2 g (36% of theory) ESI-MS: (M + H) * = 495 Rf = 0.35 (silica gel, DCM / MeOH / NH3 90: 10: 1) 85e Ester (R ) -2- (4-amino-3, 5-dimethyl-phenyl) -1-carboxy-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-) il) -piperidine-1-carboxylic acid To a solution of 6.7 g (13.6 mmol) of (R) -2- (4-amino-3,5-dimethyl-phenyl) -1-methoxycarbonyl-ethyl ester of 4- (2-Oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 50 mL of THF was added a solution of 500 mg (20.9 mmol) of LiOH in 10 mL of water and the reaction mixture was stirred overnight at RT. To complete the reaction, another 300 mg (12.5 mmol) of LiOH was added and the reaction solution was stirred for 3 h at 40 ° C. He concentrated i. vac., and the residue was taken up in 15% K2C03 solution and extracted to exhaustion with DCM. The aqueous phase was acidified with 4M HCl, extracted to exhaustion with DCM and the combined organic phases were dried over Na2SO4. After removing the drying agent and the solvent, the residue was reacted further without purification. Yield: 4.2 g (65% of theory) ESI-MS: (M + H) * = 481 Rf = 0.21 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 85 f Ester (R) -1- (4-amino-3,5-dimethyl-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo 4- (2-Oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid ethyl ester Analogously to Example lh, from 80 mg (0, 17 mmol) of (R) -2- (4-amino-3,5-dimethyl-phenyl) -1-carboxy-ethyl ester of 4- (2-oxo-l, 2, 4, 5-tetrahydro-l) , 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and 35 mg (0.19 mmol) of l-methyl-4-piperidin-4-yl-piperazine, the product was obtained. Yield: 50 mg (47% of theory)ESI-MS: (M + H) * = 646 Retention time (HPLC): 4.9 min (method B) The following compounds were prepared analogously, in each case from 80 mg (Examples 86 a 89) or in each case from 100 mg (Examples 90 to 92) of ester (R) -2- (4-amino-3,5-dimethyl-phenyl) -1-carboxy-ethyl 4- (2 -oxo-l, 2,, 5-tetrahydro-l, 3-benzodiazepin-3-yl) -1-piper ntity of amine: Example 93 Ester (R) -1- (4-amino-3, 5-dimethyl-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl 4-amino acid - (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carboxylic acid A solution of 80 mg (0.11 mmol) of ester (R) -l- (4-amino-3,5-dimethyl-benzyl) -2- [4- (l-tert-butoxycarbonyl-piperidin-4-) il) -piperazin-1-yl] -2-oxo-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 91) in 2 mL of 4 M HCl was stirred at RT overnight. The reaction mixture was made alkaline with solid K2CO3, extracted to exhaustion with DCM and the combined organic phases were concentrated i. empty The further purification was carried out by HPLC. The fractions containing the product were combined and lyophilized. Yield: 4 mg (6% of theory) ESI-MS: (M + H) + = 632 Retention time (HPLC): 3.6 min (method A) Example 94 Ester (R) -1- (4- amino-3, 5-dimethyl-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl 4- (2-oxo-1,2,4,5-amino) -tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (0.089 mmol) 4- (l-. {(R) -3- (4-amino-3,5-dimethyl-phenyl) -2- [4- (2-oxo-) tert-butyl ester. 1,2,4,5-tetrahydro-1,3-benzo-diazepin-3-yl) -piperidine-1-carbonyloxy] -propionyl-} - piperidin-4-yl) -piperazine-1-carboxylic acid (Example 92 ), the product was obtained. Yield: 7 mg (12% of theory) ESI-MS: (M + H) * = 632 Retention time (HPLC): 3.9 min (method A) Example 95 Ester (R) -l- (4-amino-3,5-dimethyl-benzyl) - 2- (1'-Carboxymethyl-4,4'-bipiperidinyl-l-yl) -2-oxo-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin- 3-yl) -piperidine-1-carboxylic acid To a solution of 55 mg (0.08 mmol) of ester (R) -1- (4-amino-3,5-dimethyl-benzyl) -2- (1'-ethoxycarbonylmethyl-4, '-bipiperidinyl-1- il) -2-oxo-ethyl 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 90) in 5 mL of THF was added a solution of 3.1 mg (0.13 mmol) of LiOH in 1 mL of water and the reaction mixture was stirred overnight at RT. He concentrated i. vac., the residue was taken up in 1 mL of DMF and the crude product was purified by HPLC. The fractions containing the product were combined and lyophilized. Yield: 22 mg (42% of the theory) ESI-MS: (M + H) * = 689 Retention time (HPLC): 4.8 min (method A) Example 96 Ester (R) -1- (3- Chloro-4-methyl-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester of., 4- (2-oxo-l) , 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 96a (Z, E) -2-acetylamino-3- (3-chloro-4-methyl-phenyl) -acrylic acid methyl ester Under an argon atmosphere were added to a mixture of 5.2 mL (39.0 mmol ) of 4-bromo-2-chloro-1-methyl-benzene and 10.0 g (69.9 mmol) of 2-acetylamino-acrylic acid methyl ester in each case 100 mL of acetonitrile and 0.65 g of triethylamine ( 2.9 mmol) of Pd (0Ac) 2 and 0.9 g (2.9 mmol) of tri-o-tolyl-phosphane, and the reaction mixture was heated for 20 h to 90 ° C. After cooling, concentrated i. vac., the residue was mixed with DCM and water, filtered and the organic phase was separated and dried over Na2SO4. After separating the drying agent and the solvent, the residue was purified by chromatography (silica gel, gradient PE / EtOAc 1: 1 to EtOAc).

Yield: 7.67 g (73% of theory) ESI-MS: (M + H) * = 268/270 (Cl) Melting point 144-145 ° C Rf = 0.65 (Polygram, EtOAc) 96 b 3- (3-Chloro-4-methyl-phenyl) -2-oxo-propionic acid To a solution of 7.67 g (28.7 mmol) of methyl (Z, E) -2-acetylamino-3-methyl ester - (3-Chloro-4-methyl-phenyl) -acrylic in 150 mL of EtOH was added 100 mL of 4 M HCl, and the reaction solution was heated to reflux for 4 h. The EtOH was removed i. vac., the residue was cooled in an ice bath, solidifying the oily residue. The solid was filtered, washed with water, mixed with stirring with PE, filtered again with suction, followed by washing with a little PE and dried. The combined filtrates were concentrated, dissolved in 50 mL of MeOH, mixed with 50 mL of 4 M NaOH and heated to reflux for 2 h. MeOH was removed i.vac., And the aqueous residue was acidified with conc. HCl. and extracted to exhaustion with EtOAc. The combined organic phases were washed with saturated NaCl solution and dried over Na2SO4. After removing the drying agent and the solvent, the residue was recrystallized from DCM and combined with the first product fraction. Yield: 2.02 g (33% of the theory) ESI-MS: (MH) "= 211/213 (Cl) 96c Acid (R) -3- (3-chloro-4-methyl-phenyl) -2- hydroxypropionic Under a nitrogen atmosphere, a mixture based on 2.6 g .. (12.23 mmol) of 3- (3-chloro-4-methyl-phenyl) -2-oxo-propionic acid and 2, 1 mL (15.1 mmol) of triethylamine in 40 mL of THF was cooled to -35 ° C. A solution of 5.87 g (18.30 mmol) of (IR) -B-chlorodiisopinocanphenylborane was then added dropwise. in 20 mL of THF so that the temperature of the reaction was maintained between -35 ° C and -25 ° C. The cooling bath was removed and the reaction mixture was allowed to stir overnight at RT. , 30 mL of 1 M NaOH and 60 mL of diethyl ether were added dropwise and stirring was continued for 15 min The aqueous phase was separated, and the organic phase was extracted twice, in each case with 20 mL of 1 M NaOH. and once with 20 mL of water, the combined aqueous phases were acidified, under cooling with ice, n HCl semiconc., were extracted twice, in each case with 60 L of EtOAc and the combined organic phases were dried over Na2SO4. After removing the drying agent and the solvent, the residue was reacted further without purification. Yield: 2.8 g (85% of theory) 96d (R) -3- (3-Chloro-4-methyl-phenyl) -2-hydroxy-propionic acid methyl ester To a solution of 2.8 g ( 10.4 mmol) of acid (R) ~ 3- (3-Chloro-4-methyl-phenyl) -2-hydroxy-propionic in 100 mL of MeOH were slowly added dropwise, under cooling with ice, 2.0 mL (27.4 mmol) of S0C12 and the reaction solution was continued stirring for 1 h at 0 ° C and for 1 h at RT. The reaction mixture was concentrated i. vac., the residue was taken up in EtOAc, the organic phase was washed with saturated solution of 10% NaHCO 3 and dried over Na 2 SO 4.

After separating the drying agent and the solvent, the residue was purified by chromatography (silica gel, gradient DCM to DCM / MeOH 50: 1). Yield: 2.12 g (89% of theory) ESI-MS: (M + H) * = 229/231 (Cl) Rf = 0.34 (Polygram, DCM) 96e Ester (R) -2- (3 -chloro-4-methyl-phenyl) -1-methoxycarbonyl-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1- carboxylic acid Analogously to Example 31f, from 2.1 g (9.18 mmol) of (R) -3- (3-Chloro-4-methyl-phenyl) -2-hydroxy-propionic acid methyl ester and 2.45 g (9.99 mmol) of 3-piperidin-4-yl-l, 3,4,4,5-tetrahydro-l, 3-benzodiazepin-2-one, the desired product could be obtained. Yield: 3.4 g (74% of theory) ESI-MS: (M + H) * = 500/502 (Cl) Rf = 0.52 (Polygram, EtOAc) 96f Ester (R) -l-carboxy 2- (2-Oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 2- (3-chloro-4-methyl-phenyl) -ethyl ester To a solution of 3.38 g (6.76 mmol) of (R) -2- (3-chloro-4-methyl-phenyl) -1-methoxycarbonyl-ethyl ester of 4- (2-oxo-l, 2, 4, 5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 30 mL of THF was added a solution of 0.34 g (14.2 mmol) of LiOH in 20 mL of water and the reaction mixture was stirred for 7 h at RT. He concentrated i. vac., diluted with 80 mL of water, the aqueous phase was extracted twice each time with 50 mL of diethyl ether, the aqueous phase was acidified with 4 M HCl and stirring was continued for 30 min. The precipitated product was filtered with suction, washed with water and dried. Yield: 3.2 g (97% of theory) ESI-MS: (M + H) * = 486/488 (Cl) 96q Ester (R) -1- (3-chloro-4-methyl-benzyl) - 2- [4- (4-Methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl 4- (2-oxo-l, 2,, 5-tetrahydro-l, 3) -benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 100 mg (0.21 mmol) of ester (R) -l-carboxy-2- (3-chloro-4-methyl-phenyl) -ethyl ester of 4- (2-oxo-1, 2,4, 5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid, 70.0 mg (0.22 mmol) of TBTU and 35 μL (0.27 mmol) of triethylamine in 10 mL of THF was stirred for 1 h at RT. The addition of 40 mg (0.22 mmol) of l-methyl-4-piperidin-4-yl-piperazine was then carried out and the reaction mixture was then stirred overnight at RT. The reaction solution was mixed by stirring with 20 mL of half saturated NaHCO 3 solution, extracted twice, in. each case with 20 mL of EtOAc and the combined organic phases were dried over Na2SO4. After separating the drying agent and the solvent, the residue was purified by chromatography (Alox, activity step II-III, DCM / MeOH 40: 1). Yield: 123 mg (83% of the theory) ESI-MS: (M + H) * = 651/653 (Cl) Rf = 0.52 (Polygram-Alox, DCM / MeOH 25: 1) The following were similarly prepared Compounds from each in each case 100 mg of 4- (2-oxo-1, 2,4, 5-ethyl) (R) -l-carboxy-2- (3-chloro-4-methyl-phenyl) -ethyl ester; -tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and the corresponding amount of amine: Example 101 Ester (R) -1- (3-Chloro-4-methyl-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl 4- ( 2-oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid To a solution of 130 mg (0.14 mmol) of 4- (l-. {(R) -3- (3-chloro-4-methyl-phenyl) -2- [4-butyl] -butyl ester. - (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carbonyloxy] -propionyl.} - piperidin-4-yl) -piperazin-1- carboxylic acid (Example 99) in 10 mL of MeOH was added 10 ml of 1 M HCl and the reaction mixture was stirred for 24 h at RT. The reaction mixture was lyophilized without further treatment. The product precipitated in the form of the bis-hydrochloride salt.

Yield: 112 mg (95% of theory) ESI-MS: (M + H) * = 637/639 (Cl) Example 102 Ester (R) -1- (3-chloro-4-methyl-benzyl) -2 4- (2-oxo-l, 2, 4, 5-) -oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl ether Analogously to Example 101, from 110 mg (0.13 mmol) ester (R) -1- (3-chloro-4-methyl-benzyl) -2- [4- (1-tert.-butoxycarbonyl-piperidin-4-yl) -piperazine- 1-yl] -2-oxo-ethyl 4- (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 100) it was able to obtain the product that precipitated in the form of the bis-hydrochloride salt. Yield: 99 mg (93% of the theory) ESI-MS: (M + H) * = 637/639 (Cl) Example 103 Ester (R) -1- (3-bromo-4-methyl-benzyl) -2 - 4- (2-oxo-l, 2, 4, 5-tetrahydro-l, 3 - [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl] -benzodiazepin-3-yl) -piperidine-1-carboxylic acid 103a (Z, E) -2-acetylamino-3- (3-bromo-4-methyl-phenyl) -acrylic acid analogously to Example la, from 6, 0 g (30.1 mmol) of 3-bromo-4-methyl-benzaldehyde and 5.3 g (45.3 mmol) of N-acetyl-glycine, the product could be obtained. Yield: 4.7 g (52% of the theory) ESI-MS: (M + H) * = 298/300 (Br) Rf = 0.12 (silica gel, DCM / MeOH / Cyc / NH3 70:15 : 15: 2) 103b 3- (3-Bromo-4-methyl-phenyl) -2-oxo-propionic acid To a solution, heated to 105 ° C, of 4.7 g (15.8 mmol) of (Z, E) -2-acetylamino-3- (3-bromo-4-methyl-phenyl) -acrylic acid in 50 mL of 1,4-dioxane, and the reaction mixture was maintained at this temperature for another 5 h. 1,4-dioxane i was separated. vacuum, the cooled residue was mixed with water, the resulting precipitate was separated by filtration and dried in the drying oven by circulating air. Yield: 2.9 g (72% of theory) ESI-MS: (MH) "= 255/257 (Br) Rf = 0.18 (silica gel, DCM / MeOH / NH3 80: 20: 2) 103c (R) -3- (3-Bromo-4-methyl-phenyl) -2-hydroxy-propionic acid Under a nitrogen atmosphere, a mixture based on 2.9 g (11.3 mmol) of 3- ( 3-bromo-4-methyl-phenyl) -2-oxo-propionic acid and 2.0 L (15.1 mmol) of triethylamine in 40 mL of THF was cooled to -35 ° C. A solution was then added dropwise. of 5.44 g (17.0 mmol) of (IR) -B-chlorodiisopinocanphenylborane in 20 mL of THF so that the temperature of the reaction was maintained between 35 ° C and -25 ° C, the reaction mixture was maintained This temperature was maintained for 1 h, then the cooling bath was removed and allowed to stir overnight at RT To add to the reaction, another 3.0 g (9.4 mmol) of (1R) -B-chlorodiisopinocanphenylborane was added and The mixture was stirred for a further 5 h, and after cooling with ice, 30 mL of 1 M NaOH and 30 mL of TBME were added dropwise and stirring was continued. for 15 min The aqueous phase was separated, and the organic phase was extracted with 15 mL of 1 M NaOH and 25 mL of water. The combined aqueous phases were acidified, under ice-cooling, with 2 M HCl, extracted three times, in each case with 40 mL of TBME and the combined organic phases were dried over Na 2 SO. After removing the drying agent and the solvent, the residue was reacted further without purification. Yield: 3.0 g (approx 70% of product portion, 72% of theory) ESI-MS: (MH) ~ = 257/259 (Br) Rf = 0.12 (silica gel, PE / EtOAc 1: 1) 103d Methyl ester of (R) -3- (3-bromo-4-methyl-phenyl) -2-hydroxy-propionic acid A solution of 2.8 g (approx 70%, 7.56 mmol) of (R) -3- (3-bromo-4-methyl-phenyl) -2-hydroxy-propionic acid in methanolic HCl (1.25 M) was stirred for 4 h at RT. He concentrated i. ac. and the residue was purified by chromatography (silica gel, gradient PE / EtOAc 9: 1 to PE / EtOAc 1: 9). Yield: 1.6 g (77% of the theory) ESI-MS: (M + H) * = 273/275 (Br) Rf = 0.72 (silica gel, PE / EtOAc 1: 1) 103e Ester ( R) -2- (3-bromo-4-methyl-phenyl) -1-methoxycarbonyl-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid analogously to Example lf, from 1.5 g (5.49 mmol) of (R) -3- (3-bromo-4-methyl-phenyl) -2-hydroxy-propionic acid methyl ester and 1, 7 g (5.52 mmol) of 4- (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carbonyl chloride, it was possible to obtain the gross product. This was purified by chromatography (silica gel, gradient DCM / MeOH / NH3 100: 0: 0 to DCM / MeOH / NH3 0: 95: 5). The product fractions were pooled, concentrated i. vac., were triturated with DIPE, filtered with suction and dried. Yield: 1.1 g (37% of theory) ESI-MS: (M + H) + = 544/546 (Br) Rf = 0.70 (silica gel, DCM / MeOH / Cyc / NH3 70:15 : 15: 2) 103f Ester (R) -2- (3-bromo-4-methyl-phenyl) -1-carboxy-ethyl of 4- (2-oxo-l, 2, 4, 5-tetrahydro-l) , 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid To a solution of 1.0 g (1.84 mmol) of ester (R) -2- (3-bromo-4-methyl-phenyl) -1 4- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid methoxycarbonyl ethyl ester in 20 mL of THF was added a solution of 70 mg (2.92 mmol) of LiOH in 5 mL of water and the reaction mixture was stirred for 5 h at RT. The reaction solution was concentrated i. vac., the residue was mixed with DCM, the organic phase was washed with 1 M KHS04 solution and dried over Na2SO4. After separating the drying agent and the solvent, the residue was mixed by triturating with DIPE, filtered with suction and dried. Yield: 0.95 g (98% of theory) ESI-MS: (M + H) * = 530/532 (Br) Rf = 0.29 (silica gel, DCM / MeOH / Cyc / NH3 70:15 : 15: 2) 103g Ester (R) -1- (3-bromo-4-methyl-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2 4- (2-Oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid-4-oxoyl acid analogously to Example lh, from 100 mg ( 0.19 mmol) of (R) -2- (3-bromo-4-methyl-phenyl) -1-carboxy-ethyl ester of 4- (2-oxo-l, 2, 4, 5-tetrahydro-l) , 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and 38 mg (0.21 mmol) of l-methyl-4-piperidin-4-yl-piperazine, the product could be obtained. Yield: 90 mg (69% of the theory) ESI-MS: (M + H) * = 695/697 (Br) Rf = 0.59, (silica gel, DCM / MeOH / Cyc / NH3 70:15: 15: 2) Similarly, the following compounds were prepared from each in each case 100 mg of (R) -2- (3-bromo-4-methyl-phenyl) -1-carboxy-ethyl ester of 4- (2- oxo-1, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and the corresponding amount of amine: Example 107 Ester (R) -1- (3-bromo-4-methyl-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl 4- (2 -oxo-l, 2, 4, 5- tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Analogously to Example 93, from 90 mg (0.12 mmol) of 4- (1- (R) -3- (3-bromo-4-methyl-phenyl) - tert-butyl ester. 2- [4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carbonyloxy] -propionyl.} - piperidin-4-yl) - piperazine-1-carboxylic acid (Example 106), the product could be obtained. Yield: 15 mg (19% of theory) ESI-MS: (M + H) * = 681/683 (Br) Retention time (HPLC): - 5.7 min (method A) Example 108 Ester (R) -1- (3-bromo-4-methyl) -benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl 4- (2-oxo-l, 2,, 5-tetrahydro-1,3-benzodiazepine) -3-yl) -piperidine-1-carboxylic acid Analogously to Example 93, from 80 mg (0.12 mmol) of ester (R) -1- (3-bromo-4-methyl-benzyl) -2- [4- (1-tert.-butoxy-carbonyl) 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) - - (piperidin-4-yl) -piperazin-1-yl] -2-oxo-ethyl acid - piperidine-1-carboxylic acid (Example 105), the product could be obtained. Yield: 44 mg (63% of theory) ESI-MS: (M + H) * = 681/683 (Br) Retention time (HPLC): 5.5 min (method A) Example 109 Ester (R) -1- (6-amino-5-methyl- 4- (2-oxo-l, 2,4-pyridin-3-ylmethyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl acid , 5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid. 109a Acid methyl ester (Z, E) -2-acetylamino-3- (6-amino-5-methyl-pyridin-3-yl) -acrylic Under a nitrogen atmosphere, to a mixture of 33.6 g (180 mmol) of 5-bromo-3-methyl-pyridin-2-ylamine was added 28.9 g (198 mmol) of 2-acetylamino-acrylic acid methyl ester, 4.42 g (14.4 mmol) of tri- o-tolyl-phosphine and 30.9 mL (180 mmol) of ethyldiisopropylamine in 500 mL of butyronitrile, 6.58 g (7.19 mmol) of tris- (dibenzylideneacetone) -palladium, and the reaction mixture was heated for 15 hours. h up to 110 ° C. The reaction solution was concentrated i. empty and the residue was mixed with stirring with ca. 500 mL of water. The precipitate was filtered, recrystallized from acetonitrile and dried. The aqueous mother liquors were concentrated and the residue was purified by chromatography (silica gel, EtOAc / MeOH / NH3 90: 10: 1). The fractions containing the product were concentrated, the residue was mixed by stirring with a little acetonitrile, filtered, dried and combined with the above product fraction. Yield: 16.6 g (37% of the theory) ESI-MS: (M + H) * = 250 Rf = 0.46 (silica gel, EtOAc / MeOH / NH3 90: 10: 1) 109b Acid 3- (6-amino-5-methyl-pyridin-3-yl) -2-oxo-propionic acid To a solution of 15.57 g (62.46 mmol) of methyl (Z, E) -2-acetylamino- 3- (6-amino-5-methyl-pyridin-3-yl) -acrylic acid in 250 mL of 1,4-dioxane was added 230 mL of 4 M HCl, and the reaction mixture was heated to reflux for 1.5 and for another 16 ha. He concentrated i. vac., and the residue was triturated with EtOAc / DIPE (1: 1), filtered and dried in the oven dried by circulating air. The product precipitated in the form of the bis-hydrochloride salt. Yield: 14.4 g (100% theory) ESI-MS: (M + H) * = 195 Retention time (HPLC): 2.7 min (method A) 109c Methyl ester of (R) -3- (6-amino-5-methyl-pyridin-3) acid -yl) -2-hydroxy-propionic Under an atmosphere of argon, a mixture based on 13.8 g (59.9 mmol) of 3- (6-amino-5-methyl-pyridin-3-yl) - 2-oxo-propionic and 17.5 mL (125.7 mmol) of triethylamine in 140 mL of THF was cooled to -35 ° C. Then a solution of 40.3 g (126 mmol) of (1R) -B-chlorodiisopinocanphenylborane in 210 mL of THF was added dropwise so that the reaction temperature was maintained between -35 ° C and -25 ° C. C; the reaction mixture was maintained for 3 h at this temperature before combining it, at 0-5 ° C, with 150 mL of 1 M NaOH and the reaction mixture was continued stirring for 2 h at RT. It was mixed with 200 mL of TBME, the organic phase was separated and acidified with 200 mL of 2 M HCl. The aqueous phase was separated., concentrated, the residue was taken up in THF / MeOH (1: 1), filtered and then the filtrate was concentrated. The crude product (12.5 g), thus obtained, was dissolved in 300 mL of MeOH, mixed dropwise, under cooling with ice, with 4.3 mL (59.3 mmol) of S0C12 and stirred for another 2 ha TA. He concentrated i. vac and the residue was purified by chromatography (silica gel, EtOAc / MeOH / NH3 90: 10: 1). Yield: 5.62 g (45% of theory) ESI-MS: (M + H) * = 211 Retention time (HPLC): 2.4 min (method A) 109d Ester (R) -2- (6 4- (2-oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-amino-5-methyl-pyridin-3-yl) -1-methoxycarbonyl-ethyl acid -1-carboxylic acid Analogously to Example 31f, from 2.75 g (13.10 mmol) of (R) -3- (6-amino-5-methyl-pyridin-3-yl) -2-methyl ester -hydroxy-propionic acid and 3.21 g (13.10 mmol) of 3-piperidin-4-yl-1,3,4,5-tetrahydro-l, 3-benzodiazepin-2-one, the desired product could be obtained . Yield: 1.38 g (22% of theory) ESI-MS: (M + H) * = 482 Retention time (HPLC): 4.9 min (method C) 109e Ester (R) -2- (6 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine -amino-5-methyl-pyridin-3-yl) -1-carboxy-ethyl acid -1-carboxylic acid To a solution of 1.27 g (2.64 mmol) of (R) -2- (6-amino-5-methyl-pyridin-3-yl) -1-methoxycarbonyl-ethyl ester of 4-carboxylic acid. - (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 30 mL of THF was added a solution of 100 mg (4.18 mmol) of LiOH in 25 mL of water and the reaction solution was stirred for 1 h at RT. He concentrated i. The residue was taken up in water, mixed with stirring with 2M KHS04 solution, the remaining solution was separated by decantation, the residue was dried, mixed with THF and the product was filtered. Yield: 0.92 g (74% of theory) ESI-MS: (M + H) * = 468 Retention time (HPLC): 4.8 min (method A) 109f Ester (R) -1- (6-amino-5-methyl-pyridin-3-ylmethyl) -2- [4- (4-Methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl of 4- (2-oxo-l, 2, 4, 5-tetrahydro-l) , 3-benzodiazepin-3-yl) -piperidin-1-carboxylic acid Analogously to Example 1, from 50 mg (0.11 mmol) of ester (R) -2- (6-amino-5-methyl-pyridine) -3-yl) -1-carboxy-ethyl 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and 20 mg ( 0.11 mmol) of l-methyl-4-piperidin-4-yl-piperazine, the product could be obtained. Yield: 6 mg (9% of theory) ESI-MS: (M + H) * = 633 Retention time (HPLC): 4.4 min (method A) The following compounds were prepared analogously from each case 50 mg of (R) -2- (6-amino-5-methyl-pyridin-3-yl) -1-carboxy-ethyl ester of 4- (2-oxo-l, 2,, 5-tetrahydro-l) , 3-benzodiazepin-3-yl) - piperidine-1-carboxylic acid? and the corresponding amount of amine: Example 115 Ester (R) -1- (6-amino-5-methyl-pyridin-3-ylmethyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl acid ester 4- (2-Oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 75 mg (0.10 mmol) of 4- (l-. {(R) -3- (6-amino-5-methyl-pyridin-3-yl) -2-tert-butyl ester. - [4- (2-Oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 114) in 5 mL of 2 M HCl was stirred at RT for 20 h After the lyophilization of the reaction mixture, the residue was dissolved in 1 mL of DMF, basified with 0.6 mL of saturated K2C03 solution and purified by HPLC. The product was collected and lyophilized again Yield: 28 mg (44% of theory) ESI-MS: (M + H) * = 619 Retention time (HPLC): 3.8 min (method A) Example 116 Ester (R) -1- (6-amino-5-methyl-pyridin-3-ylmethyl) (2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl) 4- (2-oxo-1,2,4,5,5-tetrahydro-l, 3-benzodiazepin-) 3-yl) -piperidine-1-carboxylic acid Analogously to Example 115, from 66 mg (0.09 mmol) ester (R) -1- (6-amino-5-methyl-pyridin-3-ylmethyl) -2- [4- (1-tert. -butoxy-carbonyl-piperidin-4-yl) 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid) -piperazin-1-yl] -2-oxo-ethyl ester ( Example 113), the product could be obtained. Yield: 29 mg (51% of theory) ESI-MS: (M + H) * = 619 Retention time (HPLC): 3.5 min (method A) Example 117 Ester (R) -1- (4-hydroxy-benzyl) -2- [4- ( 4-Methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl 4- (2-oxo-1,2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-) il) -piperidine-1-carboxylic acid 117a Acid (Z, E) -2-acetylamino-3- (4-benzyloxy-phenyl) -acrylic Analogously to Example la, from 30.0 g (141 mmol) of 4-benzyloxy-benzaldehyde and 24.8 g (212 mmol) of N-acetyl-glycine, the product could be obtained. Yield: 32.0 g (73% of theory) ESI-MS: (M + H) * = 312 Rf = 0.35 (silica gel, DCM / MeOH / AcOH 90: 10: 1) 117b Acid 3- (4-benzyloxy-phenyl) -2-oxo-propionic Analogously to Example Ib, from 32.0 g (103 mmol) of (Z, E) -2-acetylamino-3- (4-benzyloxy-phenyl) -acrylic acid, the product could be obtained. Yield: 12.4 g (45% of the theory) ESI-MS: (MH) "= 269 Rf = 0.30 (silica gel, DCM / MeOH / AcOH 80: 20: 2) 117c Acid (R) - 3- (4-benzyloxy-phenyl) -2-hydroxy-propionic Analogously to Example le, starting at 11.5 g (42.6 mmol) of 3- (4-benzyloxy-phenyl) -2-oxo-propionic acid and 16.7 g (52.1 mmol) of (1R) -B-chlorodiisopinocanphenylborane, the product could be obtained.

Yield: 7.43 g (64% of theory) ESI-MS: (M + Na) * = 294 Retention time (HPLC): 13.3 min (method F) 117d Methyl ester of (R) -3- (4-benzyloxy-phenyl) -2-hydroxy acid propionic Analogously to Example 46d, from 7.3 g (26.8 mmol) of (R) -3- (4-benzyloxy-phenyl) -2-hydroxypropionic acid, the product could be obtained. Yield: 7.6 g (99% of theory) Retention time (HPLC): 16.7 min (method F) 117e Ester (R) -2- (4-benzyloxy-phenyl) -1-methoxycarbonyl-ethyl of 4- (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Analogously to Example 31f, from 7.6 g (26.5 mmol) of (R) -3- (4-benzyloxy-phenyl) -2-hydroxy-propionic acid methyl ester and 6.5 g (26.5 mmol) of 3-piperidin-4-yl- 1, 3, 4, 5-tetrahydro-l, 3-benzodiazepin-2-one, the product could be obtained. Yield: 4.1 g (28% of theory) ESI-MS: (M + H) * = 558 Rf = 0.25 (silica gel, n-hexane / EtOAc 3: 7) Retention time (HPLC): 22.0 min (method F) 117f Ester (R ) -l-carboxy-2- (4-benzyloxy-phenyl) -ethyl acid 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1 -carboxylic Analogously to Example 58f, from 4.1 g (7.4 mmol) of (R) -2- (4-benzyloxy-phenyl) -1-methoxy-carbphenyl-ethyl ester of 4- (2-oxo-l, 2, 4, 5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and 264 mg (11.0 mmol) of LiOH, the product could be obtained. Yield: 2.7 g (68% of theory) ESI-MS: (M + H) * = 544 Retention time (HPLC): 18.8 min (method F) 117g Ester (R) -l-carboxy-2- (4-hydroxy-phenyl) -ethyl acid 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid To a solution of 2.2 g (4.1 mmol) of ester ( R) - l-carboxy-2- (4-benzyloxy-phenyl) -ethyl 4 - (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine- 1-carboxylic acid and 450 mg (4.4 mmol) of triethylamine in 90 mL of MeOH were added 220 mg of 10% Pd / C and the reaction mixture was hydrogenated at 3 bar of H2 for 24 h. The catalyst was filtered, washed twice with MeOH and the filtrate was concentrated i. empty The residue was taken up in 20 mL of water and adjusted to pH 2-3 with 10% HCl. The resulting precipitate was filtered, washed with a little water and dried at 50 ° C. Yield: 1.4 g (76% of theory) ESI-MS: (M + H) * = 454 Rf = 0.65 (silica gel, DCM / MeOH / AcOH 80: 20: 2) 117h Ester (R ) 4- (2-oxo-) 4- (4-hydroxy-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl of 1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Under a nitrogen atmosphere, to a solution of 140 mg (0.31 mmol) of ester (R) - 4- (2-Oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid l-carboxy-2- (4-hydroxy-phenyl) -ethyl ester 150 mg (0.39 mmol) of HATU and 80 μl (0.47 mmol) of ethyldiisopropylamine in 5 mL of DMF were added, 74 mg (0.40 mmol) of 1-methyl-4-piperidin-4-yl were added. Piperazine and the reaction mixture was stirred for 6 h at RT. The reaction solution was concentrated i. empty and the residue was purified by chromatography (silica gel, DCM / MeOH / NH3 93: 7: 0.7). Yield: 100 mg (52% of theory) ESI-MS: (M + H) * = 619 Rf = 0.6 (silica gel, DCM / MeOH / NH3 80: 20: 2) The following compounds were similarly prepared , in each case from 140 mg (Examples 118 and 119), 150 mg (Examples 120 and 121), 200 mg (Examples 122 and 123) or 230 mg (Example 124) of ester (R) -l 4- (2-Oxo-1,2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid carboxy-2- (4-hydroxy-phenyl) and the corresponding amount of amine: EXAMPLE 125 4- (2-Oxo-l) 4- (2-oxo-1-ethyl 4- (2-oxo-1-yl) -4- (4-hydroxy-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl ester 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 250 mg (0.30 mmol) of 4- (1- (R) -3- (4-hydroxy-phenyl) -2- [4- (4H-fluoren-9-ylmethyl) 4-hydroxy-phenyl ester) (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carbonyloxy] -propionyl.} - piperidin-4-yl) -piperazine-1-carboxylic acid (Example 123) in 4 mL of piperidine was stirred at RT for 30 min. The reaction mixture was concentrated i. empty and the residue was purified by chromatography (silica gel, DCM / MeOH / NH3 90: 10: 1). Yield: 40 mg (22% of the theory) ESI-MS: (M + H) * = 605 Retention time (HPLC): 4.7 min (method F) Example 126 Ester (R) -1- (4- hydroxy-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl ester of 4- (2-oxo-l, 2,4,5-tetrahydro-1,3-ethyl) -benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 210 mg (0.30 mmol) of ester (R) -1- (4-hydroxy-benzyl) -2- [4- (l-tert-butoxy-carbonyl-piperidin-4-yl) -piperazine 4- (2-Oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (-1-yl) -2-oxo-ethyl ester (Example 124) in 1.5 mL of formic acid stirred at RT for 3 h. The reaction mixture was concentrated i. empty and the residue was purified by chromatography (silica gel, DCM / MeOH / NH3 90: 10: 1). Yield: 40 mg (22% of theory) ESI-MS: (M + H) + = 605 Rf = 0.45 (silica gel, DCM / MeOH / NH3 80: 20: 2) Retention time (HPLC): 4.6 min (method F) Example 127 Ester (R) -2-4, 4'-bipiperidinyl-l-yl-1- (4-hydroxy-benzyl) -2-oxo-ethyl 4- (2-oxo-l, 2,, 5-tetrahydro) -l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Analogously to Example 126, from 130 mg (0.19 mmol) of tert-butyl ester of l- acid. { (R) -3- (4-hydroxy-phenyl) -2- [4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carbonyloxy ] -propionyl} -4,4'-bipiperidinyl-1-carboxylic acid (Example 122), the product could be obtained. Yield: 70 mg (63% of theory) ESI-MS: (M + H) * = 604 Rf = 0.20 (silica gel, DCM / MeOH / NH3 80: 20: 2) Retention time (HPLC): 6.9 min (method F) Example 128 Ester (R) -1- (3,5-dibromo-4-hydroxy-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl ester of 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid 128a Acid (Z, E) -3- (4-Acetoxy-3,5-dibromo-phenyl) -2-acetylamino-acrylic Analogously to Example la, from 30 g (107 mmol) of 3,5-dibromo- 4-hydroxy-benzaldehyde and 18.8 g (161 mmol) of N-acetyl-glycine, the product could be obtained. Yield: 35.7 g (79% of theory) ESI-MS: (M + H) * = 420/422/424 (2 Br) Rf = 0.20 (silica gel, DCM / MeOH / AcOH 90: 10: 1) 128b 3- (3,5-dibromo-4-hydroxy-phenyl) -2-oxo-propionic acid Analogously to Example Ib, from 35.7 g (84.8 mmol) of (Z, E) -3- (4-acetoxy-3,5-dibromo-phenyl) -2-acetylamino-acrylic acid, the product could be obtained. Yield: 20.5 g (72% of the theory) ESI-MS: (MH) "335/337/339 (2 Br) Rf = 0.35 (silica gel, DCM / MeOH / AcOH 80: 20: 2 128c Acid (R) -3- (3, 5-dibromo-4-hydroxy-phenyl) -2-hydroxy-propionic Analogously to Example LE, from 14.5 g (42.9 mmol) of 3- (3, 5-dibromo-4-hydroxy-phenyl) -2-oxo-propionic acid and 30.9 g (96.33 mmol) of (IR) -B-chlorodiiso-pinocanphenylborane, the product could be obtained. , 7 g (87% of theory) ESI-MS: (MH) "= 337/339/341 (2 Br) Rf = 0.4 (silica gel, DCM / MeOH / AcOH 80: 20: 2) Retention time (HPLC): 6.4 min (method F) 128d (R) -3- (3,5-dibromo-4-hydroxy-phenyl) -2-hydroxy-propionic acid methyl ester Analogously to Example 46d, from 14.0 g (34.8) mmol) of 3 (R) -3- (3,5-dibromo-4-hydroxy-phenyl) -2-hydroxy-propionic acid, the product was obtained Yield: 7.0 g (57% of the theory) ESI-MS: (MH) "= 351/353/355 (2 Br) Retention time (HPLC): 9, 8 min (method F) 128e Methyl ester of (R) -3- [3, 5-dibromo acid -4- (2-trimethylsilanyl-ethoxymethoxy) -phenyl] -2-hydroxy-propionic acid Under a nitrogen atmosphere, to a solution of 6.78 g (19.2 mmol) of methyl ester of (R) -3- acid. (3, 5-dibromo-4-hydroxy-phenyl) -2-hydroxy-propionic acid in 100 mL of acetonitrile, 11.1 g (76.6 mmol) of 40% KF / A1203 were added and the resulting suspension was stirred Then, a solution of 4.07 mL (23.0 mmol.) of (2-chloromethoxy-ethyl) -trimethylsilane in 20 mL of acetonitrile was added and the reaction mixture was stirred. for 20 h at RT, it was filtered over Celite, the solvent was concentrated i.vac and the residue was purified by chromatography (silica gel, n-hexane / EtOAc 7: 3) Yield: 5.49 g (59% strength). the theory) Rf = 0.45 (silica gel, n-hexane / EtOAc 1: 1) 128f Ester (R) -2- [3,5-dibromo-4- (2-trimethylsilanyl-etho 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid, xyethoxy) -phenyl] -1-methoxy-carbonyl-ethyl analogue to Example 31f, from 4.63 g (9.56 mmol) of (R) -3- [3,5-dibromo-4- (2-trimethylsilanyl-ethoxymethoxy) -phenyl] -2-hydroxymethyl ester -propionic and 2.35 g (9.56 mmol). of 3-piperidin-4-yl-1,3,4,5,5-tetrahydro-l, 3-benzodiazepin-2-one, the product could be obtained. Yield: 4.35 g (69% of the theory) ESI-MS: (M + H) * = 754/756/758 (2 Br) Retention time (HPLC): 29.2 min (method F) 128g Ester (R) -2- (3, 4- (2-oxo-l, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidin-1, 5-dibromo-4-hydroxy-phenyl) -1-methoxycarbonyl-ethyl acid -carboxylic Under a nitrogen atmosphere, to a solution of 4.30 g (5.69 mmol) of ester (R) -2- [3,5-dibro-4- (2-trimethylsilanyl-ethoxymethoxy) -phenyl] - 1-methoxy-carbonyl-ethyl 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid in 40 mL of THF and 40 mL of MeOH were added 5.46 mL of methanolic H2SO4 (0.5 M) and the reaction solution was stirred for 6 h at RT. The reaction mixture was concentrated i. vacuum and the residue was reacted further without purification. Yield: quantitative ESI-MS: (M + H) * = 624/626/628 (2 Br) Retention time (HPLC): 17.3 min (method F) 128h Ester (R) -l-carboxy-2- (3, 5-dibromo-4-hydroxy-phenyl) -ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid To a solution of ester (R) -2- (3,5-dibromo-4-hydroxy-phenyl) -1-methoxycarbonyl-ethyl 4- (2-oxo-1,2,4,5,5-tetrahydro) , 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (crude product from Example 128g) in 80 mL of THF was added a solution of 0.51 g (21.3 mmol) of LiOH, and the reaction mixture was stirred for 3 h at RT. I.vac was separated THF, the aqueous phase was washed with EtOAc, acidified with 10% HCl and the aqueous phase extracted to exhaustion with EtOAc. The combined organic phases were concentrated i. aq., were suspended in diethyl ether, filtered and the residue was dried and then purified by chromatography (silica gel, DCM / MeOH / AcOH 90: 10: 1). Performance: 3.5 g (100% theory) ESI-MS: (M + H) * = 610/612/614 (2 Br) Retention time (HPLC): 14.1 miri (method F) 128i Ester (R) -1- (3, 5-dibromo- 4-hydroxy-benzyl) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-ethyl acid 4- (2-oxo-l, 2,4 , 5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Under a nitrogen atmosphere, to a solution of 151 mg (0.25 mmol) of ester (R) -l-carboxy-2 - (3, 5-dibromo-4-hydroxy-phenyl) -ethyl 4- (2-oxo-l, 2,4,5,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidin-1- carboxylic acid, 104 mg (0.27 mmol) of HATU and 47 μl (0.27 mmol) of ethyldiisopropylamine in 5 mL of DMF, 55 mg was added (0.30 mmol) of l-methyl-4-piperidin-4-yl-piperazine and the reaction mixture was stirred for 3 h at RT. The reaction solution was concentrated i. empty and the residue was purified by chromatography (silica gel, DCM / MeOH / NH3 80: 20: 2). Yield: 190 mg (99% of theory) ESI-MS: (M + H) * = 775/777/779 (2 Br) Rf = 0.3 (silica gel, DCM / MeOH / AcOH 80: 20: 2) Retention time (HPLC): 7, 2 min (method F) The following compounds were similarly prepared from each in each case 151 mg of (R) -l-carboxy-2- (3,5-dibromo-4-hydroxy-phenyl) -ethyl ester of 4-carboxylic acid. - (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and the corresponding amount of amine: EXAMPLE 134 Ester (R) -1- (3,5-dibromo-4-hydroxy-benzyl) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -ethyl 4-ethyl ester (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid ? Ax 'and »< » Analogously to Example 128i, from 200 mg (0.33 mmol) of ester (R) -l-carboxy-2- (3, 5-dibromo-4-hydroxy-phenyl) -ethyl 4- (2- oxo-l, 2,4,6-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid, 140 μL (0.82 mmol) of ethyldiisopropylamine and 135 mg (0.44 mmol) of ester 4-Piperazin-1-yl-piperidine-1-carboxylic acid tert-butyl ester (used as the hydrochloride salt) the crude product was obtained. This was dissolved in 2 mL of formic acid and stirred for 2 h at RT. The reaction mixture was concentrated i. empty and the residue was purified by chromatography (silica gel, elution first with DCM / MeOH / NH3 80: 20: 2, then with DCM / MeOH / NH3 50: 50: 5). Yield: 20 mg (8% of the theory) ESI-MS: (M + H) + = 761/763/765 (2 Br) Rf = 0.35 (silica gel, DCM / MeOH / NH3 80:20: 2) Retention time (HPLC): 6.5 min (method F) Example 135 Ester (R) -1- (3,5-dibromo-4-hydroxy-benzyl) -2-oxo-2- (4-piperazine) 4- (2-Oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid-1-yl-piperidin-1-yl) -ethyl ester A 9H-fluoren-9-ylmethyl ester of 4- (l-. {(R) -3- (3, 5-dibromo-4-hydroxy-phenyl) -2- [4- (2-oxo-l) 2,4,4-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1-carbonyloxy] -propionyl.} -. - piperidin-4-yl) -piperazine-1-carboxylic acid (Example 133) in 4 mL of piperidine was stirred at RT for 30 min. The reaction mixture was concentrated i. empty and the residue was purified by chromatography (silica gel, DCM / MeOH / NH3 80: 20: 2). Yield: 20 mg (8% of the theory) ESI-MS: (M + H) + = 761/763/765 (2 Br) Retention time (HPLC): 6.8 min (method F) Example 136 Ester ( R) -1- (3,5-dibromo-4-hydroxy-benzyl) -2- (1 '-methanesulfonyl-4,4'-bipiperidinyl-1-11) -2-oxo-ethyl. of 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid A solution of 130 mg (0.21 mmol) of (R) 1-carboxy-2- (3, 5-dibromo-4-hydroxy-phenyl) -ethyl ester of 4- (2-oxo-l, 2, 4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid, 80 mg (0.25 mmol) of TBTU and 50 μL (0.27 mmol) of ethyldiisopropylamine in 10 L of THF are added. stirred for 50 min at RT. The addition of 60 mg (0.24 mmol) of the methanesulfonyl- [4, 4 'jbipiperidinyl] was then carried out and the reaction mixture was then stirred overnight at RT. The reaction solution was diluted with 50 mL of EtOAc, extracted twice, in each case with 30 mL of 15% K2C03 solution, the organic phase was separated and dried over MgSO4. After separating the drying agent and the solvent, the residue was mixed by triturating with water and filtered. The solid was mixed with 5 mL of 1 M HCl and stirred overnight. The further purification of the crude product was carried out by chromatography (silica gel, gradient DCM to DCM / MeOH / NH3 50: 45: 5). The fractions containing the product were combined, concentrated i.vac., Triturated with DIPE, filtered with suction and dried at 40 ° C. Yield: 80 mg (45% of theory) ESI-MS: (M + H) * = 838/840/842 (2 Br) Rf = 0.42 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) Example 137 Ester (R) -2- (4-amino-4-methyl-1,4'-bipiperidinyl-1'-yl) -1- (3,5-dibromo-4-hydroxy) benzyl) -2-ethyl 4- (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidin-1- Analogously to Example 1h, from 80 mg (0.13 mmol.) Of ester (R) -l-carboxy-2- (3, 5-dibromo-4-hydroxy-phenyl) -ethyl 4- ( 2-oxo-l, 2,4,5,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and 36 mg (0.14 mmol) of 4-methyl- [1,4 '] bipiperidinyl-4-ylamine (used in the form of the hydrochloride salt) it was possible to obtain the crude product that resulted in the form of the salt formate Yield: 6 mg (6% of the theory) ESI-MS: (M + H) + = 789 / 791/793 (2 Br) Retention time (HPLC): 4.9 min (method A) Example 138: Ester (R) -1- (3,5-dibromo-4-hydroxy-benzyl) -2- (1 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-ethoxycarbonylmethyl-4, '-bipiperidinyl-l-yl) -2-oxo-ethyl acid To a solution of 500 mg (0.82 mmol) of (R) -l-carboxy-2- (3, 5-dibromo-4-hydroxy-phenyl) -ethyl ester of 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid, 315 mg (0.98 mmol) of TBTU and 150 μl (1.06 mmol) of triethylamine in 5 L of DMF, 208 mg (0.82 mmol) of [4,4 '] bipiperidinyl-1-yl-acetic acid ethyl ester were added and the reaction mixture was stirred overnight at RT. To complete the reaction, another 315 mg (0.98 mmol) of TBTU, 150 μL (1.06 mmol) of triethylamine and 208 mg (0.82 mmol) of [4, 4 '] bipiperidinyl ethyl ester were added. -1-acetic acid and stirred again overnight at RT. The reaction mixture was purified, without further treatment, directly through HPLC. The fractions containing the product were pooled, concentrated i. empty neutralized with saturated NaHCO3 solution, the aqueous phase was extracted twice, in each case with 100 mL of DCM and the combined organic phases were dried over Na2SO4. After separating the drying agent and the solvent, the residue was mixed by triturating with DIPE, filtered with suction and air dried. Yield: 204 mg (29% of theory) ESI-MS: (M + H) + = 846/848/850 (2 Br) Retention time (HPLC): 6.5 min (method A) Example 139 Ester (R) -2- (1'-carboxymethyl-) 4, 4'-bipiperidinyl-1-yl) -1- (3, 5-dibromo-4-hydroxy-benzyl) -2-oxo-ethyl 4- (2-oxo-1, 2,4, 5- tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid To a solution of 30 mg (0.04 mmol) of ester (R) -1- (3,5-dibromo-4-hydroxy-benzyl) -2- (1'-ethoxycarbonylmethyl-4,4'-bipiperidinyl-1) (2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (2-oxo-ethyl) (Example 138) in 3-oxo-ethyl) mL of THF was added a solution of 1.4 mg (0.06 mmol) of LiOH in 1 mL of water and the reaction solution was stirred overnight at RT. The solvent was removed in the nitrogen stream, the residue was taken up in 1 mL of water, acidified with formic acid, the resulting precipitate was filtered off with suction and dried in vacuo. Yield: 20 mg (69% of theory) ESI-MS: (M + H) * = 818/820/822 (2 Br) Retention time (HPLC): 6.5 min (method A) Example 140 Ester (R) -2- (4-amino-4 methyl-l, 4'-bipiperidinyl-1'-yl) -1- (3, 5-bis-trifluoromethyl-benzyl) -2-oxo-ethyl of 4- (2-oxo-l, 2,4, 5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Analogously to Example lh, from 80 mg (0.14 mmol) of (R) -2- (3,5-bis-trifluoromethyl-phenyl) -1-carboxy-ethyl ester of 4- (2-oxo-l, 2, 4, 5-tetrahydro- 1, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 46f) and 38 mg (0.14 mmol) of 4-methyl- [1, '] bipiperidinyl-4-ylamine (used in the form of the hydrochloride salt) it was possible to obtain the resulting product in the form of the salt formate. Yield: 47 mg (42% of theory) ESI-MS: (M + H) + = 753 Retention time (HPLC): 5.4 min (method A) Example 141 Ester (R) -2- (1'-ethoxycarbonylmethyl-4,4'-bipiperidinyl-1) -yl) -1- (4-hydroxy-3, 5-dimethyl-benzyl) -2-oxo-ethyl 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin- 3-il) - Analogously to Example 46g, from 200 mg (0.42 mmol) of 4- (2-oxo-l, 2, 4, 5-) 4- (2-oxo-l, 2- (4-hydroxy-3,5-dimethyl-phenyl) -ethyl ester of (R) -l-carboxy-2- (4-hydroxy-3-hydroxy) tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 69h) and 117 mg (0.46 mmol) of [4,4 '] bipiperidinyl-1-yl-acetic acid ethyl ester, The product could be obtained. Yield: 222 mg (74% of theory) ESI-MS: (M + H) + = 718 Retention time (HPLC): 3.1 min (method A) Example 142 Ester (R) -2- (1'-carboxymethyl-4,4'-bipiperidinyl-1) -yl) -1- (4- hydroxy-3, 5-dimethyl-benzyl) -2-oxo-ethyl 4- (2-oxo-1, 2, 4, 5-tetrahydro-l, 3-benzodiazepin- 3-yl) -piperidin-1- Analogously to Example 139, from 100 mg (0.14 mmol) of ester (R) -2- (1'-ethoxycarbonylmethyl-4,4'-bipiperidinyl-1-yl) -1- (4-hydroxy-3) , 5-dimethyl-benzyl) -2-oxo-ethyl 4- (2-oxo-l, 2,4,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 141) and 3.8 mg (0.16 mmol) of LiOH, the product could be obtained. Yield: 56 mg (58% of theory) ESI-MS: (MH) "= 688 Retention time (HPLC): 3.0 min (method A) Example 143 Ester (R) -2- (4-cyclohexyl-piperazin-1-yl) -1- (4 -hydroxy-3, 5-dimethyl-benzyl) -2-oxo-ethyl acid 4- (2-oxo-l,, 4, 5- Analogously to Example Ih, from 69 mg (0.14 mmol) of 4- (2-oxo-l, 2, 4, 5-) 4- (2-oxo-l, 2- (4-hydroxy-3,5-dimethyl-phenyl) -ethyl ester tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid (Example 69h) and 24 mg (0.14 mmol) of 1-cyclohexyl-piperazine, the product could be obtained. Yield: 51 mg (91% of the theory) ESI-MS: (M + H) * = 632 Retention time (HPLC): 3.1 min (method E) Example 144 Ester (R) -2- [4- (4- (2-oxo-1,2,4,5) -3- (2-oxo-1,2,4,5-methyl- (3-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-l- (3-trifluoromethyl-benzyl) -ethyl ester -tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1- 144a Acid (Z, E) -2-acetylamino-3- (3-trifluoromethyl-phenyl) -acrylic Analogously to Example la, from 15.8 g (115 mmol) of 3-trifluoromethyl-benzaldehyde and 21.3 g (182 mmol) of N-acetyl-glycine, the product could be obtained. Yield: 16.7 g (53% of the theory) ESI-MS: (M + H) * = 274 Rf = 0.4 (silica gel, DCM / MeOH / AcOH 90: 10: 1) 144b 2-OXO-3- (3-trifluoromethyl-phenyl) -propionic acid Analogously to Example 46b, from 16.6 g (60.8 mmol) of (Z, E) -2-acetylamino-3- ( 3-trifluoromethyl-phenyl) -acrylic, the product could be obtained. Yield: 5.7 g (40% of theory) ESI-MS: (MH) "= 231 Rf = 0.19 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 144c Acid (R) -2-hydroxy-3- (3-trifluoromethyl-phenyl) -propionic Analogously to Example le, from 5.70 g (24.6 mmol) of 2-oxo-3- (3-trifluoromethyl-phenyl) -propionic acid and 11.8 g (36.8 mmol) of (IR) -B- 'chlorodiisopinocanphenylborane, the product was obtained.

Yield: 4.25 g (74% of theory) ESI-MS: (MH) "= 233 Rf = 0.35 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 144d Ester (R) -2-hydroxy-3- (3-trifluoromethyl-phenyl) -propionic acid methyl ester Analogously to Example 46d, from 4.20 g (17.9 mmol) of (R) -2-hydroxy- 3- (3-trifluoromethyl-phenyl) -propionic, the product could be obtained Yield: 2.47 g (55% of theory) ESI-MS: (M + H) * = 249 Rf = 0.73 (gel silica, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) 144e 4- (2-Oxo-l, 2- (3-trifluoromethyl-phenyl) -ethyl ester (R) -l-methoxycarbonyl-2- (2-oxoyl) 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Analogously to Example 31f, from 2.47 g (9.95 mmol) of (R) -2-hydroxy-3- (3-trifluoromethyl-phenyl) -propionic acid methyl ester and 4.10 g (65% purity, .9 mmol) of 3-piperidin-4-yl-1,3,4,5-tetrahydro-l, 3-benzodiazepin-2-one, the product could be obtained. Yield: 3.16 g (61% of the theory) ES.I-MS: (M + H) * = 520 Rf = 0.93 (silica gel, EtOAc / MeOH / NH3 80: 20: 2) 144f Ester (R) -l-carboxy-2- (3-trifluoromethyl-phenyl) -ethyl 4- (2-oxo-l, 2, 4, 5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin -1-carboxylic acid Analogously to Example 46f, starting from 3.10 g (5.97 mmol) of ester (R) -l-methoxycarbonyl-2- (3-trifluoromethyl-phenyl) -ethyl 4- (2- oxo-l, 2,4,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and 0.22 mg (9.00 mmol) of LiOH, the product could be obtained.

Yield: 2.80 g (93% of theory) ESI-MS: (M + H) * = 506 Rf = 0.58 (silica gel, EtOAc / MeOH / NH3 70: 30: 3) 144g Ester (R) -2- [4- (4-Methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-l- (3 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -1-piperidine-1-carboxylic acid trifluoromethyl-benzyl ester Analogously to Example lh, a from 80.0 mg (0.16 mmol) of (R) -l-carboxy-2- (3-trifluoromethyl-phenyl) -ethyl ester of 4- (2-oxo-l, 2, 4, 5- tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and 29.6 mg (0.16 mmol) of l-methyl-4-piperidin-4-yl-piperazine, it was possible to obtain the product. Yield: 67 mg (63% of theory) ESI-MS: (M + H) * = 671 Rf = 0.4 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) Analogously prepared the following compounds, in each case from 80 mg (Examples 145 to 148) or 140 mg (Examples 149 and 150) of ester (R) -l-carboxy-2- (3-trifluoromethyl-phenyl) -ethyl ester of 4- (2-oxo-1, 2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid and the corresponding amount of amine: Example 151: Ester (R) -1 - (3-Methyl-benzyl) -2-oxo-2- (4-piperazin-1-yl-piperidin-1-yl) -ethyl 4- (2-oxo-l, 2,4,5-tetrahydro) -1, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid l) of 4- tert.-butyl ester. { l- [(R) -2- [4- (2-oxo-l, 2,4,5,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carbonyloxy] -3- (3- trifluoromethyl-phenyl) -propionyl} -piperidin-4-yl-piperazine-l-carboxylic acid (Example 149) in 1.5 mL of 4 M HCl was stirred at RT overnight. The reaction solution was purified, without further treatment, by HPLC. The fractions containing the product were combined and lyophilized. Yield: 75 mg (67% of theory) ESI-MS: (M + H) * = 657 Rf = 0.38 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) Example 152 Ester (R) -2-oxo-2- (4-piperidin-4-yl-piperazin-1-yl) -1- (3-trifluoromethyl-benzyl) -ethyl 4- (2-oxo-l, 2) , 4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid Analogously to Example 151, from 149 mg (0.20 mmol) of ester (R) -1- (3-trifluoromethyl-benzyl) -2- [4- ((1-tert.-butoxycarbonyl-piperidine- 4-yl) -piperazin-1-yl] -2-oxo-ethyl acid 4- (2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1 -carboxylic acid (Example 150), the product was obtained Yield: 66 mg (51% of the theory) ESI-MS: (M + H) * = 657 Rf = 0.18 (silica gel, DCM / MeOH / Cyc / NH3 70: 15: 15: 2) Example 153: Ester (R) -2- [4- (4-methyl-piperazin-1-yl) -piperidin-1-yl] -2-oxo-1- (3- 4- (2-oxo-l, 2,4,5,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid methyl-benzyl) -ethyl ester 153a Acid (Z, E) -2-acetylamino-3-m-tolyl-acrylic Analogously to Example la, from 25.0 g (212 mmol) of 3-methyl-benzaldehyde and 24.9 g (212 mmol) of N-acetyl-g, licina, the product could be obtained. Yield: 26.0 g (56% of theory) ESI-MS: (M + H) * = 220 Retention time (HPLC): 5.4 min (method A) 153b 2-Oxo-3-.m-tolyl-propionic acid Analogously to Example 46b, from 13 , 0 g (59.3 mmol) of (Z, E) -2-acetylamino-3-m-tolyl-acrylic acid, the product could be obtained. Yield: 9.2 g (88% of theory) ESI-MS: (MH) "= 177 Retention time (HPLC): 7.3 min (method A) 153c Acid (R) -2-hydroxy-3-zp-tolyl-propionic Analogously to Example le, from 9.24 g (51.9 mmol) of 2-oxo-3-m-tolyl-propionic acid and 24.0 g (74.8 mmol) of (IR) -B-chlorodiisopinocanphenylborane, the product was obtained. : 8.4 g (90% of theory) ESI-MS: (MH) "= 179 Retention time (HPLC): 7.2 min (method A) 153d (R) -2-hydroxy-3-m-tolyl-propionic acid methyl ester Analogously to Example 31e , from 8.40 g (46.6 mmol) of (R) -2-hydroxy-3-m-tolyl-propionic acid and 3.74 mL (51.28 mmol) of S0C12, the product could be obtained.

Yield: 6.28 g (69% of theory) ESI-MS: (M + H) * = 195 Retention time (HPLC): 6.9 min (method A) 153e Ester (R) -l-methoxycarbonyl-2-m-tolyl-ethyl acid 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid analogously to Example.31f, from 1.12 g (5.76 g) mmol) of (R) -2-hydroxy-3-m-tolyl-propionic acid methyl ester and 1.41 g (5.76 mmol) of 3-piperidin-4-yl- 1, 3, 4, 5- tetrahydro-l, 3-benzodiazepin-2-one, the product could be obtained. Yield: 2.07 g (77% of the theory) ESI-MS: (M + H) * = 466 Retention time (HPLC): 9.0 min (method A) 153f Ester (R) -l-carboxy 2-m-tolyl-ethyl 4- (2-oxo-1,2,4,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid analogue to Example 46f, starting from 2.07 g (4.45 mmol) of ester (R) -l-methoxycarbonyl-2-m-tolyl-ethyl 4- (2-oxo-l, 2, 4, 5-tetrahydro-l, 3-) benzodiazepin-3-yl) -piperidine-1-carboxylic acid and 0.16 mg (6.72 mmol) of LiOH, the product could be obtained. Yield: 1.86 g (93% of theory) ESI-MS: (M + H) * = 452 Retention time (HPLC): 8.0 min (method A) 153g Ester (R) -2- [4- (4-methyl-piperazin-1-yl) - - piperidin-1-yl] -2-oxo-l- (3-methyl-benzyl) -ethyl acid 4- (2-oxo-l, 2,4,5-tetrahydro-l, 3-benzodiazepin-3-) il) -1- piperidine-1-carboxylic acid Analogously to Example Ih, from 80.0 mg (0.18 mmol) of ester. (R) -l-carboxy-2-m-tolyl-ethyl 4- ('2-oxo-l, 2,4,5,5-tetrahydro-l, 3-benzodiazepin-3-yl) -piperidin-1- carboxylic acid and 33.1 mg (0.18 mmol) of l-methyl-4-piperidin-4-yl-piperazine, the product could be obtained. Yield: 46.7 mg (43% of theory) ESI-MS: (M + H) * = 617 Retention time (HPLC): 5.5 min (method A) The following compounds were similarly prepared from each in each case 80 mg ester (R) -1-carboxy 2- (2-Oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl) -piperidine-1-carboxylic acid -2-m-tolyl and the corresponding amount of amine: The following Examples describe the preparation of pharmaceutical application forms which, as an active ingredient, contain an arbitrary compound of the general formula (I): Example I Capsules for the inhalation of powders with 1 mg of active ingredient Composition: 1 capsule for the inhalation of powders contains: active ingredient 1.0 mg lactose 20.0 mg hard gelatine capsules 50.0 mg 71.0 mg Procedure Preparation: The active ingredient is ground to the size of grains required for inhalation products. The milled active ingredient is mixed homogeneously with the lactose. The mixture is filled into hard gelatin capsules. Example II Inhalation solution for Respimat with 1 mg of active ingredient Composition: 1 run contains: active ingredient 1.0 mg benzalkonium chloride 0.002 mg disodium edetate 0.0075 mg purified water up to 15.0 μl Preparation procedure: The active ingredient and benzalkonium chloride are dissolved in water and packed in Respimat cartridges.

Example III Inhalation solution for nebulizers with 1 mg of active ingredient Composition: 1 vial contains: active substance 0.1 g sodium chloride 0.18 g benzalkonium chloride 0.002 g purified water up to 20.0 ml Preparation procedure: The principle Active, sodium chloride and benzalkonium chloride dissolve in water. Example IV Dosing aerosol with propellant gas with 1 mg of active ingredient Composition: 1 run (Contains: active ingredient 1.0 mg lecithin 0.1% propellant gas up to 50.0 μl Preparation procedure: The micronized active ingredient is suspended homogeneously in the mixture based on lecithin and propellant gas The suspension is packed in a pressure vessel with a metering valve Example V Nasal spray with 1 mg of active ingredient Composition: active ingredient 1.0 mg sodium chloride 0.9 mg chloride of benzalkonium 0.025 mg disodium edetate 0.05 mg purified water to 0.1 ml Preparation procedure: The active ingredient and the adjuvants are dissolved in water and packed in a corresponding container Example VI Solution for injection with 5 mg of active substance per 5 ml Composition: active substance 5 mg glucose 250 mg human serum albumin 10 mg glucofurol 250 mg water for injection purposes up to 5 ml preparation: Dissolve glucofurol and glucose in water for injection purposes (afi); add human serum albumin; dissolve the active ingredient under heating; complete with afi up to the volume of the batch; Pack in ampoules under gasification with nitrogen. Example VII Solution for injection with 100 mg of active substance per 20 ml Composition: active substance 100 mg dihydrogen phosphate monopotassium = KH2PO4 12 mg hydrogen-phosphate disodium = Na2HP? 4"2H2? 2 mg sodium chloride 180 mg serum albumin human 50 mg Polysorbat 80 20 mg water for injection purposes up to 10 ml Preparation: Dissolve Polysorbate 80, sodium chloride, monopotassium dihydrogen phosphate and disodium hydrogen phosphate in water for injection purposes (afi); add human serum albumin; dissolve the active ingredient under heating; complete with afi up to the volume of the batch; pack in ampoules. Example VIII Lyophilized with 10 mg of active substance Composition: active substance 10 mg mannitol 300 mg human serum albumin 20 mg water for injection purposes up to 2 ml Preparation: Dissolve mannitol in water for injection purposes (afi); add human serum albumin; dissolve the active ingredient under heating; complete with afi up to the volume of the batch; pack in vials; lyophilize. Solvent for lyophilisation: Polysorbat.80 = Tween 80 20 mg manita 200 mg water for injection purposes up to 10 ml Preparation: Dissolve Polysorbat 80 and manita in for injection purposes (afi); pack in ampoules. Example IX Tablets with 20 mg of active substance Composition: active substance 20 mg Lactose 120 mg corn starch 40 mg magnesium stearate 2 mg Povidone K 25 18 mg Preparation: Mix homogeneously active substance, lactose and corn starch; granulate with an aqueous solution of povidone; mix with magnesium stearate; pressing in a tablet press; tablet weight 200 mg.

Example X Capsules with 20 mg of active substance Composition: active substance 20 mg corn starch 80 mg silicic acid, very dispersed 5 mg magnesium stearate 2.5 mg Preparation: Mix homogeneously the active substance, corn starch and silicic acid; mix with magnesium stearate; pack the mixture in a machine for packaging in hard gelatin capsules of size 3. Example XI Suppositories with 50 mg of active substance Composition: active substance 50 mg hard fat (solid fat) q.s. up to 1700 mg Preparation: Melt the hard fat to approx. 38 ° C; homogeneously disperse the milled active substance in the molten hard fat; after cooling to approx. 35 ° C, pour into previously cooled molds. Example XII Solution for injection with 10 mg of active substance per 1 mL Composition: active substance 10 mg mannitol 50 mg human serum albumin 10 mg water for injection purposes up to 1 ml Preparation: Dissolve mannitol in water for injection purposes (afi); add human serum albumin; dissolve the active ingredient under heating; complete with afi up to the volume of the batch; Pack in ampoules under gasification with nitrogen.

Claims (7)

CLAIMS CGRP antagonists of the general formula where A means an oxygen or sulfur atom, X an oxygen or sulfur atom, (a) D, E, independently of one another, a methine group or the nitrogen atom and G a methine group substituted with the group Ra , M a methino group substituted with the group Rb, Q a methino group substituted with the group Rc, wherein one or two of the groups G, M and Q can mean in each case also a nitrogen atom, or (b) D and E, in each case, a methine group, one of groups D and E being also a nitrogen atom, and G, M and Q in each case a nitrogen atom, wherein Ra, Rb and Rc, independently one another are each a hydrogen atom or halogen, a group-C? -6, C2_6-alkenyl, C2_6-alkynyl, cyclo-C3_7-alkyl, cyclo-C3- alkenyl, cyano, hydroxy, hydroxy- alkyl-C? -6, hydroxy-alkenyl-C3-6? hydroxy-alkynyl-C3_6, alkoxy-C6-6, alkoxy-Ci-d-alkyl-Ci-e, alkoxy-C6-6-alkenyl-C3-6 / 'alkoxy-C6-6-alkynyl-C3-6 alkenoxy-C3-6-alkyl-C? -6, C3-6 alkenoxy-C3-6-alkenyl, C3-6 alkenoxy-C3-6-alkynyl, C3-6-alkynoxy-alkyl-C? _6, C 3-6 alkyloxy-C 3-6 alkenyl, C 3-6 alkyloxy-C 3-6 alkynyl, thiohydroxy, C 1-6 alkylthio, C 3-6 alkenylthio-C 3-6 alkynylthio, amino, C 1-6 -alkylamino, C3_6-alkenyl-amino, C3-6 alkynyl ~ amino, di- (Ci-ß alkyl) -amino, di- (C3_6 alkenyl) -amino, di- (C3_6-alkynyl) -amino, amino-alkyl- C? -6, alkyl-C? _3-amino-C? _6 alkyl, di- (C? _3 alkyl) -amino-C? -6 alkyl, C3-6 amino-alkenyl, C-alkyl? 3-amino-C3-6 alkenyl, di- (C3-3 alkyl) -amino-C3-6 alkenyl, C3-6 amino-alkynyl, C3-alkyl-3-amino-alkynyl-C3_6, di- (C 1 -C 3 alkyl) -amino-C 3 -C 6 alkynyl-hydroxycarbonyl, phenylcarbonyl, pyridylcarbonyl, C 1 -C 6 alkylcarbonyl, C 2 -C 6 alkenylcarbonyl, C 2 -C 6 alkynylcarbonyl, formyl, C-alkoxy ? _6-carbonyl, alkenoxy-C3_6-carbonyl, alkynoxy - C3-6-carbonyl, aminocarbonyl, alkyl-C6-aminocarbonyl, alkenyl-C3_6-aminocarbonyl, alkynyl-C3-6-aminocarbonyl, di- (alkyl-Ci-β) -aminocarbonyl, di- (alkenyl-C3_6 ) -aminocarbonyl, di- (C3_6 alkynyl) -aminocarbonyl, formylamino, C6-alkylcarbonylamino, C2_6-carbonylamino alkenyl, C2_6-alkynyl-carbonylamino, formyl-C6-amino-alkyl, formyl-alkenyl -C3_6-amino, formyl-alkynyl-C3-6-amino, alkyl-Ci-e-carbonyl-alkyl-Ci-β-amino, alkenyl-C2-6-carbonyl-alkyl-C1_6-amino, alkynyl-C2_6-carbonyl -alkyl-C? _6-amino, alkyl-C? -6-carbonyl-alkenyl-C3_6 -ann.no, alkenyl-C2_s-carbonyl-alkenyl-C3_6-amino, alkynyl-C2_6-carbonyl-alkenyl-C3_6-amino, alkyl C? _6-alkynyl-carbonyl-C3-6-alkylamino, C2-6-alkenyl-carbonyl-C3-6-alkynyl-amino, C2_6-alkynyl-carbonyl-C3_6-alkynyl-amino, alkyl-C? _6- sulfonyl, C2-6 alkenyl-sulfonyl, alkynyl C2 ~ 6-sulfonyl, alkyl- C? -6 alkylsulfinyl, C2-6 alkenyl-sulfinyl, C2-s alkynyl-ynyl sulf alkyl- C? -6 ~ sulfonylamino, alkenyl-C2_6 -sulfonylamino, C2_6-alkynyl-sulfonylamino, C6_6-sulphonyl-C6-alkyl-6-amino alkyl, C6_6-sulfonyl-C3-6-alkenyl-amino alkyl, C-alkyl-6-sulfonyl onyl C3_6-alkynyl-amino, alqueniÍ-C2_6-alkyl-sulfonyl-C? -6-'amino, C2-6 alkenyl sulphonyl-C3-6 alkenyl-amino, C2-6 alkenyl-sulfonyl-alkynyl- C3-6-amino, C2-6 alkynylsulfonyl-C6-alkyl-6-amino, C2-6 alkynylsulfonyl-alkenyl-C3-S-amino, C2-6 alkynylsulfonyl-alkynyl- C3-6-amino, aminosulfonyl, alkyl-C6-aminosulfonyl, di- (alkyl-C6-6) -aminosulfonyl, alkenyl-C3_6-aminosulfonyl, di- (alkenyl-C3_6) -aminosulf onyl, alkynyl-C3_6 -aminosulf onyl or di- (alkynyl-C3_6) -aminosulfonyl with the provisos that, insofar as none of the groups D, E, G, M and Q represents a nitrogen atom, (i) Ra does not mean a hydrogen atom, when Rb, as well as Rc represent in each case a C-alkyl group -6, (ii) Rc does not mean a hydrogen atom, when R, as well as Rb represent in each case a group Po alkyl-C? -6, (iii) Ra does not take the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or a difluoro or trifluoromethyl group, when Rc represents an alkyl-C6-6, alkenyl-C2_6 or alkynyl-C2_6 group and Rb represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, ( iv) Rc does not assume the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoro or trifluoromethyl group, when Ra represents an alkyl-C6-6, alkenyl-C2_6 or alkynyl-C2_6 and Rb represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, R1 a heterocyclic aza, diaza, triaza, oxaza, thiaza, thiadiaza or S, S-dioxido-thiadiaza of 5 to 7 members, saturated, unsaturated once or two sometimes the above-mentioned heterocycles being linked to the piperidine ring in formula I through a carbon or nitrogen atom or being linked in a spirocyclic manner with the piperidine ring in formula I through two carbon atoms, through a carbon atom and an oxygen atom or through from a carbon atom and a sulfur atom, containing one or two carbonyl or thiocarbonyl groups contiguous to a nitrogen atom, and may be substituted on one of the nitrogen atoms with a C-6-alkyl, C3-6 alkenyl group or C3-6 alkynyl, which may be substituted on one or two carbon atoms with a C-6 alkyl, C2_6 alkenyl or C2_6 alkynyl group, with a phenyl, phenylmethyl, naphthyl, biphenylyl, pyridinyl, diazinyl group, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl, 1- (C 1 -C 3 alkyl) -pyrazolyl, imidazolyl or 1- (C 1 -C 3 alkyl) imidazolyl, the substituents are the same or different, and an olefinic double bond of one of the above-mentioned unsaturated heterocycles may be condensed with a ring of phenyl, naphthyl, pyridine, diazine, 1,3-oxazole, thienyl, furan, thiazole, pyrrolo, N -alkyl-C? -3-pyrrolo or quinoline, with a ring of li? -quinolin-2-one substituted in the atom of optionally with a C6-6 alkyl, C3-6 alkenyl or C3-alkynyl group, or it can be condensed with an imidazole ring or N-alkyl-C? -3-imidazole, and two condensates can also be condensed olefinic double bonds of one of the above-mentioned unsaturated heterocycles mentioned in each case with a phenyl or pyridine ring, the groups being phenyl, pyridinyl, diazinyl, furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, isoxazolyl , pyrazolyl, l-alkyl-C? -3-pyrazolyl, imidazolyl or 1-alkyl-C? -3-imidazolyl contained in R1, as well as the heterocycles condensed with benzo,. thieno, pyrido and diazino to be mono-, di- or tri-substituted in the carbon framework additionally with halogen atoms, C alquilo _6 alkyl, C2-6 alkenyl, C2_6 alkynyl, C3-7 cyclo-alkyl groups , C3-cycloalkenyl, cyano, hydroxy, hydroxy-C6-6alkyl, C3_6-hydroxy-alkenyl, C3-6-hydroxy-alkynyl, C6-alkoxy, C6-alkoxy-6-alkyl- C? -6, C3-6 alkoxy-C3-6 alkenyl, C6-6 alkoxy-C3-6 alkynyl, C3-6 alkenoxy- C-6 alkyl, C3-6 alkenyl-C3-6 alkenyl, alkenoxy- C3_6-C3_6 alkynyl, C3_6 alkynoxy-C6_6 alkyl, C3_3 alkynyl-C3-6 alkenyl, C3_6 alkynyl-C3_6 alkynyl, thiohydroxy, C12_6 alkylthio, C3_6 alkenylthio, alkynyl -C3_6, amino, alkyl-C? -6-amino, alkenyl-C3_6-amino, alkynyl-C3-6-amino, di- (alkyl-Ci-β) -amino, di- (alkenyl-C3-6) - amino, di- (C 3-6 alkynylamino, amino-C 1 -C 6 -alkyl, C 1 -C 3 -alkylamino-C 1 -6 alkyl, di- (C 1 -C 3 alkyl) -amino- alkyl-Ca-6, amino-alkenyl-C3-6, alkyl-C? _3-amino-alkenyl-C3-6, di- (alkyl-C? _3) -amino-alkenyl-C3_6, amino-alkyl uinyl-C3_6, alkyl-C? -3-amino-alkynyl-C3_6, di- (C1-3-alkyl) -amino-C3_6 alkynyl, hydroxycarbonyl, phenylcarbonyl, pyridylcarbonyl, C6_6-alkylcarbonyl, C2_6 alkenyl -carbonyl, C 1 -C 6 alkynyl, formyl, C 1 -C 6 alkoxycarbonyl, C 3 -C 6 alkeneoxycarbonyl, C 3 -C 6 alkyanoxycarbonyl, aminocarbonyl, C 1 -C 6 alkylaminocarbonyl, C 3 -C 6 alkynylaminocarbonyl, alkynyl -C3-6-aminocarbonyl, di- (alkyl-C? -6) -aminocarbonyl, di- (C3-6 alkenyl) -aminocarbonyl, di- (C3-6 alkynyl) -aminocarbonyl, formylamino, alkyl-Ci-e-carbonylamino, C2-6 alkenyl-carbonylamino, C2_6 alkynyl-carbonylamino, formyl-alkyl-Cj.-6-amino, formyl-alkenyl-C3_6-amino-, formyl-alkynyl-C3-6-amino, alkyl-C? _6-carbonyl-alkyl-C? -6-amino, alkenyl-C2-6 -carbonyl-alkyl-C? -6-amino-, alkynyl-C2-6-carbonyl-alkyl-C? -6-amino, alkyl-C? -6-carbonyl-alkenyl-C3_6-amino, alkenyl-C2_6-carbonyl -alkenyl- C3_6-amino, alkynyl-C2-6-carbonyl-alkenyl-C3-6-amino, alkyl-C? -6-carbonyl-alkynyl-C3-6_amino, alkenyl- C2-6-carbonyl-alkynyl-C3- 6-amino, C2_6-alkynyl-carbonyl-C3-6-amino-alkynyl, -6-alkylsulfonyl, C2_6-alkenyl-sulfonyl, C2-6 alkynylsulfonyl, alkyl- Ci-e-sulfyl, alkenyl- C2_6-sulphonyl, C2_6-sulphonyl alkynyl, C6-6-sulfonylaminoalkyl, C2-6alkenyl-sulfonylamino, C2-6alkynyl-sulfonylamino, alkyl-C6-sulfonyl-alkyl-C? 6-amino, alkyl-C? -6-sulf onyl-alkenyl-C3-6_amino, alkyl-C? _6-sulfonyl-alkynyl- C3-6-amino, C2-6 alkenyl-sulfonyl-C6-amino-alkenyl, C2-6-alkenyl-sulfonyl-alkenyl-C3_6-amino, alkenyl-C2_6-sulfonyl-alkynyl-C3_6-amino, alkynyl -C2_6-sulf onyl-alkyl-Ci-g-amino, C2-6 alkynyl-sulfonyl-C3-6-alkenyl-amino, C2-6 alkynyl-sulfonyl-C3_6-amino-alkynyl, aminosulfonyl, alkyl-Ci- e-aminosulfonyl, di- (C 1-6 alkyl) -aminosulfonyl, C 3-6 alkenyl-aminosulfonyl, di- (C 3-6 alkenyl) -aminosulfonyl, C 3-6 alkynyl-aminosulfonyl, di- (C 3-6 alkynyl) ) -aminosulfonyl, the substituents being the same or different and the double and triple bonds of the C3-6 alkenyl or C3-6 alkynyl groups contained in the groups defined above being for Ra, Rb, Rc and R1 isolated from heteroatoms optionally also contained in these groups, R2 the hydrogen atom, a phenylmethyl group or a C2_7 alkyl group, which in position? may be substituted with a group C3_7-cycloalkyl, C3_7-cycloalkenyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, alkyl-C6- amino, di- (C6_6 alkyl) -amino, alkenyl- C3_6-amino, di- (C3_6 alkenyl) amino, C3_6-amino alkynyl, di- (C3_6 alkynyl) amino, hydroxycarbonyl, C6_6-carbonyl alkoxy, aminocarbonyl, aminocarbonylamino, C6_6-carbonylamino alkyl, alkenyl-C2-6-carbonylamino, alkynyl-C2-6-carbonylamino, 4-morpholinyl, [bis- (2-hydroxy-ethyl)] amino, 4- (alkyl-Ci-e) -1-piperazinyl or 4- ( ? -hydroxy-C2_7 alkyl) -1-piperazinyl, a phenyl or pyridinyl group, the phenyl, pyridinyl and diazinyl groups mentioned in the groups defined above for R2 or contained as substituents being mono-, di- or tri-substituted additionally in the carbon framework with halogen, with C 1 -C 3 -alkyl, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3 -alkoxy, hydroxy, amino, C 1 -C 3 -alkylamino, di- (alkyl- C? -3) -amino, amino-alkyl-C? -3, alkyl-C? -3-amino-alkyl-C? 3, di- (alkyl-C? -3) -amino-C? -3 alkyl, C? _3-carbonylamino alkyl, C? -3-carbonylamino-C? _3 alkyl, aminocarbonyl, C-alkyl ? 3-aminocarbonyl, di- (C 1 -C 3 alkyl) -aminocarbonyl, cyano, aminosulfonyl, C 1 -C 3 alkyl aminosulfonyl, di- (C 1 -C 3 alkyl) -aminosulfonyl, C 1 -C 3 alkylthio , alkyl-C? -3-sulfinyl or alkyl-C? _3-sulfonyl, and the substituents being the same or different, R3 the hydrogen atom or a C -3-alkyl group substituted with a phenyl or pyridinyl group, the C-3 alkyl group is linked with an alkyl group contained in R2 or with a phenyl or pyridyl ring contained in R2, under the inclusion of the nitrogen atom to which R2 and R3 are attached, under the formation of a ring of 4-7 members, or R2 and R3, together with the included nitrogen atom, a radical of the general formula where Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the numbers 0, 1 or 2, oqyr, when Y1 represents the nitrogen atom, the numbers 1 or 2, R4 the hydrogen atom, an amino group, alkyl-C? _4-amino, di- (alkyl-C? -4) -alkylamino, alkyl-C? -e, a Cyclo-C3-7alkyl group or C3_7-cycloalkenyl group optionally substituted by a hydroxycarbonyl, C6-6alkoxycarbonyl, hydroxycarbonyl-C3-6alkyl or C6-6alkylcarbonyl-C-alkoxy group? _3, an amino-C2_alkyl group, C-4alkylamino-C2_alkyl, di- (C-alkyl-amino) -C2_7alkyl, aminoiminomethyl, aminocarbonylamino, alkyl-C4-4-amino -carbonylamino, di- (alkyl-C? _4) -aminocarbonylamino, alkyl-C? _4-aminocarbonyl-alkyl-C? -amino, di- (alkyl-C? _4) -aminocarbonyl-alkyl-C? -amino , phenylaminocarbonylamino, aminocarbonyl, alkyl-C? _ -aminocarbonyl, di- (alkyl-C? _4) -aminocar bonyl, aminocarbonyl-C 1 -C 3 alkyl, C 1 -aminocarbonyl-C 1 -C 3 alkyl, di- (C 1 -4 alkyl) -aminocarbonyl-C 1 -C 3 alkyl, aminocarbonylamino-alkyl- C? -3, C6-C6-alkoxy, C3-6-alkenoxy-carbonyl, C3-C6-alkyloxycarbonyl, C6-C6-alkoxycarbonyl-C? _3alkyl, C6-C6-alkenoxy? -alkyl-C? -3, alkyloxy-C? _6-carbonyl-C? _3 alkyl or hydroxycarbonyl-C? -3 alkyl, a phenyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl, pyridylcarbonyl or phenylcarbonyl group , which in each case can be mono-, di- or tri-substituted additionally in the carbon framework with halogen, with C 1 -C 3 -alkyl, C 2 -C 3 alkenyl, C 2- alkynyl, C 1 -C 3 -alkoxy, hydroxy groups , amino, alkyl-C? _4-amino, di- (alkyl-C? 4) -amino, amino-alkyl-C? _3, alkyl-C? -amino-alkyl-C? -3, di- ( alkyl-C? _) -amino-C? -3 alkyl, C? _ carbonylamino alkyl, C? _4-carbonylamino-C? _3 alkyl, aminocarbonyl, C? -4-amino-carbonyl alkyl, di- (alkyl-C? _4) -aminocarbonyl, cyano, aminosulfonyl, alkyl-C? -amino-sul fonilo, di- (alkyl-C? _4) -aminosulfonyl, alkyl-C? _4-thio, alkyl-C? _4-sulfinyl or alkyl-C? -4-sulfonyl, and the substituents being the same or different, a heterocycle chosen from an azacycloalkyl group of 4 to 10 members, an oxaza, thiaza, S, S-dioxothiaza and diazacycloalkyl group of 6 to 10 members, as well as an azabiocycloalkyl group of 6 to 10 members, a l-alkyl-4-piperidinicarbonyl group or 4-alkyl-1-piperazinylcarbonyl, the aforementioned monocyclic and bicyclic heterocycles being linked, through a nitrogen or carbon atom, to Y 1 in the formula (II), in the aforementioned monocyclic and bicyclic heterocycles a methino group not directly linked to a nitrogen, oxygen or sulfur atom may be substituted with a fluorine atom, as well as a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom may be substituted with one or two fluorine atoms, the heterocycles mo previously mentioned nocyclic and bicyclic, as well as the group 1- (alkyl-C? ~ 6) -4-piperidinylcarbonyl and 4- (alkyl-C? 6) -1-piperazinylcarbonyl can be substituted on the ring, one to four times, with hydroxy groups, C 1 -C 6 -alkyl or hydroxy-C 1 -C 3 -alkyl, or, optionally additionally, once with a C 3-7 cycloalkyl group, C 3-7 hydroxycycloalkyl, cycloalkenyl group -C3-7, cyclo-C3_7-alkyl-C? -3, phenyl-C? _3 alkyl, pyridyl-C? -3 alkyl, C? -6-carbonyl alkyl, C? -6 alkyl -carbonyl-C 1 -C 3 -alkyl, hydroxy, C 1 -C 6 -alkoxy, amino, C 1 -4 -alkylamino, di ~ (C 1 -4 alkyl) amino, phenylcarbonyl, pyridinylcarbonyl, C 6 -alkoxy -carbonyl, hydroxycarbonylcarbonyl, alkoxy- C6-carbonylcarbonyl, hydroxycarbonyl-C3-3alkyl, C6-alkoxy -6-carbonyl-C3-3alkyl, hydroxycarbonyl-C3-carbonyl , C 1 -C 6 alkoxy -carbonyl-C 1 -C 3 -carbonyl, aminocarbonyl, C 1 -4-aminocarbonyl alkyl, di- (C 1 -C 4 alkyl) aminocarbonyl, aminosulfonyl, C 1 -4 aminosulfonyl alkyl , di- (alkyl-C? -4) aminosulfonyl, alkyl-C? -3-sulfonyl, C3-7-sulfonyl-cycloalkyl, aminocarbonyl-C3-3alkyl, alkyl-C4-4aminocarbonyl-C3-3alkyl, di- (C3-alkyl) aminocarbonyl-C3-alkyl , hydroxyamino-carbonyl-C 1 -C 3 -alkyl, C 1 -C 3 -aminocarbonyl-C 1 -C 3 -alkyl or hydroxy- (C 1 -C 3 alkyl) -aminocarbonyl-C 1 -C 3 -alkyl, with a cyclo group -alkyl-C3- -carbonyl, azacyclo-C4-7-alkylcarbonyl, diazacyclo-C5-7alkylcarbonyl or oxazcyclo-C5_7alkylcarbonyl optionally substituted on the ring with C -3alkyl, wherein the substituents may be the same or different and may be attached to a ring carbon atom or a ring nitrogen atom, the phenyl and pyridinyl radicals being contained in the radicals defined above for R4 being mono-, di- or tri-substituted , on the other hand, with halogen atoms, with C alquilo _3 alkyl, C2-3 alkenyl, C2_3 alkynyl, C alco _3 alkoxy, hydroxy, amino, C alqu-4-amino-, di- ( alkyl-C? -4) -amino, amino-C-alkyl-3, alkyl-C? _-amino-C-3-alkyl, di- (C 1 -C 4 alkyl) -amino-C 1 -C 3 alkyl, C 1 -4 -carbonylamino alkyl, C 1 -C 4 alkylcarbonylamino-C 1 -C 3 alkyl, aminocarbonyl, C 1 -C 3 alkylaminocarbonyl, alkyl-C4-aminocarbonyl, cyano, aminosulfonyl, alkyl-C4-4-aminosulfonyl, di- (alkyl-C4-4) -aminosulfonyl, alkyl-C3-3-thio, alkyl-C3-sulfinyl or alkyl-C? _3-sulfonyl, the substituents being the same or different, or also, when Y1 represents the carbon atom, the hydroxycarbonyl group, aminomethyl, alkyl-C? _4-aminomethyl or di- (C-alkyl? -4) -aminomethyl, R 5 a hydrogen atom or a hydroxy group, a C 1 -C 1 alkyl radical, an unbranched alkyl radical, in the α-position, may be substituted with a phenyl, pyridinyl, diazinyl, amino, alkyl group C 4 -amino, di- (C 1 -C 4 alkyl) -amino, 4-alkyl-C 4,4-piperazinyl or 4-morpholinyl, a C 6 -C 6 alkoxy, cyano or aminocarbonyl group or else, when Y1 represents a nitrogen atom, a pair of free electrons, or, when Y1 represents the atom or carbon, also the fluorine atom, or R4 together with R5 and Y1 a cycloaliphatic ring of 4 to 7 members, in which a methylene group can be replaced by a group -NH-, -N (C-alkyl? _) -, -N (C3-4 alkenyl) -, -N (C3_4 alkynyl) -, -N (cyclo-C3-7 alkyl) -, -N (C3-cycloalkyl-C-alkyl? 3) -, -N (hydroxycarbonyl-C 1 -C 3) - or -N (C 1 -C 6 alkoxycarbonyl C 1 -C 3 alkyl) -, a hydrogen atom being able to be attached to a nitrogen atom in one of the previously mentioned groups for R 4 be replaced by a protective radical, R 6 and R 7, which may be the same or different, in each case a hydrogen atom, a C 1 -4 alkyl group or also, when Y 1 represents a carbon atom, the fluorine atom, an amino group, C 1 -4 -alkylamino or di- (C 1 -C 4 alkyl) -amino, the two C 1 -C 4 -alkyl groups can be joined together with formation of a ring and R 8 and R9, which may be the same or. different, in each case a hydrogen atom or an alkyl-C? _3 group, where, if not otherwise mentioned, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above may be straight chain or branched, each methino group contained in the radicals mentioned above may be substituted with a fluorine atom, each methylene group may be substituted with up to 2 fluorine atoms and each methyl group may be substituted with up to 3 fluorine atoms, as well as two Alkyl and alkenyl groups attached to a nitrogen atom can be bonded to each other, under the formation of a saturated or unsaturated 4- to 7-membered heterocyclic ring, all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above can be mono- , di- or tri-substituted additionally with halogen, with cyano or hydroxy groups, and the substituents may be the same or different and by the protective radicals mentioned in the foregoing definitions and which follow below are to be understood as the usual protecting groups of peptide chemistry, in particular a phenylalkoxycarbonyl group with 1 to 3 carbon atoms in the alkoxy part, optionally substituted in the phenyl nucleus with a halogen atom, with a nitro or phenyl group, with one or two methoxy groups, for example the group benzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-methoxy-benzyloxycarbonyl, 2-chloro-benzyloxycarbonyl, 3-chloro-benzyloxycarbonyl, 4-chloro-benzyloxycarbonyl, 4-biphenylyl-a, -dimethyl-benzyloxycarbonyl or 3, 5- dimethoxy-α, α-dimethyl-benzyloxycarbonyl, an alkoxycarbonyl group with in total 1 to 5 carbon atoms in the alkyl part, for example the methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, 1-methylpropoxycarbonyl group, 2-methylpropoxycarbonyl or tert-butyloxycarbonyl, the allyloxycarbonyl group, 2,2,2-trichloro- (1,1-dimethylethoxy) -carbonyl or 9-fluorenylmethoxycarbonyl or the formyl, acetyl or trifluoroacetyl group, their tautomers, their isomers, their diastereomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, especially their physiologically compatible salts with inorganic or organic acids or bases. 2. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, D, E, G, M, Q and R1 are defined as in claim 1 and R2 denotes the hydrogen atom, a phenylmethyl group or a C2- alkyl group, which in position? may be substituted with a cyclo-C3_7 alkyl, C3_7 cyclo-alkenyl, phenyl, pyridinyl, diazinyl, hydroxy, amino, alkyl-C6-amino, di- (C6-6 alkyl) amino, alkenyl group -C3_6-amino, -di- (C3-6 alkenyl) amino, C3-6-amino alkynyl, di- (C3-6 alkynyl) amino, hydroxycarbonyl, C6-alkoxy -6-carbonyl, aminocarbonyl, aminocarbonylamino , alkyl-C6-carbonylamino, alkenyl-C2_6-carbonylamino, alkynyl-C2_6-carbonylamino, 4-morpholinyl, [bis- (2-hydroxy-ethyl)] amino, 4- (alkyl-C? _6) -1 -piperazinyl or 4- (? -hydroxy-C2_7-alkyl) -1-piperazinyl, a phenyl or pyridinyl group, the groups being able. phenyl, pyridinyl and diazinyl mentioned in the groups defined above for R2 or contained as substituents are mono-, di- or trisubstituted further in the carbon framework with halogen, with C3-alkyl, C2-3 alkenyl, C2- alkynyl groups 3, C 1 -C 3 alkoxy, hydroxy, amino, C 1 -C 3 -amino, di- (C 3 alkyl) amino, C 1 -C 3 amino, C 1 -C 3 alkylamino C 1 -C 3 alkyl, di- (C 1 -C 3 alkyl) -amino-C 1 -C 3 alkyl, C 1 -C 3 alkyl carbonylamino, C 1 -C 3 alkyl carbonylamino C 1 -C 3 alkyl , aminocarbonyl, C 1 -C 3 alkylaminocarbonyl, di- (C 1 -C 3 alkyl) -aminocarbonyl, cyano, aminosulfonyl, C 1 -C 3 alkylsulfonyl, di- (C 1 -C 3 alkyl) -aminosulfonyl, alkyl- C 3 -thio, alkyl-C 3 -sulfinyl or C 1 -C 3 alkylsulfonyl, and the substituents being the same or different, R 3 the hydrogen atom or a C 1 -C 3 alkyl group substituted with a phenyl or pyridinyl group, the C-3 alkyl group being able to be linked with an alkyl group contained in R2 or with a phenyl or pyridyl ring contained in R2, under the inclusion of the nitrogen atom to which R2 and R3 are attached, under the formation of a ring of 4-7 members, or R2 and R3, together with the included nitrogen atom, a radical of the general formula where Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the numbers 0, 1 or 2, oqyr, when Y1 represents the nitrogen atom, the numbers 1 or 2, R4 the hydrogen atom, an amino group, alkyl-C? -4-amino, di- (alkyl-C? _) -amino, alkyl-C? _6, a group C3-7-cycloalkyl, C3_7-cycloalkenyl, C2_7-aminoalkyl, C4-4alkylamino-C2_alkyl, di- (C4-4alkylamino) -alkyl-C2- alkyl 7, aminoiminomethyl, amino-carbonylamino, alkyl-C? -4-aminocarbonylamino, di- (alkyl-C? 4) -aminocarbonylamino, alkyl-C? -4-aminocarbonyl-alkyl-C? -4-amino, di- ( alkyl-C? _) -aminocarbonyl-alkyl-C? -4-amine, f-aminocarbonylamino, aminocarbonyl, alkyl-C? 4-aminocarbonyl, di- (alkyl-C? 4) -aminocarbonyl, aminocarbonyl-C-alkyl ? _3, alkyl-C? -4-aminocarbonyl-C? -3 alkyl, di- (C? _4 alkyl) -aminocarbonyl-C? -3 alkyl, aminocarbonylamino-C-alkyl? _3, C6-6-alkoxycarbonyl, C3-6-carbonyl alkenoxy, C3-6alkyloxycarbonyl, C6-alkoxy -6-carbonyl-C3-alkyl, C6-alkenoxy -6-carbonyl- C 1 -C 3 -alkinoxy-C 6 -carbonyl-C 1 -C 3 -alkyl or hydroxy-carbonyl-C 1 -C 3 -alkyl, a phenyl, pyridinyl, diazinyl, 1-naphthyl, 2-naphthyl, pyridylcarbonyl group or phenylcarbonyl, which in each case may be mono-, di- or tri-substituted additionally in the carbon framework with halogen, with C alquilo _3 alkyl, C2_3 alkenyl, C2-3 alqu alkynyl groupsalkoxy-C? -, hydroxy, amino, alkyl-C? _4-amino, di- (alkyl-C? _4) -amino, amino-alkyl-C? _3, alkyl-C? _4-amino-alkyl-C ? 3, di- (C 1 -C 4 alkyl) -amino-C 1 -C 3 alkyl / C 1 -4 alkylcarbonyl amino, C 1 -4 alkylcarbonylamino-C 1 -C 3 alkyl, aminocarbonyl, C 1 -C 4 alkyl aminocarbonyl, di- (C 1 -4 alkyl) -aminocarbonyl, cyano, aminosulfonyl, C 1 -4 aminosulfonyl alkyl, di- (C 1 -4 alkyl) -aminosulfonyl, C 1 -4 alkylthio, C-alkyl; 4-sulfinyl or C 1 -4 alkylsulfonyl, and the substituents being the same or different, a heterocycle selected from an azacycloalkyl group of 4 to 10 members, an oxaza-, thiaza- and diaza-cycloalkyl group of 6 to 10 members, as well as an azabicycloalkyl group of 6 to 10 members, a 1-alkyl-4-piperidinicarbonyl or 4-alkyl-1-piperazinylcarbonyl group, the monocyclic and bicyclic heterocycles mentioned above being linked through a nitrogen or carbon, to Y1 in the formula (II), in the monocyclic and bicyclic heterocycles In the abovementioned a methine group not directly bonded to a nitrogen, oxygen or sulfur atom can be substituted with a fluorine atom, as well as a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom can be substituted with one or two fluorine atoms, the aforementioned monocyclic and bicyclic heterocycles, as well as the groups 1- (alkyl-C6-6) -4-piperidinylcarbonyl and 4- (alkyl-C6) -1-piperazinylcarbonyl may be substituted on the ring, a to four times, with C 1 -C 6 alkyl groups, or, optionally additionally, once with a C 3 cycloalkyl group, C 3 cycloalkenyl group, C 3-7 cycloalkyl C 3 alkyl group, phenyl-C 1 -C 3 -alkyl, pyridyl-C 1 -C 3 -alkyl, C 1 -g -carbonyl, hydroxy, C 6 -alkoxy, amino, alkyl-C 4 -amino, di- (alkyl) ~ C? _4) amino, phenylcarbonyl, pyridinylcarbonyl, hydroxycarbonyl, hydroxycarbonyl-C? -3 alkyl, C? _6-carbonyl alkoxy, C? _6-carbonyl-C? _3 alkyl alkoxy, amino arbonyl, alkyl-C? _-aminocarbonyl, di- (alkyl-C? _4) aminocarbonyl or alkyl-C? -3-sulfonyl, with a cyclo-C3-7-carbonyl group, azacyclo-alkylC-7- carbonyl, diazacycloalkyl-Cs-7-carbonyl or oxazacycloalkyl-C5_7-carbonyl optionally substituted on the ring with C? _3 alkyl, the substituents being the same or different and being able to be attached to a ring carbon atom or a Nitrogen atom of the ring, the phenyl and pyridinyl radicals contained in the radicals defined above for R 4 being mono-, di- or tri-substituted, for their part, with halogen atoms, with C 1 -C 3 alkyl, alkenyl- C2_3, C2_3 alkynyl, C3_3 alkoxy, hydroxy, amino, C ?_4_alkylamino, di- (C -_4_4_alkylamino), amino_alkyl_C_3_, alkyl- C 4-amino-C 1 -C 3 -alkyl, di- (C 1 -C 4 alkyl) -amino-C 1 -C 3 alkyl, C 1 -C 4 alkylcarbonylamino, C 1 -C 4 alkylcarbonylamino C-alkyl ? _3, aminocarbonyl, alkyl-C? -3-aminocarbonyl, di-alkyl-C? _4-aminocarbonyl, cyano, amines ulphonyl, C 1 -4-aminosulfonyl-alkyl, di- (C 1 -4-alkylsulfonyl) alkyl, C 1 -C 3 -thio, C 1 -C 3 -sulfinyl alkyl or C 1 -C 3 -sulfonyl alkyl, the substituents being the same or different, or also, when Y1 represents the carbon atom, the hydroxycarbonyl, aminomethyl, alkyl-C? -4-aminomethyl or di- (alkyl-C? _) -aminomethyl group, R5 an atom of hydrogen, an alkylene-C? -4 radical, wherein an unbranched alkyl radical may be substituted, in the α-position, with a phenyl, pyridinyl, diazinyl, amino, alkyl-C?-amino, di- (alkyl-C) group ? 4) -amino, 4-alkyl-C? _4-l-piperazinyl or 4-morpholinyl, a C6-6-carbonyl alkoxy, cyano or aminocarbonyl group or else, when Y1 represents a nitrogen atom, an electron pair free, or, when Y1 represents the carbon atom, also the fluorine atom, or R4, together with R5 and Y1 a cycloaliphatic ring of 4 to 7 members, in which a methylene group may be replaced by an -NH- group , -N (alkyl-C? _4) -, -N (C3-4 alkenyl) -, -N (C3-4 alkynyl) -, -N (cyclo-C3_7 alkyl) - or -N (C3-7 cycloalkyl-C3_3 alkyl) -, a hydrogen atom bound to a nitrogen atom in one of the groups mentioned above for R4 can be replaced by a protective radical, R6 and R7, which can be the same or different, in each case a hydrogen atom, an alkyl group -C? -4 or also, when Y1 represents a carbon atom, the fluorine atom, an alkyl-C? _4-amino group or di- (alkyl-C? -4) -amino, which may be linked together two C alquilo-alkyl groups with one ring formation and R 8 and R 9, which may be the same or different, in each case a hydrogen atom or a C alquilo-3 alkyl group, where, if not mentioned otherwise In the same way, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above can be straight-chain or branched, each methino group contained in the radicals mentioned above can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be linked together under the formation of a 4 to 7 membered heterocyclic ring, saturated or unsaturated, all Aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above may be mono-, di- or trisubstituted further with halogen, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 3. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, D, E, G, M, Q, R2 and R3 are defined as mentioned in claim 1 or 2 and R1 means a 5- to 7-membered heterocyclic aza, diaza, triaza or thiaza, unsaturated once or twice, wherein the aforementioned heterocycles are linked through a carbon or nitrogen atom, or are linked in a spirocyclic manner through of a carbon atom and a nitrogen atom, through a carbon atom and an oxygen atom or through a carbon atom and a sulfur atom, contain one or two carbonyl groups. contiguous to a nitrogen atom, they may be substituted on a carbon atom with a phenyl, pyridinyl, diazinyl, thienyl, pyrrolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl or 1- (C 4 alkyl) -pyrazolyl group , and wherein an olefinic double bond of one of the above-mentioned unsaturated heterocycles can be fused with a ring of phenyl, naphthyl, pyridine, diazine, thienyl or quinoline, or with a ring of lH-quinolin-2-one optionally substituted in the nitrogen atom with a methyl group, wherein the phenyl, pyridinyl, diazinyl, thienyl, pyrrolyl, 1,3-thiazolyl, isoxazolyl, pyrazolyl or 1- (alkyl-C? _) -pyrazolyl groups contained in R1, as well as the heterocycles condensed with benzo, pyrido and diazino can be mono-, di- or tri-substituted in the carbon framework, additionally with halogen, with alkyl groups -Ca_6, cyclo-C3_7alkyl, cycloalkenyl-C3-, C6-alkoxy, hydroxycarbonyl, C6-6-carbonyl alkoxy, cyano, hydroxy, amino, alkyl-C? _-amino, di-alkyl-C? -amino, alkyl-C? -4-carbonylamino or alkyl-C? -4-carbonyl, wherein the substituents may be the same or different, wherein, if not mentioned otherwise, all the radicals mentioned above under R.sub.1 or the alkyl, alkenyl and alkynyl groups contained in R.sub.1 can be straight-chain or branched each methino group contained in the radicals mentioned above. can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be joined together under the formation of a saturated or unsaturated 4- to 7-membered heterocyclic ring, and all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above low R1 may be mono-, di- or tri-substituted additionally with halogen, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 4. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, D, E, G, M, Q, R2 and R3 are defined as mentioned in claim 1 or 2 and R1 means a 5- or 7-membered unsaturated diaza or triaza heterocycle, wherein the abovementioned heterocycles are linked through a nitrogen atom, or are linked in a spirocyclic manner through a carbon atom and a hydrogen atom. nitrogen or through a carbon atom and an oxygen atom, they contain a carbonyl group contiguous to a nitrogen atom, they can be further substituted at a carbon atom through a phenyl group, and wherein an olefinic double bond of one of the unsaturated heterocycles, mentioned above, can be fused with a phenyl, thienyl or quinoline ring, wherein the phenyl groups contained in R 1, as well as the heterocycles condensed with benzo can be mono-, di- or t re-substituted in the carbon framework additionally with halogen, with methyl, methoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, alkyl-C? _4-amino, di- (alkyl-C? _4) -amino groups, acetylamino, acetyl, hydroxycarbonyl, C ?3-carbonyl alkoxy, cyano, difluoromethoxy or trifluoromethoxy, wherein the substituents may be the same or different, but preferably are unsubstituted or are monosubstituted with a halogen atom, with a methyl or methoxy group, wherein, if not mentioned otherwise, all the alkyl groups mentioned or contained in the radicals defined above under R 1 may be straight chain or branched, each methino group contained in the radicals defined above may be substituted with one fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, their tautomers, their isomers, their diastereomers, their antimers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 5. CGRP antagonists of the general formula I according to claim 1, wherein A, X, D, E, G, M, Q, R2 and R3 are defined as mentioned in claim 1 or 2 and R1 means a 1,3,4,5-tetrahydro-1,3-benzodiazepin-2-on-3-yl, 3,4-dihydro-lE-quinazolin-2-on-3-yl, 5-phenyl-2 group 4-dihydro-1,2,4-triazol-3-on-2-yl, 1,3-dihydro-imidazo [4, 5-c] quinolin-2-on-3-yl, 1,3-dihydro- naft [1, 2-d] imidazol-2-on-3-yl, 1,3-dihydro-benzimidazol-2-on-3-yl, 4-phenyl-1,3-dihydro-imidazole-2-on- 1-yl, 3, 4-dihydro-lH-thieno [3, 2-] pyrimidin-2-on-3-yl or 3,4-dihydro-lli-thieno [3,4-d] pyrimidin-2-on -3-ilo, wherein the heterocycles mentioned above under R1 may be monosubstituted in the carbon framework additionally with a methoxy group, all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined under R1 may be mono-, di- or tri-substituted additionally with halogen atoms, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 6. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, R1, R2 and R3 are defined as mentioned in one of claims 1 to 5 and mean (a) D, E , independently of one another, a methino group or the nitrogen atom and G a methino group substituted with the group Ra, M a methino group substituted with the group Rb, Q a methino group substituted with the group Rc, may mean one or two of the groups G, M and Q in each case also a nitrogen atom, or (b) D and E, in each case, a methine group, one of the groups D and E also being able to mean a nitrogen atom, and G , M and Q in each case a nitrogen atom, wherein Ra, Rb and Rc, independently of each other, represents in each case a hydrogen or halogen atom, an alkyl-C? -4, alkenyl-C2_4, alkynyl group -C2-4, cyclo-C3-6alkyl, cyclo-C3-6alkenyl, cyano, hydroxy ', hydroxy-C4-4alkyl, hydroxy-C4-alkenyl, hydroxy-C3-4alkynyl, alkoxy -C? _4, C 1-4 alkoxy-C 1-4 -alkyl, C 1-4 -alkenyl-C 3-4 alkoxy, C 1-4 -alkynyl-C 3-4 alkynyl, thiohydroxy, C 1-4 -thio alkyl, amino, C 1 -4-amino alkyl, C 3-4 alkenyl, C 3-4 alkynyl, di- (C 1 -4 alkyl) -amino, di- (C 3-4 alkenyl) -amino, di- ( C 3-4 alkynyl) -amino, amino-C 1 -alkyl, C 1 -C 3 -alkylamino-C 1 -4 alkyl, di- (C 1 -C 3 alkyl) -amino-C-alkyl; _4, C3_ amino-alkenyl, C3_3-amino-alkenyl-C3_4 alkyl, di- (C3_3 alkyl) -amino-C3_ alkenyl, C3-4 amino-alkynyl, C-alkyl? 3-amino-alkynyl-C3_4, di- (C3_3 alkyl) -amino-C3_4 alkynyl, hydroxycarbonyl, phenylcarbonyl, pyridylcarbonyl, C 1_ -carbonyl alkyl, formyl, C 4 -4 alkoxy carbonyl, C3-4 alkenoxycarbonyl, C3-4 alkyloxycarbonyl, aminocarbonyl, C3-4alkylaminocarbonyl, C3-4alkenyl-aminocarbonyl, C3-4 alkynylaminocarbonyl, di- (C-alkyl) -aminocarbonyl, di- (C 3-4 alkenyl) -aminocarbonyl, di- (C 3-4 alkynyl) -aminocarbonyl, formylamino, alkyl-C? 4-carbonylamino, f ormyl-alkyl-C? _4-amino, mil-alkenyl-C3_4-amino, f ormyl-C3-4 alkylamino, C3-4alkynyl-carbonyl-C3-4alkylamino, C4-4alkylalkyl-C3-4alkenyl ~ amino, alky1-C4-carbonyl-alkynyl-C3_4-amino, alkyl-C2-4-sulfonyl, alkenyl-C2_-sulfonyl, alkynyl-C2-4-sulfonyl, alkyl-C4-sulfinyl, alkenyl-C2 -4-sulfinyl, alkynyl-C2_-sulfinyl, alkyl-C? _4-sulphonylamino, alkyl-C? _4-sulfonyl-alkyl-C? -4-amino, alkyl-C? -4-sulfonyl-alkenyl-C3 4-amino, C 1-4 alkylsulfonyl-C 3-4 alkylamino, aminosulfonyl, alkyl C 4 aminosulfonyl, di- (C 1 -4 alkyl) -aminosulfonyl, C 3 -4 alkenyl-aminosulfonyl, di - (C3_4 alkenyl) -aminosulfonyl, C3_4-aminosulfonyl alkynyl or di- (C3-4 alkynyl) -aminosulfonyl, with the provisos that, insofar as none of the groups D, E, G, M and Q represents a nitrogen atom, (i) Ra does not mean a hydrogen atom, when Rb, as well as Rc represent in each case a C-4 alkyl group, (ii) Rc does not mean a hydrogen atom, when Ra , as well as R b represent in each case an alkyl-C? -4 group, (iii) Ra does not take the meanings of a hydrogen, fluorine, chlorine, bromine or iodine atom or of a difluoro or trifluoromethyl group, when Rc represents an alkyl- C? _4, C2_4 alkenyl or C2-4 alkynyl and Rb represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, (iv) Rc does not have the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoro or trifluoromethyl group, when Ra represents a C alquilo -4 alquilo alquilo, alkyl, C2 ~ 4 al alkenyl or C2-4 alqu alkynyl group and R represents a chlorine or bromine atom, an amino, methylamino or hydroxy, wherein, if not mentioned otherwise, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above for Ra, Rb and Rc can be straight-chain or branched, each methino group contained in the radicals previously mentioned may be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be linked together under the formation of a ring 4 to 7 membered heterocyclic, saturated or unsaturated, the double and triple bonds of the alkenyl-C3_4 or alkynyl-C3 groups contained in the groups defined above for Ra, Rb and Rc are isolated from heteroatoms optionally also contained in these groups, and all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above can be mono-, di- or tri-substituted additionally with halogen, with cyano or hydroxy groups, and the substituents can be the same or different, their tautomers, their isomers , its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular ular its physiologically compatible salts with inorganic or organic acids or bases. 7. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, R1, R2 and R3 are defined as mentioned in one of claims 1 to 5 and mean (a) D, E , independently of one another, a methino group or the nitrogen atom and G a methino group substituted with the group Ra, M a methino group substituted with the group Rb, Q a methino group substituted with the group Rc, may mean one or two of the groups G, M and Q in each case can also mean a nitrogen atom, or (b) D and E, in each case, a methino group, one of the groups D and E also being able to mean a nitrogen atom, and G, M and Q signify in each case a nitrogen atom, in which Ra, Rb and Rc, independently of one another, each represent a hydrogen or halogen atom, a C? -4 alkyl, alkenyl- C2_4, C2_ alkynyl, C3_6 cycloalkyl, C3-6 cycloalkenyl, cyano, hydroxy, hydroxy-C2_2 alkyl / hydroxy-C3 alkenyl, hydroxy-al C3-C3-alkoxy, C4-4alkoxy, C4-4alkyl-C2-4alkyl, amino, C4-4alkylamino, C3-4alkenyl-amino, C3-4alkynyl, (C 1 -C 4 alkyl) -amino, di- (C 3-4 alkenyl) -amino, di- (C 3-4 alkynylamino), amino-C 1 -C 2 -alkyl, C 1 -C 3 -alkylamino-C-alkyl _2, di- (alkyl-C? _3) -amino-C-2-alkyl, C3-amino-alkenyl, C3-C3-amino-alkenyl-C3 alkyl, di- (C3-alkyl) - C3-amino-alkenyl, C3-amino-alkynyl, C3-C3-amino-alkynyl-C3 alkyl, di- (C3-alkyl) -amino-C3-alkynyl, hydroxy-carbonyl, C-C4 alkyl -carbonyl, formyl, C 1 -C-alkoxycarbonyl, aminocarbonyl, C 1 -4-aminocarbonyl alkyl, di- (C 1 -C 4 alkyl) -aminocarbonyl, formylamino, C 1 -C 4 alkylcarbonylamino, formyl-alkyl- C? _-Amino, alkyl-C? _4-carbonyl-alkyl-C? _-Amino, alkyl-C? _-Sulfonyl, alkyl-C? _-Sulfinyl, alkyl-C? _4-sulfonylamino, alkyl-C? 4-sulfonyl-C 4 -alkylamino, aminosulfonyl, C 1 -4-aminosulfonyl-alkyl or di- (C 1 -4) -aminosulfonyl, with the provisos that, insofar as none of the D groups , E, G, M and Q represent a nitrogen atom, (i) Ra does not mean a hydrogen atom, when Rb, as well as Rc represent in each case a C-4 alkyl group, (ii) Rc does not mean a hydrogen atom, when Ra, as well as Rb represent in each case a C-4 alkyl group, (iii) Ra does not assume the meanings of a hydrogen, fluorine, chlorine, bromine or iodine atom or of a difluoro or trifluoromethyl group, when Rc represents a alkyl-C? _4, C2- alkenyl or C2-4 alkynyl group and Rb represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, (iv) Rc does not assume the meanings of a hydrogen atom, fluorine , chlorine, bromine or iodine or a difluoro or trifluoromethyl group, when Ra represents a C 1 -4 alkyl, C 2 alkenyl or C 2 alkynyl group and R b represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, wherein, if not mentioned otherwise, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals prec edentemente mentioned for Ra, Rb and Rc can be straight chain or branched, each methino group contained in the above-mentioned radicals can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be linked together under the formation of a saturated or unsaturated 4- to 7-membered heterocyclic ring, the double and triple bonds of the alkenyl- C3_4 or alkynyl-C3_4 contained in the groups defined above for Ra, Rb and Rc are isolated from heteroatoms optionally also contained in these groups, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 8. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, R1, R2 and R3 are defined as mentioned in one of claims 1 to 5 and signify (a) D, E, independently of one another, a methino group or the nitrogen atom and G a methino group substituted with the group Ra, M a methino group substituted with the group Rb, Q a methino group substituted with the group Rc, which may mean one or two of the groups G, M and Q in each case also a nitrogen atom, or (b) D and E, in each case, a methine group, one of the groups D and E also being able to mean a nitrogen atom, and G, M and Q in each case a nitrogen atom, wherein Ra, Rb and Rc, independently of each other, represent in each case a hydrogen or halogen atom, a C-4-alkyl, C2-alkenyl group 4, C 2-4 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, cyano, hydroxy, hydroxy-C 1 -2 alkyl, C 4 -4 alkoxy, amino, C 1 -C 4 alkyl amino, di- (alkyl-C? _4) -a mino, amino-C 1 -C 2 -alkyl, C 1 -C 3 -amino-C 1 -C 2 alkyl, di- (C 1 -C 3 alkyl) -amino-C 1 -C 2 alkyl, hydroxycarbonyl, C-alkyl _4-carbonyl, formyl, C 1 -4 -alkoxycarbonyl, aminocarbonyl, C 1 -4-aminocarbonyl alkyl, di- (C 1 -C 4 alkyl) -aminocarbonyl, formylamino, C 1 -4 -carbonylamino alkyl, formyl -alkyl-C? _4-amino or alkyl-C? -4-carbonyl-alkyl-C? -4-amino, with the conditions that, insofar as none of the groups D, E, G, M and Q represents a nitrogen atom, (i) Ra does not mean a hydrogen atom, when Rb, as well as Rc represent in each case a C-4 alkyl group, (ii) Rc does not mean a hydrogen atom, when Ra, as well as Rb represent in each case a C-4 alkyl group, (iii) Ra does not assume the meanings of a hydrogen, fluorine, chlorine, bromine or iodine atom or of a difluoro or trifluoromethyl group, when Rc represents a alkyl-C? -4 group, C2_4 alkenyl or C2-4 alkynyl and Rb represents a chlorine or bromine atom, an amino group, methylamino oh idroxy, (iv) Rc does not take the meanings of a hydrogen atom, fluorine, chlorine, bromine or iodine or of a difluoro or trifluoromethyl group, when Ra represents an alkyl-C? -4, alkenyl-C2- or alkynyl- C2_4 and Rb represents a chlorine or bromine atom, an amino, methylamino or hydroxy group, wherein, if not otherwise mentioned, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above for Ra, Rb and R c can be straight chain or branched, each methino group contained in the above-mentioned radicals can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom may be linked together under the formation of a saturated or unsaturated 4- to 7-membered heterocyclic ring, their tautomers, their somers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 9. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, R1, R2 and R3 are defined as mentioned in one of claims 1 to 5 and mean (a) D, E, independently of one another, a group methino or the nitrogen atom and G a methino group substituted with the group Ra, M a methino group substituted with the group Rb, Q a methino group substituted with the group Rc, being able to mean one or two of the groups G, M and Q in each case also a nitrogen atom, or (b) D and E, in each case, a methine group, one of the groups D and E also being able to mean a nitrogen atom, and G, M and Q signify in each case a nitrogen atom, wherein Ra, Rb and Rc, independently of one another, represent a hydrogen or halogen atom, a methyl, difluoromethyl, trifluoromethyl, ethyl, vinyl, ethynyl, cyano, hydroxy, methoxy, difluoromethoxy, trifluoromethoxy, amino, methylamino or dimethylamino, with the conditions that, insofar as none of the groups D, E, G, M and Q represent a nitrogen atom, (i) Ra does not mean a hydrogen atom, when Rb, as well as Rc represent in each case a methyl or ethyl group, (ii) Rc does not mean a hydrogen atom, when Ra, as well as Rb represent in each case a methyl or ethyl group, (iii) Ra does not assume the meanings of a hydrogen, fluorine, chlorine, bromine or iodine atom or of a difluoro- or trifluoromethyl group, when Rc represents a group methyl, ethyl, vinyl or ethynyl and Rb represents a chlorine bromine atom, an amino, methylamino or hydroxy group, (iv) Rc does not have the meanings of a hydrogen, fluorine, chlorine, bromine or iodine atom or a difluoro group - or trifluoro-methyl, when Ra represents a methyl, ethyl, vinyl or ethynyl group and Rb represents a chlorine or bromine atom, an amino, methylamino or .hydroxy group, their tautomers, their isomers, their diastereomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in part Its salts are physiologically compatible with inorganic or organic acids or bases. 10. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, D, E, G, M, Q and R1 are defined as mentioned in one of claims 1 to 9 and R2 represents the hydrogen atom, or a phenylmethyl group or a C2_7 alkyl group, which in position? may be substituted with a C3_7-alkyl-cyclo-C3-7-cycloalkyl group, phenyl, pyridinyl, hydroxy, amino, alkyl-C6-amino, di- (alkyl-C6-6) -amino, hydroxycarbonyl alkoxy-C6-carbonyl, aminocarbonyl, aminocarbonylamino, alkyl-C6-amino, 4-morpholinyl, wherein the phenyl and pyridinyl radicals mentioned in the groups defined above for R2 or contained as substituents may be mono-, di- or tri-substituted additionally in the carbon framework with halogen, with C 1 -C 3 alkyl, C 1 -C 3 alkoxy, hydroxy, amine, C 1 -C 3 alkylamino, di- (C-alkyl) ? -3) -amino, amino-alkyl-C? -3, alkyl-C? _3-amino-alkyl-C? -3, di- (alkyl-C? -3) -amino-alkyl-C? _3, alkyl-C? -3-carbonylamino, alkyl-C? -3-carbonyl-alkyl-C? _3-amino, aminocarbonyl, alkyl-C? -3-aminocarbonyl or di- (alkyl-C? -3) -aminocarbonyl, and the substituents may be the same or different, R3 represents the hydrogen atom or an alkyl group -C3_3 or R2 and R3, together with the nitrogen atom incl. uido, a radical of the general formula where Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the 'numbers 0 or 1, oqyr, when Y1 represents the Nitrogen atom, the numbers 1 or 2, R4 the hydrogen atom, an amino group, C C-amino alkyl, di- (C C4 alkyl) -amino, C alqu alkylated, a C3_7 cycloalkyl group or C3_7 cycloalkyl optionally substituted by a hydroxycarbonyl group, C6_6-carbonyl alkoxy, hydroxycarbonylC1_3alkyl or C6_6alkylcarbonyl-C3_3alkyl, an amino-C2_7alkyl group, C4_4alkyl- amino-alkyl C2_, di- (C 1 _4-amino alkyl) -C 2_7 alkyl, C 1 _ 4-aminocarbonyl alkyl, di- (C 1 _) alkyl-aminocarbonyl, aminocarbonyl-C 1 _ 3 alkyl, C 1 _-aminocarbonyl alkyl C alkyl? _3, di- (C C_4 alkyl) -aminocarbonyl-C ?3 alkyl, aminocarbonylamino-C ?3 alkyl, C?-6-carbonyl alkoxy, C?-6-carbonyl-C ?_3 alkyl or hydroxycarbonyl-C-alkyl ? 3, a phenyl, pyridinyl or diazinyl group, which in each case may be substituted with a halogen, with a C 1 _ 3 alkyl, C 1 _ 3 alkoxy, hydroxy, amino, C 4 amino, di- (C 1 -C 4 alkyl) -amino, amind-C 1 -C 3 alkyl, C 1 -C 4 alkyl-amino-C 1 -C 3 alkyl, di- (C 1 -C 4 alkyl) -amino-C-alkyl -3, a heterocycle chosen from an azacycloalkyl group of 4 to 7 members, an oxaza group, S, S-dioxotiaza and diazacycloalkyl of 6 to 7 members, and an azabicycloalkyl group of 7 to 9 members, the monocyclic heterocycles being bound and bicyclics mentioned above, through a nitrogen or carbon atom, to Y1 in the formula (II), in the previously mentioned monocyclic and bicyclic ocs a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom can be substituted with one or two fluorine atoms and the aforementioned monocyclic and bicyclic heterocycles can be substituted once or twice with groups hydroxy, alkyl. C? _3 or hydroxy-C? _3 alkyl, or once with a benzyl group, cyclo-C3_6 alkyl, hydroxycyclo-C3_6 alkyl, cyclo-C3_6 alkyl-C? _3 alkyl, C-4 alkylcarbonyl, C? _4 alkyl -carbonyl-C C -3alkyl, hydroxy, C? _4alkoxy, amino, C C4-aminoalkylamino, di- (C? -4) alkyl-amino, C?-3-carbonyl alkoxy, hydroxycarbonyl-carbonyl, alkoxy C3-carbonylcarbonyl, hydroxycarbonyl-C3-3alkyl, C3-3alkylcarbonyl-C3-3alkyl, hydroxycarbonyl-C3-3alkylcarbonyl, C3-3alkoxycarbonyl-C3alkyl3 -carbonyl, aminosulfonyl, C 1 4-aminosulfonyl alkyl, di- (C 4 -4 alkyl) -aminosulfonyl, C 1 -C 3 alkylsulfonyl, cyclo-C 3-7 alkylsulfonyl, aminocarbonyl C 1 -C 3 alkyl, C 4 alkyl -aminocarbonyl-C-3 alkyl, di- (C 1 -4 alkyl) -aminocarbonyl-C 1 -C 3 alkyl, hydroxy-aminocarbonyl-C 1 -C 3 -alkyl, C 1 -C 3 -alkoxycarbonyl-C 1 -C 3 -alkyl or hydroxy- (C-alkyl? _3) -aminocarbonyl-C_3 alkyl, or else, when Y1 represents the carbon atom, the hydroxycarbonyl, aminomethyl, alkyl-C? _4-aminomethyl group or di- ( alkyl-C? _4) -aminomethyl, R5 a hydrogen atom, a C-alkyl radical -3 or, when Y1 represents a nitrogen atom, also a pair of free electrons, R6 and R7, which may be the same or different , in each case a hydrogen atom, a C 1 -C 3 alkyl group or also, when Y 1 represents a carbon atom, an amino group, C 1 -C 3 -amino or di- (C 1 -C 3 alkyl) -amino, the two C-3-alkyl groups being able to be linked together with the formation of a ring, and R 8 and R 9, which may be the same or different, represent in each case a hydrogen atom or a C-alkyl group? 3, wherein, if not mentioned otherwise, all the alkyl, alkenyl and alkynyl groups mentioned or contained in the radicals mentioned above can be straight chain or branched, each methino group contained in the radicals mentioned above can be substituted With one fluorine atom, each, methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be linked together under the formation of a saturated or unsaturated, 4- to 7-membered heterocyclic ring, all Aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above may be mono-, di- or tri-substituted additionally with halogen, with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereomers , its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. 11. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, D, E, G, M, Q and R1 are defined as mentioned in one of claims 1 to 9 and R2 represents the hydrogen atom, or a phenylmethyl group or a C2_7 alkyl group , what in position? may be substituted with a C3_7-alkyl-cycloalkenyl-C3_, phenyl, pyridinyl, hydroxy, amino, alkyl-C? -6-amino, di- (alkyl-C6) -amino, hydroxycarbonyl, alkoxy-C group ? 6-earbonyl, aminocarbonyl, aminocarbonylamino, alkyl-C? -6-amino, 4-morpholinyl, wherein the phenyl and pyridinyl radicals mentioned in the groups defined above for R2 or contained as substituents may be mono-, di- or tri? additionally substituted in the carbon framework with halogen, with C 1 -C 3 -alkyl, C 3 -alkoxy, hydroxy, amino, C 1 -3-amino alkyl, di- (C 1 -C 3 alkyl) amino, amino-C 1 -C 3 -alkyl, C 3 alkyl-amino-C 1 -3 alkyl, di- (C 1 -C 3 alkyl) -amino-C 1 -C 3 alkyl, C-alkyl ? 3-carbonylamino, alkyl-C? -3-carbonyl-alkyl-C? _3-amino, aminocarbonyl, alkyl-C? _3-aminocarbonyl or di- (alkyl-C? -3) -aminocarbonyl, and the substituents can be equal or different, R3 represents the hydrogen atom or a C -3 alkyl group or R2 and R3, together with the nitrogen atom included or, a radical of the general formula in which Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, the numbers 0 or 1, oqyr, when Y1 represents the atom of nitrogen, the numbers 1 or 2, R4 the hydrogen atom, an amino group, alkyl-C? -4-amino, di- (alkyl-C? -) -alkylamino, alkyl-C? -6, cycloalkyl -C3_7, C3-7-cycloalkenyl, amino-C2_7-amino, C4-4alkylamino-C2_7alkyl, di- (C- 4alkylamino) -C2-7alkyl, alkyl- C 4-aminocarbonyl, di- (C 1 -4 alkyl) -aminocarbonyl, aminocarbonyl-C 1 -C 3 -alkyl, C 1 -C 4 -aminocarbonyl-C 1 -C 3 -alkyl, di- (C-alkyl) -4) -aminocarbonyl-C 1 -C 3 alkyl, aminocarbonylamino-C 1 -C 3 alkyl, C 6 -C 6 alkoxycarbonyl, C 1 -C 6 alkoxycarbonyl C 1 -C 3 alkyl or hydroxycarbonyl alkyl -C? -3, a phenyl, pyridinyl or diazinyl group, which in each case can be substituted with a halogen, with a C-3-alkyl, C-3 alkoxy, hydroxy, amino, alkyl-C? 4-amino, di- (alkyl-C? _4) -amino, amino-alkyl-C? -3, alkyl-C? -4-amino-alkyl-C? _3, di- (alkyl-C? _4) - amino-C 1 -C 3 -alkyl, a heterocycle chosen from an azacycloalkyl group of 4 to 7 members, an oxaza- and diaza-cycloalkyl group of 6 to 7 members and an azabicycloalkyl group of 7 to 9 members, the monocyclic heterocycles being bound and bicyclics mentioned above, through a nitrogen or carbon atom, to Y in the formula (II), in the aforementioned monocyclic and bicyclic heterocycles a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom can be substituted with one or two fluorine atoms and the aforementioned monocyclic and bicyclic heterocycles can be substituted once or several times, for example one to three times, with C 1 -C 3 alkyl groups, or once with a benzyl group, cyclo- C3_6alkyl, C3-6cycloalkyl-C1_3alkyl, C4_4alkylcarbonyl, hydroxy, C4_4alkyl, amino, alkyl-C? -4-amino, di- (alkyl-C? 4) -amino, hydroxycarbonyl, alkoxy-C? -3-carbonyl, hydroxycarbonyl-carbonyl, alkoxyC? 3-carbonyl-carbonyl, hydroxycarbonyl-alkyl- C? -3, C3-C3-alkoxycarbonyl-C3-3alkyl or C3-3alkylsulfonyl, or also, when Y1 represents the carbon atom, the hydroxycarbonyl, aminomethyl, alkyl-C4- or 4-aminomethyl group or di- (alkyl-C? _) -aminomethyl, R5 a hydrogen atom, an alkyl-C? _3 radical or, when Y1 represents a nitrogen atom, also a pair of free electrons, R6 and R7, which may be the same or different, in each case a hydrogen atom, a C 1 -C 3 -alkyl group or also, when Y 1 represents a carbon atom, an alkyl-C 3 -amino group or di- (C 1 -C 3 alkyl) amino, the two C 1 -C 3 -alkyl groups being able to be linked together with the formation of a ring, and R 8 and R 9, which may be the same or different, represent in each case a hydrogen atom or a C-3 alkyl group, where, if not mentioned otherwise, to two the alkyl, alkenyl and alkynyl groups mentioned or contained in the aforementioned radicals can be straight chain or branched, each methino group contained in the radicals mentioned above can be substituted with a fluorine atom, each methylene group can be substituted with up to 2 fluorine atoms and each methyl group can be substituted with up to 3 fluorine atoms, as well as two alkyl and alkenyl groups attached to a nitrogen atom can be linked together under the formation of a 4 to 7 membered heterocyclic ring, saturated or unsaturated, all the aromatic and heteroaromatic radicals mentioned or contained in the radicals defined above can be mono-, di- or trisubstituted further with halogen, with cyano or hydroxy groups, and the substituents can be the same or different, their tautomers, their isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts s, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 12. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, D, E, G, M, Q and R1 are defined as mentioned in one of claims 1 to 9 and R2 represents the hydrogen atom, or a phenylmethyl group or a C2_7 alkyl group , what in position? it can be substituted with a phenyl, amino, alkyl-C? -6-amino, di- (alkyl-Ci-β) -amino group, wherein the aforementioned phenyl and phenylmethyl groups can be mono- or di-substituted further in a . aromatic carbon atom with halogen, with C 1 -C 3 -alkyl, C 1 -C 3 -alkyl, C 1 -C 3 -alkyl, C 1 -C 3 -amino-C 1 -C 3 alkyl or di- (alkyl) groups -C? _3) -amino-alkyl-C? _3, and the substituents may be the same or different, R3 represents the hydrogen atom or an alkyl-C? _3 or R2 and R3 group, together with the included nitrogen atom, a radical of the general formula where Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents -the carbon atom, the numbers 0 or 1, oqyr, when Y1 represents the Nitrogen atom, the numbers 1 or 2, R 4 the hydrogen atom, an amino group, C 1 _ 4-amino alkyl, di- (C 1 - alkylamino) alkyl, C 6 alkyl, a C 3 7 cycloalkyl group or C3_7-cycloalkenyl optionally substituted with a hydroxycarbonyl group, C6-C6-alkoxy, hydroxycarbonyl-C3-3alkyl or C6-6alkyl-carbonyl-C3-3alkyl, an amino-C2-7alkyl group, C-alkyl? _-amino-C2_7alkyl, di- (C4_4alkylamino) -alkyl C2-, C6_6alkoxycarbonyl, C6_6alkoxycarbonyl-C3_3alkyl or hydroxycarbonyl-C3_alkyl , a phenyl or pyridyl group, which in each case may be substituted with a halogen, with a C 1 -C 3 -alkyl, C 1 -C 3 -alkoxy, amino, C 1 4 -amino, di- (C-alkyl) group -4) -amino, a heterocycle chosen from a group 6 to 7 membered azacycloalkyl, a S, S-dioxothiaza and diazacycloalkyl group of 6 to 7 members, and an azabicycloalkyl group of 7 to 9 members, the aforementioned monocyclic and bicyclic heterocycles being linked through a nitrogen atom or of carbon, to Y1 in the formula (II), in the aforementioned monocyclic and bicyclic heterocycles a methylene group not directly bonded with a nitrogen, oxygen or sulfur atom can be substituted with one or two fluorine atoms and the monocyclic heterocycles and The aforementioned bicyclics can be substituted once or twice with a hydroxy group, C 1 -C 3 -alkyl or hydroxy-C 1 -C 3 -alkyl, with a benzyl group, cyclo-C 3-6 alkyl, hydroxy-C 3-6 cycloalkyl, cyclo- alkyl-C3_6-alkyl-C? -3, alkyl-C? -3-carbonyl-alkyl-C? _3, amino, alkyl-C? -4-amino or di- (alkyl-C? -4) -amino, hydrocarbonylcarbonyl, alkoxy-C? _5-carbonylcarbonyl, hydroxycarbonyl-alkyl-C? -3-carbonyl, a l-C 1 -C 3 -carbonyl-C 1 -C 3 -carbonyl, aminosulfonyl, C 1 -4-aminosulfonyl-alkyl, di- (C 1 -C 4 alkyl) -aminosulfonyl, cyclo-C 3-7 alkylsulfonyl, aminocarbonyl -alkyl-C? -3, alkyl-C? -4-aminocarbonyl-alkyl-C? -3, di- (alkyl-C? _4) -aminocarbonyl-alkyl-C? _3, hydroxy-aminocarbonyl-alkyl-C? -3 , C 1 -C 3 alkylaminocarbonyl-C 1 -C 3 alkyl or hydroxy- (C 1 -C 3 alkyl) -aminocarbonyl-C 1 -C 3 alkyl, or else, when Y 1 represents the carbon atom, the hydroxycarbonyl group, aminomethyl , alkyl-C? _4-aminomethyl or di- (alkyl-C-4) -aminomethyl, R5 a hydrogen atom or, when Y1 represents a nitrogen atom, also a pair of free electrons, R6 and R7, which can be same or different, in each case a hydrogen atom, a C 1 -C 3 alkyl group or also, when Y 1 represents a carbon atom, the fluorine atom, an alkyl-C 3 -amino group or di- (alkyl) C? -3) -amino, the two C-3-alkyl groups being able to be linked together with formation of a ring and R8 and R9, which can be the same or different, represent in each case a hydrogen atom or a C-3-alkyl group, its tautomers, its isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 13. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, D, E, G, M, Q and R1 are defined as mentioned in one of claims 1 to 9 and mean R2 a phenylmethyl group or "a C2_7 alkyl group, which in position" can be substituted with a phenyl, amino, alkyl-C? _6-amino, di- (alkyl-Cx-.beta.-amino) group, wherein the groups The aforementioned phenyl and phenylmethyl can be substituted on an aromatic carbon atom with an amino-C-3 alkyl group, C 1 -C 3 -alkylamino-C 1 -C 3 alkyl or di- (C 1 -C 3 alkyl) ) -amino-C 1 -C 3 alkyl, R 3 represents the hydrogen atom or a C 1 -C 3 alkyl group or R 2 and R 3, together with the included nitrogen atom, a radical of the general formula .00 wherein R6 and R7 in each case mean a hydrogen atom or a dimethylamino group, R8 and R9 in each case the hydrogen atom, and (a) Y1 the carbon atom, q and r the numbers 0 or 1, R4 the hydrogen atom, a phenyl, pyridinyl or pyrimidinyl group, which in each case may be substituted with a halogen, with an amino, methylamino, dimethylamino, methyl or methoxy group, a hydroxy, 2-diethylamino-ethyl, amino, methylamino group , dimethylamino, diethylamino, pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2-hydroxycarbonyl-pyrrolidin-1-yl, 2-methoxycarbonyl-pyrrolidin-1-yl, piperidin-1-yl, 4, 4 -dimethylpiperidin-1-yl, 4-amino-4-methyl-piperidin-1-yl, 2-hydroxycarbonyl-piperidin-

1-yl,

2-methoxycarbonyl-pichandidin-1-yl, 4-hydroxymethyl-piperidin-1-yl, 4- (1-hydroxycyclopropyl) -piperidin-1-yl, 4-amino-piperidin-1-yl, 4-methylamino-piperidin- l -yl, 4-dimethylamino-piperidin-1-yl, 4-hydroxy-4-methyl-piperidin-1-yl, 4-hydroxy-4-ethyl-piperidin-1-yl, 4-hydroxy-4-trifluoromethyl-piperidin-1-yl, 4-hydroxy-4-hydroxymethyl-piperidin-1-yl, 3-amino-piperidin-1-yl, 3-methylamino-piperidin-1-yl, 3- dimethylamino-piperidin-1-yl, 3-hydroxy-piperidin-1-yl, 4-hydroxy-piperidin-1-yl, 4-hydroxycarbonylmethyl-piperidin-1-yl, 4-ethoxycarbonylmethyl-piperidin-1-yl, perhydro-azepin-1-yl, perhydro-1,4-diazepin-1-yl, 4-methyl-perhydro-l, 4-diazepin-1-yl, l-methyl-piperidin-4-yl, piperidin-4- ilo, l-ethylpiperidin-4-yl, 1- (2-hydroxyethyl) -piperidin-4-yl, l-cyclopropyl-piperidin-4-yl, 1-cyclopropylmethyl-piperidin-4-yl, l-methylsulfonyl-piperidin- 4-yl, l-ethylsulfonyl-piperidin-4-yl, 1-isopropylsulfonyl-piperidin-4-yl, l-cyclopropylsulfonyl-pipe-ridin-4-yl, 4-hydroxy-l-methylsulfonyl-piperidin-4-yl, 1-aminosulfonyl-piperidin-4-yl, 1- (methylaminosulfonyl) -piperidin-4-yl, 1- (dimethylaminosulfonyl) -piperidin-4-yl, 1-hydroxy-arbonylmethyl-piperidin-4-yl, 1-ethoxycarbonylmethyl- piperidin-4-yl, 1- (2-hydroxycarbonylethyl) -piperidin-4-yl, 1- (2- ethoxycarbonylethyl) -piperidin-4-yl, 1- (3-hydroxycarbonyl-propionyl) -piperidin-4-yl, 1- (3-ethoxycarbonyl-propionyl) -piperidin-4-yl, 1- (hydroxycarbamoyl-methyl) -piperidine -4-yl, 1- (hydroxy-methyl-carbamoyl-methyl) -piperidin-4-yl, 1- (methoxycarbamoyl-ethyl) -piperidin-4-yl, l-oxalyl-piperidin-4-yl, l-ethoxyoxalil -piperidin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 4-cyclopropylmethyl-piperazin-1-yl, 4-ethyl-piperazin-1-yl, 4- (2-hydroxyethyl) -piperazin-1-yl, 4-cyclopropyl-piperazin-1-yl, 4-methylsulfonyl-piperazin-1-yl, 4-aminosulfonyl-piperazin-1-yl, 4- (methylaminosulfonyl) -piperazin-1-yl, 4- (dimethylaminosulfonyl) -piperazin-1-yl, 4-hydroxycarbonylmethyl-piperazin-1-yl, 4-ethoxycarbonylmethyl-piperazin-1-yl, 4- (2-hydroxycarbonylethyl) ) -piperazin-1-yl, 4- (2-ethoxy-arbonyl-ethyl) -piperazin-1-yl, 4- (3-hydroxycarbonyl-propionyl) -piperazin-1-yl, 4- (3-ethoxycarbonyl-propionyl) -piperazin-1-yl, 4- (hydroxycarbamoyl) -methyl-piperazin-1-yl, 4- (hydroxy-methyl-carbamoyl) -methyl-piperazin-1-yl, 4- (methoxycarbamoyl) -methyl-pipérazin-1 -yl, 1,2-dimethyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, 3, 4, 5-trimethyl-piperazin-1-yl, 3, 5-dimethyl-piperazin-1-yl , 3, 3, 4-trimethyl-piperazin-1-yl, 3, 3-dimethyl-piperazin-1-yl, 3, 3,, 5, 5-pentamethyl-piperazin-1-yl, 3.3.5, 5-tetramethyl-piperazin-1-yl, 3, 3, 3-trifluoro-2-oxo-propyl) -piperazin-1-yl, morpholin-4-yl, 1, 1-dioxo-l? -thiomorpholin-4-yl, tetrahydropyran-4-yl, 4,4-difluoro-piperidin-1-yl, 8-methyl-8-aza-bicyclo [3.2.1] oct-3-yl, 8-aza-bicyclo [3.2.1] oct-

3-yl, azetidin-1-yl, 1- (methoxycarbonylmethyl) -piperidin-4-yl, 1- (ethoxycarbonyl-ethyl) -piperidin-4-yl, 4- (ethoxycarbonylmethyl) -piperazin-1-yl, l-hydroxycarbonylmethyl-piperidin-4-yl or 4- hydroxycarbonylmethyl-piperazin-1-yl, and R5 a hydrogen atom, or b) Y1 a nitrogen atom, and r the numbers 1 or 2, R4 the hydrogen atom, a phenyl, pyridinyl or pyrimidinyl group, which in each case may be substituted with a halogen, with an amino, methylamino, dimethylamino, methyl or methoxy group, a methyl, ethyl, isopropyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-hydroxycarbonylmethyl-cyclohexyl group,

4-ethoxycarbonylmethyl-cyclohexyl, cyclopropylmethyl, 2-diethylamino-propyl, l-quinuclidin-3-yl, tetrahydropyran-4-yl, l-piperidin-4-yl, 1-methyl-piperidin-4-yl, l-ethyl- piperidin-4-yl, 1- (2-hydroxyethyl) -piperidin-4-yl, 1-methylsulfonyl-piperidin-4-yl, l-aminosulfonyl-piperidin-4-yl, 1- (methylaminosulfonyl) -piperidin-4- ilo, 1- (dimethylaminosulfonyl) -piperidin-4-yl, l-hydroxycarbonylmethyl-piperidin-4-yl, 1-ethoxycarbonyl-methyl-piperidin-4-yl, 1- (2-hydroxycarbonylethyl) -piperidin-4-yl, 1- (2-ethoxycarbonylethyl) -piperidin-4-yl, 1- (3-hydroxycarbonyl-propionyl) -piperidin-4-yl, 1- (3-ethoxycarbonyl-propionyl) -piperidin-4-yl, 1- ( hydroxycarbamoyl-methyl) -piperidin-4-yl, 1- (hydroxy-methyl-carbamoyl-methyl) -piperidin-4-yl, 1- (methoxycarbamoyl-methyl) -piperidin-4-yl, l-cyclopropyl-piperidin-4 -yl, 1-cyclopropylmethyl-piperidin-4-yl, 1-hydroxycarbonylmethyl-piperidin-4-yl or l-ethoxycarbonylmethyl-piperidin-4-yl and R5 represents a pair of free electrons, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 14. CGRP antagonists of the general formula (I) according to claim 1, wherein A, X, D, E, G, M, Q and R1 are defined as mentioned in one of claims 1 to 9 and R2 denotes a phenylmethyl group or a C2_-alkyl group, which in the? position can be substituted with a phenyl, amino, alkyl-C? _6-amino, di- (alkyl-C-.beta.-amino) group, wherein the The aforementioned phenyl and phenylmethyl groups can be substituted on an aromatic carbon atom with an amino-C 1 -C 3 -alkyl group, C 1 -C 3 -alkylamino-C 1 -C 3 alkyl or di- (C 1 -C 3 alkyl) - amino-C 1 -C 3 -alkyl, R 3 represents the hydrogen atom or a C-3-alkyl group or R 2 and R 3, together with the included nitrogen atom, a radical of the general formula in which R6 and R7 in each case mean a hydrogen atom or a dimethylamino group, R8 and R9 in each case the hydrogen atom, and (a) Y1 the carbon atom, q and r the numbers 0 or. 1, R4 the hydrogen atom, a phenyl, pyridinyl or pyrimidinyl group, which in each case may be substituted with a halogen, with an amino, methylamino, dimethylamino, methyl or methoxy group, a hydroxy group, 2-diethylamino-ethyl, amino, methylamino, dimethylamino, diethylamino, pyrrolidin-1-yl, piperidin-1-yl, 4-amino-piperidin-1-yl, 4-methylamino-piperidin-1-yl, 4-dimethylamino-piperidin-1-yl, 3-amino-piperidin-1-yl, 3-methylamino-piperidin-1-yl, 3-dimethylamino-piperidin-1-yl, perhydro-azepin-1-yl, perhydro-1,4-diazepin-1-yl, 4-methyl-perhydro-1,4-diazepin-1-yl, l-methyl-piperidin-4-yl, piperidin-4-yl, l-ethylpiperidin-4-yl, 1-cyclopropyl-piperidin-4-yl, l-cyclopropylmethyl-piperidin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, 4-cyclopropylmethyl-piperazin-1-yl, 4-ethyl-piperazin-1-yl, 4-cyclopropyl- piperazin-1-yl, 1,2-dimethyl-piperazin-1-yl, 3-methyl-piperazin-1-yl, 3, 4,

5-trimethyl-piperazin-1-yl, 3,5-dimethyl-piperazin- l -yl, 3, 3, 4-trimethyl-piperazin-1-yl, 3, 3-dimethyl-piperazin-1-yl, 3, 3, 4, 5, 5-pentamethyl-piperazin-1-yl, 3, 3, 3, 5, 5-tetramethyl-piperazin-1-yl, morpholin-4- ilo, 4, 4-difluoro-piperidin-l-yl, 8-methyl-8-aza-bici.clo [3.2.1] oct-3-yl, 8-aza-bicyclo [3.2.1] oct-3- ilo, azetidin-1-yl, 1- (methoxycarbonylmethyl) -piperidin-4-yl, 1- (ethoxycarbonylmethyl) -piperidin-4-yl, 4- (ethoxycarbonylmethyl) -piperazin-1-yl, 1-hydroxycarbonylmethyl-piperidin- 4-yl or 4-hydroxycarbonylmethyl-piperazin-1-yl, and R 5 a hydrogen atom, or (b) Y 1 a nitrogen atom, q and y the numbers 1 or 2, R 4 the hydrogen atom, a phenyl group, pyridinyl or pyrimidinyl, which in each case may be substituted with a halogen, with an amino, methylamino, dimethylamino, methyl or methoxy group, a methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, 2-diethylamino-propyl, l-quinuclidin-3 group -yl, l-piperidin-4-yl, l-methyl-piperidin-4-yl, l-ethyl-piperidin-4-yl, 1-cyclopropyl-piperidin-4-yl, 1-cyclopropylmethyl-piperidin-4-yl, l-hydroxycarbonylmethyl-piperidin-4- ilo or 1-ethoxy-carbonylmethyl-piperidin-4-yl and R5 represents a pair of free electrons, their tautomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. 15. CGRP antagonists of the general formula (I) according to claim 1, wherein D, E, G, M, Q, R1, R2 and R3 are defined as mentioned in one of claims 1 to 13 and A and X represent in each case an oxygen atom, its tautomers, its isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with acids or bases inorganic or organic 16. CGRP antagonists of the general formula (I) according to claim 1, wherein A and X represent in each case an oxygen atom, Rx means a 1,3,4,5-tetrahydro-1,3- group benzodiazepin-2-on-3-yl, 3,4-dihydro-li? -quinazolin-2-on-3-yl, 5-phenyl-2,4-dihydro-1,2,4-triazole-3-on -2-yl, 1,3-dihydro-imidazo [4, 5-c] quinolin-2-on-3-yl, 1,3-dihydro-napht [1,2-d] imidazol-2-on-3 -yl, 1,3-dihydro-benzimidazol-2-on-3-yl, 4-phenyl-1,3-dihydro-imidazol-2-on-1-yl, 3,4-dihydro-1-thieno [3] , 2-d] pyrimidin-2-on-3-yl or 3,4-dihydro-lJ-thieno [3,4-ci] pyrimidin-2-on-3-yl, and R2 and R3 are defined as mentioned in claim 1 or 2, wherein the heterocycles mentioned above under R1 may be monosubstituted in the carbon framework additionally with a methoxy group, and wherein all the aromatic and heteroaromatic radicals mentioned or "contained in the radicals previously defined under R1 and the parts of the molecule can n be mono-, di- or tri-substituted additionally with halogen atoms, - with cyano or hydroxy groups, and the substituents may be the same or different, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and its salts, as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 17. CGRP antagonists of the general formula (I) according to claim 1, wherein A and X in each case mean an oxygen atom, R1 is defined as in claim 5, D and E each represent a methino group, G represents a methine group substituted with the group Ra, M represents a methino group substituted with the group Rb, Q represents a methino group substituted with the group Rc and Ra, Rb and Rc, independently of one another, represent a hydrogen or halogen atom, a methyl group, difluoromethyl , trifluoromethyl, ethyl, vinyl, ethynyl, cyano, hydroxy, methoxy, difluoromethoxy, trifluoromethoxy, amino, methylamino or dimethylamino, its tautomers, its isomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 18. CGRP antagonists of the general formula (I) according to claim 1, in which A and X in each case mean an oxygen atom, D and E in each case mean a methino group, G means a methino group substituted with the group Ra, M means a methino group substituted with the group Rb, Q means a methino group substituted with the group Rc, Ra, Rb and Rc, independently of one another, each meaning a hydrogen or halogen atom, a group C 1 -C 3 alkyl, trifluoromethyl, cyano, hydroxy, methoxy, trifluoromethoxy, amino, methylamino or dimethylamino, R 1 means a 5 'to 7-membered heterocycle diaza, unsaturated once, linked to the piperidine ring in the formula (I) through a nitrogen atom, wherein the above-mentioned heterocycle contains a carbonyl group contiguous to a nitrogen atom and the carbonyl group is bonded-preferably with two nitrogen atoms, as well as the olefinic double bond of the heterocycle is condensed with a phenyl or thienyl ring and the phenyl and thienyl rings can be mono-, di- or tri-substituted with halogen atoms, with methyl, methoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, alkyl-C? _3-amino, di- (C 1 -C 3 alkyl) -amino, acetylamino, acetyl, cyano, difluoromethoxy or trifluoromethoxy, wherein the substituents may be the same or different, but preferably is monosubstituted with a halogen atom, with a methyl group or methoxy, and for R 1, there can be mentioned, for example, a 1,3,4,5-tetrahydro-1,3-benzodiazepin-2-on-3-yl group, 3,4-dihydro-l -quinazolin- 2-on-3-yl, 5-phenyl-2,4-dihydro-l, 2,4-triazol-3-on-2-yl, 1,3-dihydro-imidazo [4, 5-c] quinolin- 2-on-3-yl, 1,3-dihydro-napht [1,2-d] imidazol-2-on-3-yl, 1,3-dihydro-benzimidazol-2-on-3-yl, 4- phenyl-l, 3-dihydro-imidazol-2-on-l-yl, 3,4-dihydro-lH-thieno [3,2-d] pyrimidin-2-on-3-yl or 3,4-dihydro- l-thieno [3,4-d] pyrimidin-2-on-3-yl, which in a carbohydrate atom unsaturated of the aromatic or heteroaromatic part is mono-, di- or tri-substituted with halogen atoms, with cyano or hydroxy groups, and the substituents may be the same or different, but preferably not substituted, R2 and R3, together with the included nitrogen atom, a radical of the general formula where Y1 means the carbon atom or, when R5 represents a pair of free electrons, also means the nitrogen atom, qyr, when Y1 represents the carbon atom, mean the numbers 0, 1 or 2, ascending the sum of qyral, 2 or 3, qyr, when Y1 represents the nitrogen atom, means the numbers 1 or 2, ascending the sum of qyra 2 or 3, R4 the hydrogen atom, an amino group, alkyl C? _4-amino, di - (C 4 alkyl) -alkylamino, C 6 alkyl, a C 3 7 cycloalkyl group optionally substituted with a hydroxycarbonyl group, C

6 -alkoxycarbonyl, hydroxycarbonyl-C 1 -C 3 alkyl or C 6 -alkoxy carbonyl-C C_3alkyl, an amino-C2_7alkyl group, C ?_4alkylamino-C2_7alkyl, di- (C ?_4alkylamino) -alkyl C2_7alkyl, C ?_6alkoxycarbonyl, Calkoxyalkoxy; -6-carbonyl-C-3 alkyl or hydroxycarbonyl-C-3 alkyl, a phenyl or pyridyl group, which in each case can be substituted with a halogen atom, with a C-3-alkyl, C-3-alkoxy, amino, C 1 -4-amino or di- (C 1 -4 alkyl) group -amino, a heterocycle selected from an azacycloalkyl group or S, S-dioxothiaza from 5 to 7 members and a diazacycloalkyl group from 6 to 7 members, wherein the aforementioned heterocycles are linked to Y1 in the formula (II) through a nitrogen atom or a carbon atom and with one or two hydroxy groups, C 1 -C 3 -alkyl or hydroxy-C 1 -C 3 -alkyl, with a cyclo-C 3-6 alkyl group, hydroxy-cycloalkyl-C 3 -6, alkyl-C3-6-alkyl-C? _3, alkyl-C? -3-carbonyl-C? -3 alkyl, amino, alkyl-C? -4-amino, di- (alkyl-C) ? 4) -amino, hydroxycarbonylcarbonyl, alkoxy-C? _3-carbonylcarbonyl, hydroxycarbonyl-alkyl-C? _3-carbonyl, alkoxy-C? -carbonyl-alkyl-C? -3-carbonyl, aminosulfonyl, alkyl -C? -4-aminosulfonyl, di- (C 1 -4 alkyl) -aminosulfonyl, cyclo-C 3-7 alkylsulfonyl, aminocarbonyl-C 1 -C 3 alkyl, C 4 alkyl-aminoca rbonyl-C 1 -C 3 -alkyl, di- (C 1 -C 4 alkyl) -aminocarbonyl-C 1 -C 3 -alkyl, hydroxy-aminocarbonyl-C 1 -C 3 -alkyl, C 1 -C 3 -aminocarbonyl-C 1 -C 6 -alkyl 3 or hydroxy- (C 1 -C 3 alkyl) -aminocarbonyl-C 1 -C 3 alkyl, R 5 means a hydrogen atom or, when Y 1 represents a nitrogen atom, it also means a pair of free electrons, and R 6, R 7 , R8 and R9, which may be the same or different, in each case represent a hydrogen atom or a C3 -3 alkyl group, their tautomers, their isomers, their diastereoisomers, their enantiomers, their hydrates, their mixtures and their salts , as well as the hydrates of the salts, in particular their physiologically compatible salts with inorganic or organic acids or bases. 19. CGRP antagonists of the general formula (I) according to claim 1, in which A and X in each case mean an oxygen atom, D and E in each case mean a methino group, G means a methino group substituted with the group Ra, M means a methino group substituted with the group Rb, Q means a methino group substituted with the group Rc, Ra, Rb and Rc, independently of one another, each meaning a hydrogen or halogen atom, a group C 1 -C 3 alkyl, trifluoromethyl, cyano, hydroxy, methoxy, trifluoromethoxy, amino, methylamino or dimethylamino, R 1 means a 5- to

7-membered heterocycle diaza, unsaturated once, linked to the piperidine ring in the formula (I) through a nitrogen atom, wherein the above-mentioned heterocycle contains a carbonyl group contiguous to a nitrogen atom and the carbonyl group is preferably linked with two nitrogen atoms, just as the olefinic double bond of the heterocycle is condensed with a phenyl or thienyl ring and the phenyl and thienyl rings may be mono-, di- or tri-substituted with halogen atoms, with methyl, methoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, alkyl-C? -3-amino, di- (alkyl-C? -3) -amino, acetylamino, acetyl, cyano, difluoromethoxy or trifluoromethoxy, wherein the substituents may be the same or different, but preferably is monosubstituted with a halogen atom, with a methyl or methoxy group, and for R1 there may be mentioned, for example, a 1,3-, 4,5-tetrahydro-1,3-benzodiazepin-2-on-3-yl, 3,4-dihydro-lH-quinazolin group -2-on-3-yl, 5-phenyl-2,4-dihydro-l, 2,4-triazol-3-on-2-yl, 1,3-dihydro-imidazo [4, 5-c] quinolin -2-on-3-yl, 1,3-dihydro-napht [1,2-d] imidazol-2-on-3-yl, 1,3-dihydro-benzimidazol-2-on-3-yl, 4 phenyl-l, 3-dihydro-imidazol-2-on-l-yl, 3,4-dihydro-lH-thieno [3,2-d] pyrimidin-2-on-3-yl or 3,4-dihydro -li? -thieno [3, 4-d] pyrimidin-2-on-3-yl, which in a carbon atom unsaturated of the aromatic or heteroaromatic part is mono-, di- or tri-substituted with halogen atoms, with cyano or hydroxy groups, and the substituents may be the same or different, but preferably not substituted, R2 and R3, together with the Nitrogen atom included, a radical of the general formula in which they mean Y means the carbon atom or, when R5 represents a pair of free electrons, it also means the nitrogen atom, qyr, when Y1 represents the carbon atom, they mean the numbers 0, 1 or 2, ascending the sum of qyral, 2 or 3, qyr, when Y1 represents the nitrogen atom, means the numbers 1 or 2, ascending the sum of qyra 2 or 3, R4 means the hydrogen atom, an amino group, alkyl-C? -4 -amino, di- (alkyl-C? -4) -alkylamino, -alkyl-6alkyl, cyclo-C3_7alkyl, amino-C2-7alkyl, alkyl-C? _4-amino-C2-7alkyl, di- (C 1 -4 -alkylamino) -C 2-7alkyl, C 6 -alkoxycarbonyl, C 6 -alkoxy-6-carbonyl-C?-3alkyl or hydroxycarbonyl-C alquilo-3alkyl , a phenyl or pyridyl group, which in each case may be substituted with a halogen atom, with a C 1 -C 3 -alkyl group, C 1 -C 3 alkoxy, amino, C 1 -4 -alkylamino or di- ( alkyl-C? -) -amino, a heterocycle selected from an azacycloalkyl group of 5 to 7 members and a diazacy group 6 to 7 membered chloralkyl, wherein the above-mentioned heterocycles are linked to Y1 in the formula (II) through a nitrogen atom or a carbon atom and can be substituted with a C-3 alkyl group, C3-6-cycloalkyl, C3_6-cycloalkyl-C3_3alkyl, amino, C4-4alkylamino or di- (C4_4alkylamino) amino, R5 means a hydrogen atom or when Y1 represents a nitrogen atom, it also means a pair of free electrons, and R6, R7, R8 and R9, which may be the same or different, each represent a hydrogen atom or a C? -3 alkyl group, its tautomers, its diastereoisomers, its enantiomers, its hydrates, its mixtures and its salts, as well as the hydrates of the salts, in particular its physiologically compatible salts with inorganic or organic acids or bases. 20. Physiologically compatible salts of the compounds according to at least one of claims 1 to 19 with inorganic or organic acids or bases. 21. Medicament containing a compound according to one of claims 1 to 19 or a physiologically compatible salt according to claim 20, optionally together with one or more support substances and / or inert diluents. 22. Use of a compound according to one of claims 1 or 20 for the preparation of a medicament for the acute and prophylactic treatment of headaches, in particular migraine or cluster headache, for the treatment of non-insulin-dependent diabetes mellitus ( "NIDDM"), complex regional pain syndrome (CRPS1), cardiovascular diseases, tolerance to morphine, hyperemias caused by Clostridium toxin, skin diseases, in particular thermal and radiation-induced skin lesions, including sunburns, inflammatory diseases, p. ex. inflammatory diseases of the joints (arthritis), neurogenic diseases of the oral mucosa, inflammatory diseases of the lungs, allergic rhinitis, asthma, diseases that are accompanied by an excessive widening of the vessels, and reduced irrigation of the tissues, conditioned by it, p. ex. shock and sepsis, to calm states of pain, or for the symptomatology, preventive or therapeutic acute of menopausal hot flashes caused by a widening of the vessels and an increased blood flow of estrogen-deficient women, as well as prostate carcinoma patients treated with hormones. 23. Process for the preparation of a medicament according to claim 21, characterized in that a compound according to one of claims 1 to 20 is incorporated by non-chemical means into one or more support substances and / or inert diluents. 24. Process for the preparation of the compounds of the general formula (I) according to one of claims 1 to 20, characterized in that (a) a piperidine of the general formula -NH ((m) wherein R1 is defined as in claim 1, is reacted with a carbonic acid derivative of the general formula,? , (iv) wherein A is defined as in claim 1 and Yx and Y2 mean nucleo-fuel groups, as well as with a compound of the general formula wherein X, D, E, G, M and Q are defined as in claim 1 and x represents a protecting group for a carboxy group, wherein, before carrying out the reaction, carboxylic acid functions, primary or secondary amino functions or hydroxy functions optionally present in the radical R 1 of a compound of the formula (III) and / or of a compound of the formula (V) are protected, if necessary, by protective radicals, and the optionally used protective radicals are separated again after carrying out the reaction, or b) a carboxylic acid of the general formula is coupled (VO in which all the radicals are defined as in claim 1, with an amine of the general formula HNR2R3, wherein R2 and R3 are defined as in claim 1, wherein before performing the reaction, acid functions carboxylic, primary or secondary amino functions or hydroxy functions optionally present in a compound of the formula (VI) and / or in the radicals R2 and R3 of the amine of the formula HNR2R3 are protected, if necessary, by protective radicals, and the optionally used protective radicals are separated again after carrying out the reaction, or (c) a compound of the with an amine of the general formula HNR2R3, in which all the radicals are defined as in claim 1 and Nu means a leaving group, wherein before carrying out the reaction, carboxylic acid functions, primary or secondary amino functions or hydroxy functions eventually present in a compound of the formula (VI) and / or in the radicals R2 and R3 of the amine of the formula HNR2R3 are protected, if necessary, by protective radicals, and the optionally used protective radicals are separated again after carrying out the reaction, if desired, a compound of the general formula (I), thus obtained, is separated into its stereoisomers and / or a compound of the general formula (I) thus obtained, is transformed into its salts, in particular for the pharmaceutical application, in its physiologically compatible salts.